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BURDEN OF OSTEOPOROSIS 
Osteoporosis is an increasingly major public health problem. It is a disease characterized by bone 
fragility and low bone mass, leading to increased fracture risk. In western countries, at least one in 
three women and one in five men over 60 years will suffer from an osteoporotic fracture during 
their remaining lifetime [1]. Osteoporotic fractures results in significant morbidity, mortality, and 
reductions in quality of life [2, 3]. They also double the risk of subsequent fractures [4] and impose 
a huge financial burden on healthcare systems [5, 6]. In the Netherlands, a recent report by the 
International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical 
Industry Associations (EFPIA) [5] estimated that approximately 76,000 new fragility fractures were 
sustained in 2010, comprising 13,000 hip fractures and 12,000 vertebral fractures. The economic 
burden of incident and previous fragility fractures was estimated at €824 million for the same year. 
Previous and incident fractures also accounted for 26,300 quality-adjusted life years (QALYs) lost 
during 2010. Taking into account demographic changes, it was estimated that the number of 
fractures will increase by 40% in 2025 [5]. 
Fortunately, several medications are available to reduce the risk of fractures [7]. Oral 
bisphosphonates (alendronate, risedronate and etidronate) were developed in the 1990s [8, 9] and 
are still the most widely prescribed medications for the prevention and treatment of osteoporosis 
worldwide [6]. Several clinical trials and meta-analyses have shown that oral bisphosphonates 
significantly reduce the risk of non-vertebral and vertebral fractures [10]. Over recent years, new 
treatment alternatives have become available to prevent and treat osteoporosis, including 
bazedoxifene, raloxifene, strontium ranelate, oral and intravenous ibandronate, teriparatide, 
strontium ranelate, subcutaneous injection of denosumab every 6 months and once-yearly 
intravenous zoledronic acid [7].  
HEALTH TECHNOLOGY ASSESSMENT AND ECONOMIC EVALUATION 
With the rapid development of new medications and considering limited healthcare resources 
available, it is becoming important to help decision makers to allocate healthcare resources and to 
make appropriate and efficient decisions about the use and reimbursement of osteoporosis 
medications. Health technology assessment (HTA) aims to assess the medical, social, economic and 
ethical implications of health technologies and could thus be very useful to inform and guide health 
policy decisions. In particular, economic evaluations that compare health technologies in terms of 
costs and outcomes are increasingly used to promote a more rational use of health resources. In the 
field of osteoporosis, the number of published economic evaluations has markedly increased in 
recent years [11-13]. In 2007, two systematic reviews [11, 13] were published suggesting that oral 
bisphosphonates are cost-effective for the prevention and treatment of osteoporosis in women aged 
over 70 years. In the appraisal of new and existing medications, consideration about their cost-
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effectiveness is unavoidably important for decision makers. Understanding and critically appraising 
evidence about the cost-effectiveness analyses of (new) anti-osteoporosis medications would 
therefore be very important to help decision makers when prioritizing health technologies, to 
identify gap in the current evidence and to inform the development of future economic evaluations. 
MEDICATION ADHERENCE 
In recent years, the problem of non-adherence with oral bisphosphonates has been recognized as a 
major obstacle in the treatment of osteoporosis [14]. Several studies have reported poor and 
suboptimal adherence levels among patients taking oral bisphosphonates [15, 16]. In the 
Netherlands, it was shown that only 43% of patients treated by oral bisphosphonates are still on 
treatment after 1 year [17]. Poor adherence with medications leads to reduced effectiveness, higher 
fracture rates [18] and could potentially have a large impact on the cost-effectiveness of drug 
therapies. Few studies have however been carried out to assess the economic implications of poor 
adherence with osteoporosis medications. With the development of new treatments with longer 
dosing regimens that could potentially improve adherence, as well as behavioural interventions to 
improve adherence, assessing the economic value of improving adherence would be very 
worthwhile for decision makers. In addition, reviewing the published literature about interventions 
and programs to improve adherence would be interesting to inform them about effective 
interventions to improve medication adherence. 
PATIENTS’ PREFERENCES 
Alongside medical and economic considerations, insights into the preferences of patients should 
also be taken into account in policy decisions. The patient’s perspective is nowadays becoming 
increasingly important. Information about what patients need and prefer, and how they value 
various aspects of a health intervention could indeed be very useful when evaluating healthcare 
programs [19]. Understanding the preferences of patients, addressing patients’ concerns with 
treatment and involving them in clinical decision-making may also lead to improved adherence 
[19]. In recent years, discrete choice experiments (DCEs) have been increasingly used to elicit 
patients’ preferences for health care [20, 21]. DCEs can quantify the relative importance of various 
attributes that characterize a treatment and allow the trade-offs that respondents make between these 
to be quantified [22]. Some DCEs have been conducted in the field of osteoporosis [23-25] but they 
did not incorporate preferences for recently introduced routes and timing of administration, which 
would be very useful for decision makers and clinicians. 
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OBJECTIVES OF THE THESIS 
The aim of this thesis is to review health technology assessment in osteoporosis and to provide new 
perspectives from adherence and preference studies.  
The aim can be further divided into three objectives:  
1. To review evidence about cost-effectiveness of drugs in postmenopausal women and to gain 
insights into the main drivers of cost-effectiveness (Part I – cost-effectiveness studies) 
2. To assess the economic implications of poor adherence with oral bisphosphonates and the 
economic value of improving adherence, and to review the published literature about 
interventions to improve adherence (Part II – adherence studies) 
3. To evaluate the preferences of patients for osteoporosis medication attributes, and to 
establish how patients trade between these attributes (Part III – preference studies). 
OUTLINE OF THE THESIS  
First of all, chapter 2 provides a general overview of HTA including economic evaluations and 
reviews the various aspects of HTA in osteoporosis, including epidemiology, and burden of disease, 
and assessment of the cost-effectiveness of recent advances in the treatment of osteoporosis.  
The next three chapters, chapters 3 to 5, are dedicated to answering the first objective of the thesis. 
More specifically, chapter 3 provides a systematic literature review of published research articles 
and research abstracts presented at congress about the cost-effectiveness of denosumab, a new 
(promising) agent for the treatment of osteoporosis. Chapter 4 updates and critically appraises the 
recent evidence about cost-effectiveness of all available drugs in postmenopausal women and 
provides insights about the key drivers of cost-effectiveness. Chapter 5 describes and illustrates the 
importance of integrating medication adherence into economic evaluations in osteoporosis. This 
chapter forms a bridge between the first two objectives of the thesis. 
With regard to the second objective of this thesis, the next two chapters focused on adherence 
studies. Using a Markov microsimulation model, chapter 6 quantifies the clinical and economic 
implications of poor adherence with oral bisphosphonates from an Irish setting and investigates the 
economic value of improving adherence by means of hypothetical interventions. In chapter 7, a 
systematic review and critical appraisal of interventions to improve medication adherence in 
osteoporosis is presented.  
Chapters 8 and 9 address the development and application of the DCE to cover the third aim of the 
thesis. Chapter 8 describes and discusses the qualitative research method used to select the 
attributes for the DCE. Chapter 9 provides the results of the DCE and therefore explains the 
preferences of patients for osteoporosis medications attributes and how patients trade between these 
attributes. 
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Finally, chapter 10 presents the main findings of the thesis and discusses theoretical and 
methodological considerations. Future directions for research are also addressed. 
Figure 1| Outline of the thesis 
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ABSTRACT 
We review the various aspects of health technology assessment in osteoporosis, including 
epidemiology and burden of disease, and assessment of the cost-effectiveness of recent advances in 
the treatment of osteoporosis and the prevention of fracture, in the context of the allocation of 
healthcare resources by decision-makers in osteoporosis. This article was prepared on the basis of a 
symposium held by the Belgian Bone Club and the discussions surrounding that meeting, and is 
based on a review and critical appraisal of the literature. Epidemiological studies confirm the 
immense burden of osteoporotic fractures for patients and society with lifetime risks of any fracture 
of the hip, spine and forearm of around 40% for women and 13% for men. The economic impact is 
also large, for example, Europe's six largest countries spent €31 billion on osteoporotic fractures in 
2010. Moreover, the burden is expected to increase in the future with demographic changes and 
increasing life expectancy. Recent advances in the management of osteoporosis include novel 
treatments, better fracture risk assessment notably via fracture risk algorithms, and improved 
adherence to medication. Economic evaluation can inform decision-makers in healthcare on the 
cost-effectiveness of the various interventions. Cost-effectiveness analyses suggest that the recent 
advances in the prevention and treatment of osteoporosis may constitute an efficient basis for the 
allocation of scarce healthcare resources. In summary, health technology assessment is increasingly 
used in the field of osteoporosis and could be very useful to help decision-makers efficiently 
allocate healthcare resources. 
KEYWORDS 
Burden of disease, cost-effectiveness, economic evaluation, health technology assessment, 
osteoporosis. 
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INTRODUCTION 
Osteoporosis is a major cause of fracture worldwide, most notably of the hip, spine, and forearm. 
Osteoporotic fracture is strongly associated with morbidity, especially in terms of pain and 
disability. Hip and vertebral fractures are also associated with high mortality in the 2 years after the 
event [1, 2]. Osteoporosis is a common disease and is associated with a substantial healthcare 
burden. In western countries, one in two women and one in five men over the age of 50 years will 
experience an osteoporotic fracture during their remaining lifetime [3, 4]. Heterogeneity in hip 
fracture risk is observed around the world [5], with estimates of a lifetime risk at the age of 50 years 
that vary from 1% in women from Turkey to 28.5% in women from Sweden [6]. The worldwide 
direct and indirect annual costs of hip fracture in 1990 were estimated at US$35 billion, with further 
increases predicted over the next 50 years [7]. In six major European countries, the burden of 
osteoporotic fractures was estimated in 2010 at €31 billion [8]. Fortunately, there is currently an 
array of diagnostic tools and effective treatments available for the management of osteoporosis [9]. 
Considering the limited healthcare resources available, alongside major recent innovations in the 
management of osteoporosis, it is becoming increasingly important to allocate healthcare resources 
appropriately and efficiently. Health technology assessment (HTA) aims to evaluate the clinical, 
economic, social, and ethical implications of the prevention and treatment of a condition—in this 
case osteoporotic fracture—to guide national healthcare policies (for example, reimbursement 
decisions). The principal aim of HTA is to form a bridge between scientific experts in clinical 
practice and decision-makers in healthcare, in order to make the most appropriate use of available 
strategies for prevention and management. The ultimate target is evidence-based prioritization of 
national needs for healthcare technology—be it for the prevention of fracture itself or management 
post-fracture—for optimization of public health initiatives. It was against this background that the 
Belgian Bone Club held a symposium to explore the issue from the clinician's point of view. This 
paper was prepared on the basis of the presentations and discussions surrounding that meeting, as 
well as review and critical appraisal of the literature. Our aim was to discuss the various aspects of 
HTA in osteoporosis, including epidemiology and estimation of the burden of disease, and 
assessment of the cost-effectiveness of the recent advances in the management of osteoporosis. 
HEALTH TECHNOLOGY ASSESSMENT 
According to the International Network of Agencies for Health Technology Assessment [10], HTA 
is the systematic evaluation of “the medical, social, ethical and economic implications of 
development, diffusion, and use of health technology.” Its purpose is to support healthcare decisions 
and inform policy-making through objective information at local, national, or international levels. 
The aim of HTA is to improve the quality of care by promoting an appropriate and rational use of 
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healthcare technologies [11] and by facilitating the introduction and dissemination of new 
technologies.  
Health technology includes not only drugs, medical equipment, and devices, but also prevention, 
diagnostic, and treatment procedures. HTA is conducted by interdisciplinary groups that use explicit 
analytical frameworks and draw from a variety of methods [10]. This field of research was 
developed in the 1970s and 1980s in the USA and Europe, and has spread to the rest of the world 
over the last two decades [12]. HTA government agencies are now operating in many countries. 
They have been established to provide advice to governments and address, at the national level, the 
containment of healthcare costs and the assessment of the impact of new technologies [13]. The 
organization of HTA and its influence on the public policy-making process can vary markedly 
between countries [14]. In addition, many research institutions are concerned with HTA [15], for 
example, the National Health Service Centre for Reviews and Dissemination in the UK. In 2012, 
the International Network of Agencies for Health Technology Assessment consisted of 53 members 
from 29 countries [10].  
HTA is increasingly used by regulatory agencies to authorize a drug, device, or technology for 
market or reimbursement. HTA can be used to support decision-making by clinicians and patients. 
It may also be used by other bodies, for example, associations of health professionals, hospitals (for 
acquisition of new technologies), and companies (to aid product development and marketing 
decisions) [16]. 
EPIDEMIOLOGY AND BURDEN OF OSTEOPOROSIS 
The first step of HTA is to assess the epidemiology and burden of the disease or outcome 
concerned. Epidemiological studies performed in the early 1990s in white North American 
individuals aged over 50 years indicated that the lifetime risk for any fracture of the hip, spine, or 
forearm was 40% in women and 13% in men [17]. Similar rates of fracture were reported in a study 
performed 10 years later in the UK General Practice Research Database (GPRD), with values of 
53% for women and 21% for men [18]. These data include fractures not linked to osteoporosis, such 
as those of the skull, hands or fingers, and ankles or toes. Lifetime risk for fracture of the hip, spine, 
and wrist has been estimated as 14%, 28%, and 13%, respectively, for women in the UK, and 3%, 
6%, and 2% for their male counterparts [7]. The risk of fracture rises progressively from the age of 
50 years, and there is a substantial female excess at all-time points above that age. 
Fracture rates are known to vary considerably according to geographical location [5], which also 
influences HTA. Age-standardized incidences of hip fractures are currently available in 63 
countries [5]. The age-standardized incidence of hip fracture in Europe and North America is 
generally higher than in Asia and Africa, and there is also a large difference within Europe (763 per 
100 000 women in Norway versus 418 per 100 000 women in England) [19]. These differences 
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correlate weakly with latitude [20], activity [21], and fall risk [19, 22], but not with bone mineral 
density (BMD). Geographical differences may be partly explained by time trends. Age, period, and 
birth cohort all impact on secular trends in hip fracture [23, 24], suggesting that there are 
determinants that operate throughout life; for example, even maternal vitamin D status may play a 
role [25]. 
Data are available regarding incident trends in hip fracture from around 1928 up to the present. 
Steep and statistically significant increases in age-adjusted rates among men and women were 
observed in the middle to late 20th century. However, whilst global projections for hip fracture in 
the 1990s suggested sustained increases due to demographic changes in populations [26], there is 
evidence that the trends in incidence are reaching a plateau, or may even have declined. This trend 
is most consistent in the USA, where hip fracture rates and subsequent mortality are declining 
(though with coincident increase in morbidities associated with hip fracture) [27]. There is also 
evidence for similar trends in Europe and Oceania, but not (for the time being) in Asia [28, 29]. In 
Belgium, the age-standardized incidence of hip fracture fell from 5.60 per 1000 women aged over 
50 years in 2000, to 5.22 per 1000 in 2007 [30]. These data (excluding readmissions) also highlight 
a reversal of the secular trend for hip fracture in Belgian women, with a 1.1% reduction in the 
average yearly change in the incidence of hip fractures in the period 2000 to 2007 [30], compared 
with a 2.1% increase reported between 1984 and 1996 [31]. The reasons for this reversal are not 
entirely clear, though it could be linked to changes in risk factors [28], most notably those acting in 
later life; for example, changes in patterns of physical activity, vitamin D insufficiency, and 
increasing survival of the frailest elderly were likely to contribute to the rise in hip fracture 
incidence in the second half of the century. On the other hand, reduction in rates of hip fracture in 
the last two decades may be linked to wider use of osteoporosis treatments—and some studies have 
revealed the recent decrease in hip fracture incidence coincided with increased use of osteoporosis 
treatments [27, 30, 32]—as well as other possible factors, such as increased rates of obesity or 
improvements in nutrition or tobacco consumption. However, there is no single explanation, and no 
causal relationship can be ascertained between the increase in the use of osteoporosis medications 
and the decrease in hip fracture incidence [30, 33]. Further research is necessary to explore these 
trends in more depth. Despite a reduction in age-adjusted incidence in many countries, the absolute 
number of fractures is still increasing due to the aging of the population and increasing life 
expectancies. In Belgium, for example, the absolute number of hip fractures increased by 9% 
between 2000 and 2007 [30].  
A report launched by the International Osteoporosis Foundation (IOF) in collaboration with the 
European Federation of Pharmaceutical Industry Associations (EFPIA) has revealed the immense 
burden of osteoporotic fracture [8]. For the year 2010, approximately 2.5 million new fractures 
occurred in Europe's five largest countries (France, Germany, Italy, Spain, UK) and Sweden alone 
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[8]. The economic impact of these fractures was estimated to be nearly €31 billion in that year [8]. 
Approximately 34 000 deaths were causally related to these fractures and the burden expressed in 
quality-adjusted life years (QALYs) was estimated at 850 000 QALYs. Considering current trends 
in demography, the burden of osteoporosis is expected to further increase in the near future. The 
projected number of fractures in these major countries is 3.2 million by 2025, an increase of 29% 
[8].  
RECENT ADVANCES IN THE TREATMENT OF OSTEOPOROSIS 
The diagnosis and treatment of osteoporosis is rapidly evolving. A variety of new treatments for 
osteoporosis has become available over the past few years [34]. Fracture risk assessment is 
increasingly used to guide treatment decisions [35], and the impact of non-adherence with 
osteoporosis medications on treatment efficacy has led to the development of behavioural 
interventions to improve adherence [36, 37]. The assessment of these major advances from a 
clinician’s point of view is provided below, while the economic assessment will be discussed later. 
NOVEL TREATMENT STRATEGIES 
Over recent years, new treatment strategies have become available to prevent and treat osteoporosis, 
including bazedoxifene [38], denosumab [39], ibandronate [40], strontium ranelate [41], and 
zoledronic acid [42]. Other promising drugs are currently in development, such as odanacatib (a 
specific inhibitor of the osteoclast protease cathepsin K) and antibodies against the sclerostin and 
dickkopf-1 proteins [34]. Systematic review of the clinical efficacy, effectiveness, and side effect 
profiles of these drugs is a crucial part of HTA. Good-quality systematic reviews of the evidence for 
the efficacy and safety of these drugs are available [9, 34, 43-46], and will not be discussed further 
here. 
FRACTURE RISK ASSESSMENT 
Evaluation of risk and prediction of outcome is another important component of HTA. It is well 
established that BMD is inversely related to fracture risk [47]. For every 1.0 SD decrease in BMD 
at the hip, spine, or radius, there is an approximately 1.5- to 2-fold increase in fracture risk at any 
site. Measurement of BMD is therefore an integral part of the prediction of fracture risk. However, 
there are a host of other clinical risk factors that can improve fracture risk prediction, notably 
because they increase fracture risk in a manner that is at least partially independent of BMD. 
Examples are a prior history of fragility fracture, a parental history of hip fracture, current smoking, 
high alcohol intake, systemic glucocorticoids, and the presence of rheumatoid arthritis [48]. 
Fracture risk prediction algorithms have been generated to combine results of BMD assessment 
with the presence of clinical risk factors, thereby improving the prediction of osteoporotic fracture. 
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Current fracture risk algorithms generally produce estimates of 10-year risk of fracture. The most 
widely used is the World Health Organization (WHO) fracture risk assessment tool, FRAX®, 
which is recommended by guidelines in North America, Europe, and Japan. The FRAX algorithm 
was developed using international population-based data for men and women aged 40 to 90 years. 
FRAX combines 11 parameters of risk (femoral neck BMD, age, sex, body mass index, prior 
fracture, parental history of hip fracture, rheumatoid arthritis, glucocorticoids, smoking, alcohol, 
and secondary osteoporosis) to calculate a 10-year probability for major osteoporotic fracture and 
for hip fracture [35]. Other fracture risk prediction algorithms have also been produced which are 
not based on probability (i.e. do not incorporate the death risk), and are less widely used [49-51]. A 
simpler score, produced by Ensrud et al, used a USA-based population of women aged 65 years or 
older to determine a 10-year risk of major osteoporotic or hip fracture using the risk factors of age 
and previous fractures with and without BMD. They considered that this simpler model may predict 
risk as well as the more complex FRAX algorithm [49], but this is the subject of some debate [52]. 
The Garvan Fracture Risk Calculator includes BMD, age, sex, previous fracture, and falls to 
produce 5- and 10-year risks of any fracture in men and women aged over 60 years [51]. Finally, 
the Qfracture algorithm employs multiple risk factors, including comorbidities, medications, and 
falls, but not a prior fracture or BMD, to estimate 2-, 5-, and 10-year risks of hip, wrist, and 
vertebral fracture [50]. 
The FRAX algorithm is the most widely used tool, and has been endorsed by international 
guidelines. However, it does have a number of limitations; for example, it only allows for inclusion 
of femoral neck BMD, but not BMD values at other sites. Moreover, FRAX does not incorporate 
the notion of dose-response for some of the risk factors, for example, previous fracture and 
glucocorticoids [53]. Simple guidance for the adjustment of fracture probabilities on the basis of 
exposure to glucocorticoids and information on lumbar BMD are available [54, 55]. FRAX, like all 
the models except QFracture (which ignores all previous fracture), may also underestimate risk if 
previous vertebral fractures are not accounted for, despite established evidence for the influence of 
incident fracture. Moreover, it does not formally take into account the number of previous fractures. 
The recent observational cohort study GLOW (Global Longitudinal Study of Osteoporosis in 
Women) collected information on 50 000 women in 10 countries [56]. Compared with women with 
no previous fracture, the hazard ratio for incident fracture was 1.81 (95% confidence interval [CI], 
1.66–1.97) in patients with one prior fracture, 2.98 (95% CI, 2.63–3.38) with two prior fractures, 
and 4.80 (95% CI, 4.11–5.60) with three prior fractures [56]. Similarly, the presence of undiagnosed 
vertebral fracture was associated with a substantially increased risk for hip and new vertebral 
fracture [57], but could only be incorporated in risk prediction algorithms by systematic evaluation 
of spinal radiographs. Clearly, this is not feasible for all consultations, though possible indications 
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for vertebral imaging in fracture assessment should include low BMD, height loss, kyphosis, pain 
suggestive of a vertebral fracture, previous non-vertebral fracture, and reduced rib-to-pelvis 
distance. One potential drawback to FRAX may be that it does not include falls, which clearly 
contribute to the occurrence of fracture and are included in other risk tools [50, 51]. Although there 
is some evidence that including falls into FRAX would improve fracture risk prediction [58], the 
incorporation of falls into FRAX may be problematic for a number of reasons discussed elsewhere 
[53]. 
In conclusion, FRAX and other fracture risk algorithms enable fracture prediction based on clinical 
risk factors with or without BMD and provide a basis for setting intervention thresholds. Current 
strategies for external validation and comparisons of fracture risk algorithms involve procedures of 
discrimination, calibration, classification, and decision curve analysis, all of which have drawbacks 
and require further study [52]. 
ADHERENCE TO TREATMENT 
The problem of medication non-adherence has emerged as a critical hurdle to osteoporosis 
management. Adherence with osteoporosis medications is poor and suboptimal [59-61]. Several 
studies have suggested that between 50% and 75% of women who initiate oral bisphosphonate 
therapy are non-adherent within 1 year. Poor adherence reduces the effectiveness of osteoporosis 
treatment, resulting in lower BMD gains and subsequently higher fractures rates [62, 63]. 
Approximately 50% of the potential clinical benefits of oral bisphosphonates are lost due to non-
adherence [36, 37, 64] and the costs per QALY from these medications are doubled when assuming 
non-adherence [64]. Non-persistence is the leading problem with adherence, with more than 90% of 
the clinical and economic burden of poor adherence resulting from non-persistence [64]. 
Over the past few years, behavioural interventions and treatments with longer intervals between 
doses have been developed in order to improve medication adherence. Systematic reviews of these 
interventions identified a limited number of studies of variable quality suggesting that some 
intervention techniques may help improve medication adherence, but this requires further 
investigation [65, 66]. Different dosing regimens [67], the use of a decision aid [68], and education 
programs [69] may also improve medication adherence. 
ECONOMIC EVALUATION 
Economic evaluation is as important a branch of HTA as the epidemiological and treatment aspects. 
The aim of economic evaluation is to examine outcomes and costs of healthcare interventions; it 
could be defined as the comparative analysis of two or more healthcare interventions in terms of 
both costs and impact on outcomes [70]. By informing decision-makers about the relative cost-
effectiveness of different healthcare interventions, economic evaluation can help decision-makers 
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make rational decisions and efficiently allocate resources. Cost-effectiveness is currently considered 
to be the fourth hurdle in drug development, behind quality, safety, and efficacy [71]. Although the 
most common application of economic evaluation is drug pricing and reimbursement [72], the 
implementation and viability of any other health intervention (such as screening or information 
campaigns) also depend on their evaluation and their relative cost-effectiveness. 
With the rising demand for healthcare, budget constraints, and the rapid development of health 
technologies, economic evaluation plays an increasingly large role in the decision-making process 
for healthcare interventions. This has led to an increase in the number of published economic 
evaluations in the literature and to an increased use of economic data in the healthcare decision-
making process (in particular, for drug reimbursement). Many countries currently require economic 
evaluation as part of the reimbursement process for drugs [73]. 
The four main types of economic evaluation all approach costs in the same way, but differ in the 
way they approach outcomes [70]:  
 Cost-minimization analysis is used where the consequences of two or more interventions are 
broadly equivalent, and so the difference between them is limited to a cost comparison. This 
approach is only meaningful for agents with similar efficacies or side effects, which is 
difficult to apply to a heterogeneous class like the osteoporosis drugs [74].  
 Cost-benefit analysis measures both costs and benefits in monetary terms. This approach 
aims to demonstrate that a program will yield to a net welfare gain, and ranks interventions 
according to the net benefit they provide. The practical difficulties of measurement and 
valuing health benefits have limited the use of this type of analysis in healthcare [75]. 
 Cost-effectiveness analysis (CEA) compares costs and outcomes expressed in a single 
dimension, such as fracture saved, BMD gained, or life-years gained.  
 Cost-utility analysis (CUA) is considered as a specific case of CEA where the outcome 
measure is expressed in QALYs. The QALY estimator is an attractive outcome 
measurement in the field of osteoporosis because it offers the advantage of simultaneously 
capturing the benefits from a reduction in mortality and from a reduction in morbidity [76]. 
In addition, this approach allows comparison across different health programs and diseases 
by using a generic unit of measure. 
There are different categories of costs that may or may not be included in an economic evaluation. 
It is essential to specify and justify the perspective in which the analysis is undertaken. The most 
common perspectives used are those of healthcare payers and society. The societal perspective is 
the broadest, including direct and indirect medical costs, and is theoretically preferred [70]. 
However, most local guidelines recommend the use of a healthcare payer perspective [73]. 
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The results of a CEA or CUA are usually expressed in terms of the incremental cost-effectiveness 
ratio (ICER), which is defined as the difference in terms of costs between two interventions divided 
by their difference in effectiveness. An ICER represents the additional cost of an intervention per 
effectiveness unit (for example, fracture saved or QALY gained) versus the comparator. The results 
can be presented graphically on the cost-effectiveness plane (Figure 1), where the difference in 
effectiveness between intervention A and comparator O is represented on the horizontal axis, and 
the difference in cost on the vertical axis [77]. If A is located in quadrants II or IV, the choice is 
straightforward: in quadrant II, intervention A is more effective and less costly than comparator O, 
and said to be dominant; in quadrant IV, intervention A is less effective and more costly than O, and 
should be rejected. In quadrants I and III, there is no obvious decision; intervention A is either more 
effective and more costly than comparator O (quadrant I), or less effective and less costly (quadrant 
III). The choice will depend on the maximum amount the decision-maker is willing to pay (or 
accept) for a unit of effect (for example, a fracture prevented or a QALY). The slope of the line 
between intervention A and comparator O is the ICER. As shown in Figure 1, if intervention A falls 
below the ICER threshold, then it is deemed cost-effective. 
Figure 1| Cost-effectiveness plane 
 
 
 
 
 
 
 
 
 
 
 
 
 
The difference in QALYs between intervention A and comparator O is represented on the horizontal axis, and the 
difference in cost on the vertical axis. The slope of the line between intervention A and comparator O is the incremental 
cost-effectiveness ratio (ICER). If A is located in quadrants II or IV, intervention A is dominant (more effective and less 
costly than comparator O), in quadrant IV, intervention A is less effective and more costly than O. In quadrants I 
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intervention A is more effective but more costly and in III less effective and less costly. The choice will depend on the 
cost-effectiveness threshold that represents the maximum amount the decision-maker is willing to pay for a unit of 
effectiveness. Interventions that fall below the cost-effective threshold would be deemed cost-effective.  
In order to draw conclusions about an intervention’s cost-effectiveness, ICER should be compared 
with a cost-effectiveness threshold, above which the intervention would be deemed not cost-
effective (because the additional cost for an additional unit of effect is too high) and below which it 
would be deemed cost-effective. The UK currently uses a threshold of £20 000 to £30 000 per 
QALY gained [78], though most other countries define no generally accepted or recommended 
thresholds for cost-effectiveness. The objections to the specifications of a fixed cost-effectiveness 
threshold are numerous. First, any threshold for cost-effectiveness would be somewhat arbitrary and 
would be variable over time. A threshold would also vary between countries to reflect differences in 
resources. The WHO has suggested a cost-effectiveness threshold based on evaluating each 
disability-adjusted life-year (DALY) as three times the gross domestic product (GDP) per capita 
[79]. On this basis, a willingness-to-pay of two times GDP per capita was used to define 
intervention thresholds in osteoporosis [80, 81]. In addition, healthcare decision-making remains a 
multifactorial process and depends on many factors other than cost-effectiveness. As decisions are 
not solely based on ICER, it is probably not necessary to define a fixed threshold below which an 
intervention can be considered cost-effective. This should, however, not be used as an argument 
against the use of economic considerations in healthcare [82]. In most countries, interventions with 
a low ICER have a higher probability of being adopted/accepted than those with a high value [82, 
83]. Factors to considered alongside cost-effectiveness include burden of disease, uncertainty 
regarding cost-effectiveness, lack (or inadequacy) of alternative treatments, and overall financial 
implications for government [84]; the seriousness of the disease and equity objectives are also 
important. Recently, the UK National Institute for Health and Clinical Excellence (NICE) 
introduced new criteria and increased the threshold for end of life treatments [85]. 
Economic evaluation can be performed alongside randomized controlled trials [86] or separately 
using decision-analytic modelling [87]. The first approach estimates costs, effects, and utilities 
using individual patient data [88], but suffers from a number of limitations that reduce its usefulness 
in informing decision-makers about the economic value of interventions. These include, for 
example, a failure to compare with all relevant options, a truncated time horizon, and a lack of 
relevance of the decision context [89]. In addition, reliance on a single trial may ignore results from 
other clinical trials, meta-analyses, and observational studies [87]. Decision-analytic models are 
therefore becoming a necessary feature for estimating the economic value of health interventions. 
This is especially true in osteoporosis since the prevention of an osteoporotic fracture (in particular 
of the hip or vertebra) has long-term consequences on costs and outcomes that may not be captured 
by trial data. 
CHAPTER 2 
26 
 
Healthcare modelling involves the application of mathematical techniques to summarize available 
information about healthcare processes and their implications [90], usually with computer software. 
A model aims to represent the complexity of the process in a simple and comprehensible form [91]. 
Modelling is useful to extrapolate beyond clinical trials, to combine multiple sources of evidence, to 
incorporate epidemiological, clinical, and economic data, and therefore to answer more relevant 
policy questions [90]. In addition, modelling is also appropriate at the early stages of the 
development of a new technology to inform research priorities prior to initiation of clinical trials 
[90, 91]. 
There may be some problems with using modelling in the economic evaluation of healthcare [92]. 
Inappropriate use of modelling could lead to unreliable conclusions, as would be the case for 
combination of evidence from incompatible studies with a high degree of uncertainty, and 
oversimplification of some aspects of reality [88, 90]. Manipulation could also be greater when 
modelling reflects commercial and government interests [93]. An example is the discussion about 
the appraisal of NICE on the health economic assessment of interventions for the primary and 
secondary prevention of osteoporotic fractures in postmenopausal women in the UK [94]. Some 
authors do not support the view of the NICE guideline and doubt the validity of the model and the 
appropriateness of the use of the model to inform its guidance [95]. Interestingly, a recent study has 
shown that funding source (industry versus non-industry) did not seem to significantly affect the 
reporting of low or high ICERs for bisphosphonates [96]. 
Models are only as good as their ability to represent the real world. In order for the results and 
conclusions of economic evaluation to be reliable and valid, it is crucial that the model and the data 
both represent the reality of the disease as accurately as possible. Guidelines have been developed 
to increase the quality and reliability of modelling [73, 97]. These include the characterization of 
uncertainty using appropriate statistical approaches. There could be a substantial amount of 
uncertainty in the model parameters (and assumptions), and this should be explored using univariate 
and probabilistic sensitivity analyses. Univariate sensitivity analyses assess the impact of single 
parameters on the results (which can be represented as a tornado diagram [98]), while probabilistic 
sensitivity analyses examine the effect of the joint uncertainty surrounding the model variables. 
Cost-effectiveness acceptability curves (CEAC) can then be constructed to show the probability that 
the intervention is cost-effective compared with the alternative, for a range of decision-maker’s 
willingness-to-pay thresholds. An example is shown in Figure 2. CEAC has been widely adopted to 
represent uncertainty in cost-effectiveness analyses [99]. 
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Figure 2| Example of a cost-effectiveness acceptability curve 
 
This graph shows the probability of an osteoporotic treatment being cost-effective compared with no treatment in 
patients aged 70 years with prevalent vertebral fractures, as a function of the decision-maker's willingness-to-pay per 
one QALY [108]. The curve was estimated from probabilistic sensitivity analyses where most parameters (such as 
therapeutic effect, fracture risk, cost, and disutility) were assigned a probability distribution (e.g. normal or uniform 
distribution) and values from each distribution were randomly selected during a predefined number of simulations.  
Economic evaluations conducted in the field of osteoporosis are usually based on so-called Markov 
state-transition models [76]. Markov models are particularly appropriate when a decision problem 
involves a continuous risk over time, when the timing of events is important, and when events may 
happen more than once [100], which is the case for osteoporosis. In a Markov model, a cohort of 
patients is followed over time along mutually exclusive health states (such as healthy, fracture 
states, and death). At the end of a cycle, patients can move to another health state according to 
transition probabilities. Values (typically cost and utilities) are assigned to each state and expected 
values are then obtained by summing costs and utilities across health states, weighted by the 
proportion of patients in each state, and then summing across cycles [77]. To assess Markov 
models, either cohort or individual simulations can be carried out. A microsimulation model follows 
one individual at a time throughout the model. Due to the probabilistic structure of the model, there 
will be random variation in individual outcomes (called first-order uncertainty) [101], which can be 
reduced by simulating a large number of patients. The major advantage of microsimulation is that a 
full patient history is recorded, which increases the reliability of the results and is currently largely 
compatible with existing state-of-the-art, evidence-based literature [101]. The weakness of such 
models is that they require more sophisticated and detailed data than cohort-based models. This fact 
was invoked as a rationale for remaining with cohort modelling approaches in osteoporosis [76]. 
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ECONOMIC EVALUATION IN OSTEOPOROSIS 
With limited healthcare resources, increasing awareness of osteoporosis, and new diagnostic tools 
and effective treatments, economic evaluation is increasingly widespread to help decision-makers 
allocate resources in osteoporosis. The number of published economic evaluations in osteoporosis 
has therefore markedly increased over recent years [76, 102-104]. They have mainly concerned 
treatment [76, 105, 106] and screening strategies [102, 107]. Recent advances in the diagnosis and 
treatment of osteoporosis have provided new insights and challenges for economic evaluation that 
will be discussed below. 
ECONOMIC EVALUATION OF NEW OSTEOPOROSIS TREATMENTS 
As many countries now require economic evaluation as part of the submission file for drug 
reimbursement, novel drug treatments have been the subject of many economic analyses. 
Osteoporotic treatments are usually cost-effective in women aged over 60 or 70 years with low 
bone mass, especially those with prior fractures [76, 104, 105]. In osteoporotic women aged over 80 
years, drug therapies are generally reported to be cost-saving [108, 109], meaning that the cost of 
treating these patients is lower than the averted costs resulting from prevented fractures. 
With the development of new products, the question of relevant comparators arises. Health 
economic evaluations should ideally compare a new intervention with the interventions it is likely 
to replace. In osteoporosis, there is a lack of head-to-head comparisons, which has led to a paucity 
of ICER comparisons between active treatments [110]. No treatment (or calcium and vitamin D 
supplement) appears as the most widely used comparator [76]. Cost-effectiveness analyses often 
replicate both arms of clinical trials (higher level of evidence) when active treatment is compared 
with placebo. It has also been argued that the current standard of care is no treatment, since 
osteoporosis is an undertreated disease and the majority of patients with osteoporosis do not receive 
any treatment [110]. However, this is no longer true since there are many treatments available for 
osteoporosis that could be considered as standard care. Decision-makers are more interested in 
comparisons between active drugs to determine first-line options. As there is a lack of trial data 
directly comparing the effectiveness of different treatments, indirect comparison is required to 
assess cost-effectiveness between active comparators. 
Cost-effectiveness analyses between active comparators have started to appear in the osteoporosis 
literature, for example, for denosumab [98, 111], strontium ranelate [112] and zoledronic acid 
[113]. Indirect comparisons of efficacy between drugs are less robust because of different baseline 
characteristics of the populations studied and overlapping confidence intervals for the effect of 
treatment [114]. Such analyses should therefore be interpreted with great caution. 
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COST-EFFECTIVE INTERVENTION THRESHOLDS 
Recent developments in fracture risk assessment, such as the use of the FRAX algorithm, have led 
to new applications in health economics of osteoporosis. First, there is a growing body of literature 
on the interaction between FRAX and treatment efficacy suggesting that for some agents (for 
example, bazedoxifene, clodronate, denosumab), there is a significant interaction between fracture 
probability and efficacy [115]. This has a significant impact on summary estimates of efficacy, and 
hence on cost-effectiveness. 
Secondly, FRAX enables the estimation of risk based on a wider range of clinical risk factors and 
evaluation of treatment efficacy in populations at differing levels of risk [116]. The cost-
effectiveness of drug treatments can therefore be estimated in various types of patients with 
different combinations of clinical risk factors. FRAX can therefore help identify new high-risk 
populations (i.e. patients with different combinations of clinical risk factors) that could benefit from 
cost-effective treatment. 
Finally, economic evaluations are also increasingly being used to determine cost-effective 
intervention thresholds in order to guide clinical guidelines. Thus, health economic evaluations have 
been conducted in several countries to determine at what levels of fracture risk treatment should be 
initiated [80, 81, 117, 118]. In the UK, the intervention threshold at the age of 50 years corresponds 
to a 10-year probability of a major osteoporotic fracture of 7.5% [117]. This increases progressively 
with age to 30% at the age of 80 years. In Switzerland, use of a fixed FRAX-based intervention 
threshold of 15% for both women and men would permit cost-effective treatment [80]. In Belgium, 
a “translational approach” was used to define intervention thresholds by examining 10-year fracture 
probabilities equivalent to those currently accepted for reimbursement of treatment in Belgium 
(Figure 3) [119]. This approach will, however, need to be supported by health economic analyses 
[119]. Many country-dependent factors could have an impact on intervention thresholds, including 
fracture cost, intervention cost, and willingness-to-pay [81]. Intervention thresholds should 
therefore be determined on a per-country basis. 
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Figure 3| Intervention thresholds in Belgium [119]. 
 
ECONOMIC VALUE OF IMPROVING ADHERENCE 
Consideration of new therapeutic options and behavioural interventions that improve medication 
adherence is currently leading to questions regarding their impact on clinical and economic 
outcomes. Several studies have assessed the effects of improvements in adherence on fracture 
outcomes [120-123]. Other studies have estimated the potential economic value (in terms of cost 
per QALY gained) of interventions that improve medication adherence [36, 37, 64, 124]. Currently, 
no studies have examined the cost-effectiveness of a specific adherence-enhancing intervention. 
The economic value of improving adherence was assessed using a variety of hypothetical 
interventions, which differ according to cost (e.g., marginal or one-time cost) and improvements in 
adherence (between 10% and 50%). 
The results of these studies suggest that interventions that improve adherence are likely to confer 
cost-effective benefits [36, 37, 64, 124]. Therefore, in the USA, a hypothetical intervention with a 
one-time cost of $250 that reduced discontinuation by 30% was reported to have an ICER of $29 
571 per QALY gained [124]. In studies conducted in Belgium [36], Sweden [37], and Ireland [64], 
it has been estimated that an intervention that improves adherence by 10% is cost-effective at a 
maximum yearly cost of between €45 and €70 (Figure 4). For a hypothetical intervention that 
improves adherence by 50%, it is cost-effective to spend between €140 and €239 per year. The 
economic value of improving adherence could be situation-specific and improve with the increasing 
baseline risk for fractures [64, 124]. 
 
HEALTH TECHNOLOGY ASSESSMENT IN OSTEOPOROSIS 
 
31 
 
Figure 4|  Maximum yearly cost (in €) for an adherence-enhancing intervention to be considered 
cost-effective. Data from [36, 37, 64].  
 
For Sweden, improvement in medication adherence at 25% should be read at 30%. In Ireland, a longer refill gap 
period (9-weeks) was selected to define persistence resulting in higher base-case adherence levels.  
This work has required methods of incorporating medication adherence into the models. As 
medication non-adherence affects both costs and outcomes, it could have a substantial impact on the 
cost-effectiveness of management strategies in osteoporosis and should be incorporated in 
pharmacoeconomic analyses [64, 122, 125]. In particular, when comparing drugs with different 
adherence profiles, the lack of inclusion of these concepts could bias the results and lead to 
suboptimal allocation of resources [126]. Integrating medication adherence into economic analyses 
in osteoporosis is a complex and difficult task, and has been extensively discussed elsewhere [74, 
126].  
DISCUSSION 
An increasing number of epidemiological and economic studies have revealed the immense burden 
of osteoporotic fractures, and this is expected to increase further in the future. Information from 
these studies will help establish priorities between interventions and diseases and guide research 
priorities. Furthermore, economic analyses have suggested that recent advances in the prevention 
and treatment of osteoporosis, including novel treatments, fracture risk assessment, and improved 
medication adherence, are an appropriate and efficient way of allocating healthcare resources. Such 
analyses may also contribute to a more efficient healthcare system. 
HTA is a rapidly evolving discipline. As more countries use HTA to inform healthcare decisions, 
the harmonization of HTA between jurisdictions has been discussed in order to avoid duplication of 
effort [127]. Clinical data for new technologies usually apply across countries, but cost-
effectiveness (and therefore appraisals of technologies for reimbursement) should be evaluated at a 
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national level because differences in the incidence of the disease, the availability of health 
resources, clinical practice patterns, and relative prices may impact on cost-effectiveness [128]. The 
development of key principles [129] and good practice, as well as international collaboration 
between experts, could facilitate a common process for the conduct of HTA for resource-allocation 
decisions. 
There are currently major developments in the methods for economic evaluation in osteoporosis:  
 Incorporation of medication adherence into pharmacoeconomic analyses in osteoporosis [74, 
126].  
 Use of FRAX in health economics of osteoporosis [116].  
 Use of microsimulation models, which are beginning to supplant cohort models in HTA 
[130].  
 In the absence of randomized controlled trials directly comparing active comparators, use of 
indirect treatment comparisons and network meta-analysis may provide useful evidence for 
selecting the best option [131]. 
 Characterization of uncertainty.  
Alternative approaches to the assessment of QALY have also been developed, including discrete-
choice experiment (DCE) [132, 133] and contingent valuation. DCEs have been increasingly used 
to elicit collective preferences of subgroups of patients in healthcare [134]. DCE is an attribute-
based survey approach for measuring value, in which patient preference is determined by the levels 
of different attributes [135]. DCEs help determine important attributes and provide input on what 
patients with a particular disease prefer and/or are willing to pay. 
Despite the growth of HTA over the past decades, its overall impact on policy-making may be 
limited [14]. The role of science is however to inform, not to dictate policy decisions. Humphreys 
and Piot recently argued that scientific evidence alone is not a sufficient basis for health policy and 
that other factors (such as democratic and human rights considerations) should be taken into 
consideration in health policy [136].  
In summary, HTA helps decision-makers efficiently allocate healthcare resources. In the field of 
osteoporosis, HTA reports have revealed a considerable burden of fracture and the economic value 
of the prevention of fracture and the treatment of osteoporosis. 
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ABSTRACT  
Denosumab is a novel biological agent for the treatment of osteoporosis in postmenopausal women 
with increased risk of fractures. With limited health care resources, economic evaluations are 
increasingly being used by decision-makers to optimize health care resource allocation. The cost-
effectiveness of denosumab has been evaluated in various studies and a systematic literature 
research was conducted up to April 2012 to identify all published research articles and research 
abstracts presented at various congresses. This article provides a systematic review of 4 articles and 
8 abstracts reporting on cost-effectiveness of denosumab in the treatment of osteoporosis. In most 
economic evaluations, denosumab has been considered as a cost-effective treatment compared with 
first-line and second-line options (including generic alendronate) in the treatment of women with 
high risk of fractures. 
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INTRODUCTION 
Osteoporosis is an increasingly major public health problem around the world. It is estimated that, 
in western countries, one in three women and one in five men over the age of 50 years will 
experience an osteoporotic fracture during their remaining lifetime [1].  Osteoporotic fractures 
result in significant morbidity, excess mortality and reduction in quality of life [2-4]. They also 
impose a financial burden on health-care systems. In six major European countries, the burden of 
osteoporotic fractures was estimated in 2010 at €31 billion [5]. 
Oral bisphosphonates have been the most widely prescribed drugs for the treatment and prevention 
of osteoporosis, with demonstrated efficacy in reducing the risks of vertebral and non-vertebral 
fractures [6].  However, effectiveness in real-life settings is jeopardized by poor adherence. Several 
studies have reported that between 50% and 75% of women who initiate oral bisphosphonates are 
non-adherent within one year [7, 8], and that the majority of patients with hip fractures did not 
receive any medication [9-11]. Poor adherence reduces the effectiveness of osteoporosis treatment, 
increasing fracture rates [12]. Approximately 50% of the potential clinical benefits of oral 
bisphosphonates are expected to be lost due to non-adherence and, thus, reduces the cost-
effectiveness of osteoporosis medications [13-15].   
Denosumab is a novel agent for the treatment of osteoporosis in postmenopausal women with 
increased risk of fractures. In a 3-year randomized clinical trial including postmenopausal women 
with osteoporosis, subcutaneous injection of denosumab every 6 months significantly reduced the 
risk of hip, vertebral and non-vertebral fractures [16]. An attractive feature of the 6-monthly 
regimen with denosumab is that adherence may be improved compared with weekly regimens, 
thereby improving effectiveness in real-life settings and preventing more fractures [17]. Recently, a 
2-year randomized open label study indeed demonstrated significantly greater treatment adherence 
and persistence for subcutaneous injection of denosumab every 6 months compared with oral 
alendronate once weekly [18, 19]. Risks ratio for denosumab compared with alendronate at 12 
months were estimated at 0.58 for non-adherence (p = 0.043) and 0.54 for non-persistence (p = 
0.049) [19]. 
With introduction of new (and more expensive) treatments, the economic value of newer agents 
compared with existing alternatives needs to be assessed. Health economic evaluations have 
become increasingly important to support priority setting in health care and help decision makers to 
efficiently allocate healthcare resources. It is therefore not surprising that studies on the cost-
effectiveness of denosumab have been recently performed. Understanding the different aspects of 
the evidence of cost-effectiveness of denosumab would be very useful for health care decision-
making and also to identify gaps in the current evidence that could inform future economic 
evaluations. This study was therefore designed to systematically review and critically appraise 
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existing economic evaluations of denosumab for the treatment of postmenopausal osteoporotic 
women.  
METHODS 
SEARCH STRATEGY 
A systematic literature search was conducted to find all published research articles as well as all 
research abstracts presented in various congresses. The literature search was conducted using 
various databases: Medline, Centre for Reviews and Dissemination databases, Cost-effectiveness 
Analysis Registry and the Cochrane Library for articles up to April, 30
th
 2012. In addition, congress 
abstracts were searched directly from four congress organizers: the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR), the European Congress for Clinical and 
Economic Aspects of Osteoporosis (ECCEO), the International Osteoporosis Foundation (IOF), and 
the American Society for Bone and Mineral Research (ASBMR). Abstracts presented at the ISPOR 
Annual International Meeting in June 2012 were also searched. For the ISPOR abstracts, the related 
congress posters were searched on the congress web site. 
The following search terms were used: denosumab AND (cost-effectiveness or cost-utility or 
economic or evaluation or cost) for research articles and the term ‘denosumab’ was used to find 
congress abstracts. Evaluation reports from the manufacturer or from different national agencies 
were not searched. Nevertheless, formal Health Technology Assessment (HTA) reports are covered 
by the searched HTA database and these were not excluded if found in the database search. 
Editorials or comments were excluded. The search was also restricted to English-language 
literature. 
SELECTION OF STUDIES 
We included full economic evaluation of denosumab (in one of the treatment arms) for the 
treatment of postmenopausal women with osteoporosis. A full economic evaluation was defined as 
the comparison of costs and outcomes, including cost-effectiveness analyses (CEAs) in which 
results are usually expressed as a cost per unit of effect (e.g. cost per fracture prevented gained), and 
cost-utility analyses (CUAs) in which results are generally expressed as a cost per quality-adjusted 
life year (QALY) gained [20]. Two reviewers (MH and WBS) independently applied these criteria 
to identify citations during title and abstract screening. Reference lists of identified economic 
evaluation were also manually searched. Congress abstracts that were published as full articles were 
excluded as well as duplicate abstracts reporting the same data. 
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Data extraction and critical appraisal 
Data were extracted using a standard collection form. We extracted study characteristics from 
articles related to: 1) study design (country, perspective, outcome measure, model type, time 
horizon, price year, discount rates, funding), 2) population, comparator and treatments 
characteristics (efficacy source, adherence, treatment duration, offset time, drug cost) and 3) study 
outcomes (results, sensitivity analyses). Reported incremental cost-effectiveness ratios (ICER) were 
presented in Euros, British pounds or US dollars, no other adjustments were made. A simple 
extraction form was used to extract information for congress abstracts including congress name, 
year/month, country, perspective, model, population, comparator, ICER and funding. Two 
reviewers (MH and WBS) independently extracted data from articles and congress abstracts.  
Quality of selected articles were appraised with the British Medical Journal (BMJ) checklist [21] by 
two independent reviewers (AB and CD), not being authors of any of the original articles. Thirty-
five items related to study design, data collection, analysis and interpretation of results were scored 
using “Yes”, “No”, “Not Clear”, “Substandard”, and “Not Applicable”. Discrepancies in rating 
were resolved by consensus and a third reviewer (MH) was consulted to reconcile disagreements. 
The methodological quality of the congress abstracts was not evaluated.  
RESULTS 
The initial database search identified 72 research articles and 113 congress abstracts; of which 18 
articles were excluded as duplicates (Figure 1). We reviewed all titles and abstracts of these articles 
and subsequently excluded 50 research articles and 105 congress abstracts that did not meet our 
inclusion criteria. Four abstracts were excluded because they were published as full articles [22-25] 
and one abstract was a duplicate result [26]. A total of four research articles [17, 27-29] and eight 
congress abstracts [30-37] fulfilled our inclusion criteria. Among the published articles, three of 
these were ‘original research’ [17, 27, 28] (funded by the manufacturer of denosumab, Amgen) and 
the last one provided a description of a dossier submitted by Amgen in UK and the subsequent 
NICE appraisal [29, 38]. 
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Figure 1| Literature search flow chart (electronic databases and congress proceedings) 
             
Source n 
ISPOR 
ECCEO-IOF 
ASBMR 
46 
29 
38 
 
Excluded 
Not cost-effectiveness 
Not osteoporosis 
 
Source n 
ISPOR 
ECCEO-IOF 
ASBMR 
8 
4 
1 
 
Excluded 
Published as full article (n=4) 
Duplicate result (n=1) 
 
Source n 
ISPOR 
ECCEO-IOF / ASBMR 
7 
1 
 
Excluded (n=18) 
All duplicate results 
 
Source n 
PubMed 
CRD 
CEA Registry 
Cochrane 
48 
11 
2 
11 
Included studies n 
Research articles 
 
54 
Excluded 
Not cost-effectiveness 
Not osteoporosis 
 
Included studies n 
Research articles 
 
4 
Electronic databases
   
Congress proceedings
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SELECTED ARTICLES 
Two studies were conducted in Belgium [27, 28], one in Sweden [17] and one in UK [29] (Table 1). 
Economic perspectives included societal (n=1) [17] and health care payer (n=3) [27-29]. All studies 
used a lifetime time horizon and were Markov models with quality-adjusted life-years (QALY) as 
the outcome measure. Markov models were analyzed using a cohort-based approach [17, 29] or an 
individual patient simulation [27, 28]. Discount rates varied between studies and were based on 
local guidelines for economic evaluations. Three studies were funded by the manufacturer of 
denosumab [17, 27, 28] and the last one was a review of the manufacturer submission to the 
National Institute of Clinical Excellence (NICE) in UK and the NICE appraisal funded by a UK 
Health Technology Assessment program [29]. 
Efficacy data from the FREEDOM Trial [16] that was published in 2009 was used in all studies. 
Treatment duration in modeling was assumed for a maximum of 3 [27, 28] or 5 [17, 29] years 
although all models used a lifetime horizon to capture the long-term effects of preventing fractures. 
Adherence to denosumab was included in the base-case in only two studies [17, 28]. For the main 
comparators, Hiligsmann et al. [28] incorporated both compliance and persistence, while Jonsson et 
al. [17] only included medication persistence. Treatment duration was assumed to linearly decline 
to zero after stopping therapy, for a maximum of 1-year [27-29] or over the same period as the time 
on treatment [17]. Two studies used the same assumption for denosumab and the comparators [17, 
29] while the effect of denosumab after stopping therapy was conservatively assumed to be shorter 
compared with the alternatives in another study [28]. None of the studies included side-effects for 
denosumab as the clinical trial reported no significant differences in the total incidence of adverse 
events and serious adverse events between subjects who received denosumab and those who 
received placebo [16]. In addition to drug cost (estimated at €415 [27, 28], €425 [17] and £366 [29] 
per year), all studies incorporated the cost of two yearly visits to general physicians (GPs) in the 
base-case. However, the Evidence Review of Group (ERG) commissioned by the NICE expressed 
concerns about this assumption, suggesting that denosumab might be flagged for administration and 
monitoring in secondary care only [29]. Nevertheless, assuming one dose of denosumab 
administrated per year in secondary care had a limited impact on the cost-effectiveness of 
denosumab [29]. 
Out of the four articles, fourteen comparisons between denosumab and alternative treatment were 
performed. Comparator treatments included no treatment (n=3), generic alendronate (n=2), branded 
alendronate (n=1), ibandronate (n=1), raloxifene (n=1), risedronate (n=2), strontium ranelate (n=2), 
teriparatide (n=1) and zoledronic acid (n=1). 
  
 
Table 1| Characteristics of published articles assessing the cost-effectiveness of denosumab in the treatment of osteoporosis 
First author Country Perspective Outcome 
measure 
Model type Time 
horizon 
Price 
year 
Discount rates 
(cost, QALY) 
Funding 
Hiligsmann et al., 2010 
[27] 
Belgium Health-care 
payer 
QALYs Markov: 
microsimulation 
Lifetime € 2009 3% - 1.5% Amgen 
Hiligsmann et al., 2011 
[28] 
Belgium Health-care 
payer 
QALYs Markov: 
microsimulation 
Lifetime € 2009 3% - 1.5% Amgen 
Jonsson et al., 2011 [17] Sweden Societal QALYs Markov: cohort Lifetime € 2008 3% - 3% Amgen 
Scotland et al., 2011 
[29] 
UK UK health and 
social care 
perspective 
QALYs Markov: cohort Lifetime £ 2009 3.5% - 3.5% NIHR 
HTA - 
Amgen 
QALY Quality-adjusted life-year 
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Results of the cost-effectiveness literature of denosumab are reported on Table 2. Overall, the ICER 
of denosumab falls below commonly accepted thresholds for cost-effectiveness. Although, in most 
countries, there are no generally accepted or recommended thresholds for cost-effectiveness, 
interventions with cost per QALY gained lower than €30,000-€60,000 were usually considered as 
‘good value for money’ in treating osteoporosis [39, 40]. Using a Belgian healthcare payer 
perspective, denosumab was deemed to be cost-effective compared with no treatment in patients 
with similar characteristics to those included in the FREEDOM Trial and in a population of patients 
that would be eligible to receive treatment in many European countries based on osteoporosis 
medication reimbursement guidelines, i.e. with BMD T-score ≤-2.5 or prevalent vertebral fracture 
[27]. The same authors further assessed the cost-effectiveness of denosumab compared with the 
most relevant alternatives (i.e. branded and generic oral bisphosphonates) [28]. The analysis 
demonstrated that denosumab was cost-effective compared with oral bisphosphonates (including 
generic alendronate) in the treatment of postmenopausal women with osteoporosis aged over 60 
years, assuming a willingness to pay of €40,000 per QALY gained. A sensitivity analysis suggested 
that results were influenced by adherence to oral bisphosphonates and fracture risk. In a Swedish 
setting using a societal perspective, denosumab was also shown to be cost-effective compared with 
generic alendronate, risedronate and strontium ranelate for typical Swedish women receiving 
osteoporosis medications [17]. In the UK, the cost-effectiveness of denosumab was demonstrated 
compared with no treatment, strontium ranelate, raloxifene, intravenous ibandronate and 
teriparatide [29]. The cost-effectiveness of denosumab versus zoledronic acid, which was 
considered by the ERG as the main comparator, is however uncertain, and is sensitive to the 
assumptions associated with the costs of administration of denosumab (i.e. two GPs visits per year 
or one dose of denosumab per year in secondary care). The ERG founded it difficult to separate 
denosumab and zoledronic acid on grounds of cost-effectiveness in UK [29]. Table 3 presents the 
appraisal of the original studies on the cost-effectiveness of denosumab (except the NICE appraisal 
[29]) using the BMJ criteria. Published articles are based on good-quality models that have been 
previously validated [41, 42]. Study design was generally clearly described. Studies did however 
not describe quantities of resource use separately from their unit costs, likely because in models no 
original costing studies were done but costs related to these events were derived from other sources. 
All studies reported incremental analyses and major outcomes were presented in a disaggregated 
and aggregated form. Only two studies reported stochastic data and performed probabilistic 
sensitivity analyses [27, 28], while the choice of variables for sensitivity analyses and the range 
over which they are varied were not fully reported. 
  
 
Table 2| Results of published articles assessing the cost-effectiveness of denosumab in the treatment of osteoporosis 
Article Population Comparator Results (ICER of denosumab vs comparator 
treatment) 
Hiligsmann et al., 
2010 [27] 
FREEDOM Trial* No treatment €28,441 
Women with BMD T-score ≤-2.5 
and no prior fracture 
No treatment €25,061 (60 y), €8948 (70 y), €-642 (80 y) 
Hiligsmann et al., 
2011 [28] 
Women aged 70 years with BMD 
T-score ≤-2.5 and no prior 
fracture 
Generic alendronate 
Branded alendronate 
Branded risedronate 
€22,220 
€14,120 
€-209 
Women aged 70 years with 
prevalent vertebral fracture 
Generic alendronate 
Branded alendronate 
Branded risedronate 
€14,166 
€19,718 
€4456 
Jonsson et al., 2011 
[17] 
Typical Swedish patient 
population** 
Generic alendronate 
Risedronate 
Strontium ranelate 
No treatment 
€27,090 
€11,545 
€5015 
€14,458 
Scotland et al., 2011 
[29] 
Women aged 70 years with a T-
score of -2.5 or less and no prior 
fracture 
Strontium ranelate 
Raloxifene 
No treatment 
Zoledronic acid (ZoL) 
Intravenous ibandronate 
Teriparatide (PTH) 
Dominant  
£9289  
£29,223  
ICER of Zol***: £70,900 
Dominant  
ICER of PTH***: £772,424 
Women aged 70 years with a T-
score of -2.5 or less with a prior 
fragility fracture 
Strontium ranelate 
Raloxifene 
No treatment 
Zoledronic acid (ZoL) 
Intravenous ibandronate 
Teriparatide (PTH) 
Dominant  
£2000 
£12,381  
ICER of ZoL***: £29,029 
Dominant  
ICER of PTH***: £451,269 
ICER Incremental cost-effectiveness ration (expressed in cost per QALY gained), Y years. 
* Women aged 72 years, T-score of -2.2 and 23.6% of those had prevalent vertebral fracture 
** Women aged 71 years, T-score≤-2.5 and a prevalence of morphometric vertebral fractures of 34% 
*** Incremental cost-effectiveness ratio of zoledronic acid or of teriparatide compared with denosumab 
  
  
Table 3| Results of quality appraisal of articles assessing the cost-effectiveness of denosumab: BMJ criteria 
 
Hiligsmann et al. 
2010 [27] 
Hiligsmann 
et al. 
2011[28] 
Jonsson et 
al. 2011 
[17] 
Study Design    
1 The research question is stated. Yes Yes Yes 
2 The economic importance of the research question is stated. Sub Yes Yes 
3 The viewpoint(s) of the analysis is (are) clearly stated and justified. Yes Yes Yes 
4 The rationale for choosing alternative programmes or interventions compared is stated. Yes Yes Yes 
5 The alternatives being compared are clearly described. Yes Yes Yes 
6 The form of the economic evaluation used is stated. Yes Yes Yes 
7 The choice of form of economic evaluation is justified in relation to the questions addressed. Yes Yes No 
Data Collection    
8 The source(s) of effectiveness estimates used is (are) stated. Yes Yes Yes 
9 Details of the design and results of effectiveness study are given (if based on a single study). NA NA NA 
10 Details of the methods of synthesis or meta-analysis of estimates are given  NA NA NA 
11 The primary outcome measures(s) for the economic evaluation are clearly stated. Yes Yes Yes 
12 Methods to value benefits are stated. Sub Sub Yes 
13 Details of the subjects from whom valuations were obtained were given. Sub Yes Yes 
14 Productivity changes (if included) are reported separately. NA NA No 
15 The relevance of productivity changes to the study question is discussed. No No No 
16 Quantities of resource use are reported separately from their unit costs. Sub Sub  Sub 
17 Methods for the estimation of quantities and unit costs are described. No Sub No 
18 Currency and price data are recorded. Yes Yes Yes 
19 Details of currency of price adjustments for inflation or currency conversion are given. Yes Yes Yes 
20 Details of any model used are given. Yes Yes Yes 
21 The choice of model used and the key parameters on which it is based are justified. Yes Yes Yes 
  
 
Analysis and Interpretation of Results    
22 Time horizon of costs and benefits is stated. Yes Yes Yes 
23 The discount rate(s) is (are) justified. Yes Yes Yes 
24 The choice of discount rate(s) is (are) justified. Yes Yes Yes 
25 An explanation is given if costs and benefits are not discounted. NA NA NA 
26 Details of statistical tests and confidence intervals are given for stochastic data. Yes Yes No 
27 The approach to sensitivity analysis is given. Yes Yes Sub 
28 The choice of variables for sensitivity analysis is justified. Sub Sub No 
29 The ranges over which the variables are varied are justified. Sub Sub No 
30 Relevant alternatives are compared. Sub Sub Sub 
31 Incremental analysis is reported. Yes Yes Yes 
32 Major outcomes are presented in a disaggregated as well as aggregated form. Yes Yes Yes 
33 The answer to the study question is given. Yes Yes Yes 
34 Conclusions follow from the data reported. Yes Yes Yes 
35 Conclusions are accompanied by the appropriate caveats. Yes Yes Yes 
 
NA Not Applicable, NC  Not Clear, Sub  Substandard 
  
COST-EFFECTIVENESS OF DENOSUMAB 
 
57 
 
SELECTED ABSTRACTS 
Most of the included congress abstracts (7 out of 8) were presented at different ISPOR meetings 
between 2009 and 2012. One study was presented at the ECCEO-IOF meeting. From the 7 included 
ISPOR abstracts, the related congress posters were available in 4 cases [31, 32, 35, 37]. Five 
abstracts were funded by the manufacturer of denosumab and three did not provide information 
about funding sources. 
Characteristics and results from these abstracts are reported in Table 4. Research was conducted by 
8 different authors in 6 different countries. Abstracts during 2009-2011 provided further evidence 
on the cost-effectiveness of denosumab in other European settings, suggesting that denosumab is 
also cost-effective compared with current treatment options in Greece, Portugal, Scotland, Spain 
and UK [30, 31, 35-37].  
Recently, three abstracts reported the cost-effectiveness of denosumab in the Unites States at the 
ISPOR Annual International Meeting in June 2012, with contrasting results. Based on a previously 
validated model, Parthan et al. showed that denosumab represented a good value for money 
compared to branded bisphosphonates in the overall postmenopausal population and was either 
cost-effective or dominant compared with generic alendronate in the higher-risk subgroups [32]. 
Jiang et al. also compared denosumab and generic alendronate in US using a new type of model and 
concluded that denosumab was not cost-effective [33]. Finally, Beaubran et al. suggested that 
denosumab was not cost-effective compared with raloxifene [34]. Unfortunately, posters were not 
available for these two last congress abstracts and limited information was available on the new 
model structure and the efficacy data used in the abstract, making it difficult to assess the quality of 
these evaluations. 
  
 
Table 4| Characteristics and results of congress abstracts assessing the cost-effectiveness of denosumab in the treatment of osteoporosis 
Year 
(month) 
Congress First author Country Perspective Population Comparators ICER of denosumab 
vs comparator 
Funding 
2009 (09) ASBMR 
and IOF-
ECCEO 
Ström UK Health care 
payer 
Women aged 70 years with 
BMD T-score of -2.5 
Risedronate 
Placebo 
£14,300 
£10,700 
Amgen 
2011 (05) ISPOR Cristino Portugal National 
health 
service 
NR Alendronate-
colecalciferol 
€14,487 NR 
2011 (11) ISPOR Davies Scotland National 
health 
service 
Women aged 70 years with 
BMD T-score of -2.5 (and no 
prior fracture) 
Strontium ranelate 
Ibandronate 
Raloxifene 
No treatment 
Zoledronate (ZoL) 
Dominant 
Dominant 
£4,339 
£22,380 
ICER of ZoL = 
£120,000 
Amgen  
2011 (11) ISPOR Darba Spain National 
healthcare 
system 
Women aged 65years with 
BMD T-score of -2.5 and a 
prevalence 
of morphometric vertebral 
fractures of 36% 
No treatment 
Generic alendronate 
Generic risedronate 
Ibandronate 
Strontium ranelate 
€17,345 
€15,397 
€14,543 
Dominant 
Dominant 
Amgen 
2011 (11) ISPOR Athanasakis Greece Third party 
payer 
FREEDOM TRial No treatment 
Alendronate 
Ibandronate 
Risedronate 
Strontium ranelate 
€18,813 
€24,784 
€13,727 
€18,436 
€11,114 
Amgen 
2012 (06) ISPOR Parthan USA Third party 
payer 
High risk subgroups (Overall 
PMO population) 
Risedronate 
 
Ibandronate 
 
Generic alendronate 
Dominant (NR) 
Dominant 
(Dominant) 
$28,200 ($103,000) 
Amgen 
2012 (06) ISPOR Jiang USA Societal Not clear Generic alendronate $2,111,647 NR 
2012 (06) ISPOR Beaubran USA Managed 
care 
Women aged over 65 years with 
BMD T-score ≤ -2.5 
Raloxifene Dominated NR 
 
BMD Bone mineral density, ICER Incremental cost-effectiveness ratio, NR Not reported, PMO Postmenopausal osteoporosis 
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EXPERT COMMENTARY 
Denosumab represents a new therapeutic option for the treatment of postmenopausal women at high 
risk of fractures. The cost-effectiveness of denosumab in this indication has been assessed against 
multiple treatments in several studies. In these analyses, denosumab has been considered to be cost-
effective compared with most treatment options (including oral treatments). The cost-effectiveness 
of densoumab versus once yearly injection of zoledronic acid remains however uncertain, 
depending mainly on assumptions about the costs of administration of denosumab. 
This review identified 4 published articles based on good-quality models and 8 additional congress 
abstracts that estimated the cost-effectiveness of denosumab in the treatment of postmenopausal 
osteoporotic women. Published articles were only conducted in three European countries (Belgium, 
Sweden and UK). Congress abstracts suggest that denosumab is likely to be cost-effective in other 
European countries with similar characteristics. The transferability of economic evaluations across 
jurisdictions could however be uncertain as differences in the incidence of disease, the availability 
of health resources, clinical practice patterns, and relative prices may impact cost-effectiveness 
[43]. Recently, research abstracts about the cost-effectiveness of denosumab in US were presented 
at the ISPOR congress (2012) and we could therefore expect full articles in non-European countries 
in the near future. 
Other gaps were identified. First, adherence and persistence with osteoporosis medications were not 
incorporated in all studies, despite their potential impact on the cost-effectiveness results [13, 44]. 
In particular, when comparing drugs with potential differences in adherence and persistence (e.g. 
denosumab versus oral drug treatment), the lack of inclusion of these concepts could bias the results 
and lead to suboptimal allocation of resources [13]. Recently published data on adherence and 
persistence to denosumab compared with alendronate would definitely be interesting for further 
cost-effectiveness analyses of denosumab [18, 19]. There are also some investigations of 
denosumab in particularly high risk patients, suggesting a better cost-effectiveness profile of this 
drug in this particular clinical condition [45, 46]. 
Second, no direct comparisons between denosumab and other treatments are currently available. 
Indirect comparisons of efficacy between drugs are less robust because of different baseline 
characteristics of the populations studied and overlapping confidence intervals for the effect of 
treatment [47]. Further research would therefore be required to confirm the findings, ideally with 
head-to-head observational studies of denosumab compared with oral bisphosphonates, to provide 
more robust data. Further studies are also required to evaluate adverse events and long-term safety 
of denosumab in real-world clinical practice that could potentially be included in further cost-
effectiveness analyses. 
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Further investigation is also needed to assess the effect of denosumab after stopping therapy. Recent 
data suggest that the treatment benefit achieved (changes in BMD) with 2 years of denosumab 
therapy was reversed within 2 years of treatment discontinuation, and remained above those of the 
group previously treated with placebo [48]. There is however no consensus on this effect, including 
potential differences with other osteoporotic treatments. Another issue is the monitoring costs of 
denosumab. Existing economic evaluations incorporated the cost of two yearly visits to general 
physicians, but the ERG in the UK expressed concerns about this assumption, suggesting that 
denosumab might be flagged for administration and monitoring in secondary care only. Finally, 
assessing the value of perfect information would be useful to inform policy decisions about future 
research in this topic [49]. 
We followed recommendations for conducting reviews of economic evaluations [50]. Two 
independent reviewers were used for literature search, data extraction and quality assessment. 
Critical appraisal of published articles was done by two authors that were not authors of the original 
articles, using the BMJ checklist, as recommended [50]. Some discrepancies were observed 
between reviewers, but were only a matter of interpretation. The critical appraisal of congress 
abstracts is not meaningful as too little information is included in congress abstracts which must 
therefore be interpreted with the greatest caution. 
Most studies included in these review were funded by the manufacturer of denosumab: three 
published articles out of the four and five of the eight congress abstracts. However, as reported in a 
case study in bisphosphonates, the funding source did not seem to significantly affect the reporting 
of low or high incremental cost-effectiveness ratios in the treatment of osteoporosis [51]. In 
addition, models used in funding studies were previously validated and have been used to assess the 
cost-effectiveness of other osteoporosis medications [41, 42]. 
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FIVE-YEAR VIEW 
Poor adherence to therapy represents a major problem in the treatment of osteoporosis. Improving 
medication adherence is becoming urgently needed and the use of longer dosing regimen could be 
an effective way to enhance medication adherence. Administered as a subcutaneous injection every 
six months, denosumab is a novel attractive drug for the treatment of osteoporosis. Denosumab also 
represents a cost-effective alternative compared with existing oral osteoporosis treatments, and may 
be considered as a first-line treatment option for patients at high risk of fracture. As a future 
standard of treatment, it is likely that there will be a number of cost-effectiveness articles of 
denosumab in the future. In particular, one would expect cost-effectiveness articles of denosumab in 
non-European countries, as well as using real-world adherence and effectiveness data. 
KEY ISSUES 
 Denosumab is a novel agent for the treatment of osteoporosis in postmenopausal women 
with demonstrating efficacy in reducing the risk of hip, vertebral and non-vertebral 
fractures. 
 The cost-effectiveness of denosumab in the treatment of postmenopausal women with 
osteoporosis has been evaluated in various published research articles and abstracts 
presented at various congresses. 
 In most economic evaluations, denosumab has been deemed to be cost-effective 
compared with first-line and second-line drug therapies in the treatment of 
postmenopausal women with high risk of fractures. 
 Further articles on the cost-effectiveness analyses of denosumab are expected in non-
European countries and using real-world adherence and effectiveness data. 
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ABSTRACT  
BACKGROUND: Given the limited availability of healthcare resources and the recent introduction of 
new anti-osteoporosis drugs, the interest in cost-effectiveness of drugs in postmenopausal 
osteoporosis remains and even increases. 
OBJECTIVE: This study aims to identify all recent economic evaluations on drugs for 
postmenopausal osteoporosis, to critically appraise the reporting quality and to summarize the 
results. 
METHODS: A literature search using Medline, the National Health Service Economic Evaluation 
database and the Cost-Effectiveness Analysis Registry was undertaken to identify original articles 
published between January 1, 2008 and December 31, 2013. Studies that assessed cost-effectiveness 
of drugs in postmenopausal osteoporosis were included. The Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS) statement was used to assess the quality of reporting of 
these articles. 
RESULTS: Of 1,794 articles identified, 39 studies fulfilled the inclusion criteria. They were 
conducted in 14 different countries and 9 active interventions were assessed. When compared with 
no treatment, active osteoporotic drugs were generally cost-effective in postmenopausal women 
aged over 60-65 years with low bone mass, especially those with prior vertebral fractures. Key 
drivers of cost-effectiveness included individual fracture risk, medication adherence, selected 
comparators and country-specific analyses. Quality of reporting varied between studies with an 
average score of 17.9 out of 24 (range from 7 to 21.5). 
CONCLUSION: This review found a substantial number of published cost-effectiveness analyses of 
drugs in osteoporosis in the last six years. Results and critical appraisal of these articles can help 
decision makers when prioritizing health interventions and can inform the development of future 
economic evaluations. 
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INTRODUCTION 
Osteoporosis represents a major public health problem, especially in the Western world. It is 
estimated that 27.5 million of people have osteoporosis in the 27 countries of the European Union 
[1]. In 2010, approximately 3.5 million new fractures occurred in these countries and the economic 
impact of these fractures was estimated to be nearly €37 billion and accounted for 1,180,000 
quality-adjusted life years lost [1]. In the Unites States, osteoporosis is responsible for more than 2 
million fractures every year, and these are associated with costs estimated to be US$19 billion in 
2005, rising to US$25.3 billion by 2025 [2].  
Considering the limited availability of healthcare resources alongside major recent innovations in 
the management of osteoporosis, health technology assessment is increasingly important to help 
decision makers to efficiently allocate healthcare resources [3]. In 2007, two systematic reviews [4, 
5] were published suggesting that oral bisphosphonates are cost-effective for the prevention and 
treatment of osteoporosis in women aged over 70 years, particularly in patients with risk factors for 
fracture. Over recent years, new treatment strategies have become available to prevent and treat 
osteoporosis, including bazedoxifene, denosumab, ibandronate, strontium ranelate and zoledronic 
acid [6]. Evidence about the safety and efficacy of these drugs has been provided [6, 7] and 
consideration of the cost-effectiveness of these new interventions has been adressed  [8, 9]. 
An overview of the recent literature of cost-effectiveness analyses of drugs in postmenopausal 
osteoporosis would thus be important to help decision makers when prioritizing health 
interventions, to identify gaps in the current evidence and to inform the development of future 
economic evaluations. We therefore undertook a systematic review of the literature to identify 
recent economic evaluations of drugs for postmenopausal osteoporosis. Using narrative summaries, 
the review also aimed to provide insight into key drivers of cost-effectiveness ratios. Because the 
interpretation of the results depends on the quality of conducting and reporting studies, the quality 
of reporting of these economic evaluations was appraised using the recently developed 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement [10, 11].  
METHODS 
LITERATURE SEARCH 
A literature search was conducted using Medline, the National Health Service Economic Evaluation 
database (NHS EED) and the Cost-Effectiveness Analysis (CEA) Registry. We restricted our 
analysis to articles published after 2008, January 1st, since prior articles were covered in prior 
reviews [4, 5]. Titles and abstracts were initially searched in Medline using the following search 
algorithm: ‘osteoporosis OR fracture AND cost-effectiveness OR cost-utility OR economic OR 
cost’ (between 1/01/2008 and 31/06/2013). The search words ‘osteoporosis’ and ‘fractures’ were 
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used in NHS EED database and the CEA Registry. The search was restricted to English-language 
literature. Reference lists of identified economic evaluations and reviews [12] were manually 
searched. A last update using the same methodology was performed in January 2014 including 
articles published between 1/07/2013 and 31/12/2013. 
SELECTION OF STUDIES 
In a first step, we included in this systematic review full economic evaluations for the treatment or 
prevention of osteoporosis that compared at least two alternatives in terms of costs and outcomes, 
including cost-effectiveness and cost-utility analyses. In the second step, we excluded review 
articles, economic evaluations in male populations and other specific populations (such as women 
with glucocorticoid-induced osteoporosis), studies about screening strategies and intervention 
thresholds (using hypothetical treatment) as well as evaluations that did not include a drug (by 
example model of care, lifestyle or nutritional intervention) or that focused on improving 
medication adherence. Three reviewers (MH, SS, CW) independently applied these criteria to 
identify articles during title and abstract screening. A consensus meeting was used to resolve 
discrepancies. 
DATA EXTRACTION AND QUALITY ASSESSMENT 
Data were extracted using a standardized extraction table. We extracted study characteristics related 
to publication (year, journal name), study design (country, perspective, outcome measure, model 
type, time horizon, discount rates and funding), population, comparators and results. Two reviewers 
(MH and WBS) extracted data of the articles. Incremental cost-effectiveness ratios were reported as 
in the articles and no adjustment for year or purchasing power parity was done. Some key-drivers of 
cost-effectiveness such as fracture risk and medication adherence were also identified and reported. 
Studies were then appraised for quality of reporting using the CHEERS statement [10, 11]. This 
checklist was produced with the aim of harmonizing the presentation of information and thus 
raising the quality standard of economic evaluations and improving interpretation of systematic 
reviews of such analyses. At least two reviewers (MH, SE, WBS, BR, SS, CW and/or AB) 
independently appraised the studies. Twenty-four items addressed in six categories (title and 
abstract, introduction, methods, results, discussion and other) and were scored using ‘Yes’ (reported 
in full), ‘Partially reported’, ‘No’ (not reported), ‘Not Applicable’. In order to estimate a score of 
reporting, we assigned a score of 1 if the fulfilled the requirement of reporting for that item 
completely, 0.5 for partial report and otherwise zero. Therefore, the maximum score for an article 
that reported completely all information was 24. 
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RESULTS 
STUDY SELECTION PROCESS 
Figure 1 shows the flow chart for the identification of studies. The initial database search identified 
1,794 articles, of which 117 were excluded as duplicates. After screening by title and abstract, 94 
full economic evaluations were identified. Of those, only 42 remained after the second step. Studies 
were mainly excluded because they did not include a drug (n=15), or because they concerned 
screening and intervention thresholds (n=15) or the burden of the improvement of medication 
adherence (n=8). Other excluded articles concerned male populations (n=2), specific populations 
(n=4), nutrition (n=4) or were about surgery (n=4), methodological work (n=1) or an abstract (n=1). 
After reading the full-text of the remaining 42 articles, 6 articles were excluded because they were 
not original studies or were not written in English language, or concerned screening programs or 
methodological issues. Thirty-six studies were then identified between 2008, January 1st and 2013, 
June, 30th. Further three articles were identified after the update of the literature till 2013, 
December, 31st. 
 OVERVIEW OF INCLUDED STUDIES 
The characteristics of included studies are reported in Table 1. Twenty four of the 39 studies were 
conducted in the period 2008-2010 and fifteen between 2011 and 2013. Articles were mainly 
published in osteoporosis journals such as Osteoporosis International (n=10) and Bone (n=7), but 
also in health economic journals such as Journal of Medical Economics (n=4), Value in Health 
(n=2), Pharmacoeconomics (n=1) or Applied Health Economics & Health Policy (n=1). Most 
studies were conducted in Europe (n=29) (and especially in United Kingdom (n=9), Belgium (n=8) 
and Sweden (n=8)), followed by the United States and Canada (n=9) and Japan (n=2). Five articles 
considered several countries in the analysis [13-17]. 
A societal perspective was used in 10 studies and all studies used quality-adjusted life-years 
(QALY) as outcome except the article of Fardellone et al. [18] that used fractures avoided as 
outcome. Model-based cost-effectiveness analyses were used in all studies. Twenty-eight articles 
used a Markov cohort model while 8 studies used a microsimulation Markov model (mainly the 
model developed by Hiligsmann et al.[19]) and one used a discrete-event simulation model [13]. 
Seven studies applied fixed time horizon such as 3, 5 or 10 years [20-22, 18, 15, 23, 24], while the 
remaining studies (n=32) considered a lifetime horizon. Seven studies were not funded by 
pharmaceutical companies [25, 22, 19, 26-28, 24] and two did not mention the source of funding 
[17, 29].  
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Figure 1| Literature search flow chart 
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Table 2 presents characteristics of the studied population, the active intervention and comparator 
and the main results of the articles. Different study populations were investigated, including women 
with a low bone mass density based on the definition of the World Health Organization (bone 
mineral density (BMD) T-score of -2.5) [30], women with previous vertebral fractures, and 
populations similar to that of the clinical trials [31-34]. Fracture risk algorithms such as FRAX® 
that represents the 10-year probability of a major fracture and of hip fracture [35], were increasingly 
used to assess the cost-effectiveness of drugs among patients differing in specific combinations of 
clinical risk factors [36, 14, 37, 38, 26, 27, 39]. 
Nine active interventions were included in the studies, i.e. alendronate, bazedoxifene, denosumab, 
hormone therapy, ibandronate, raloxifene, risedronate, teriparatide and zoledronic acid. Generic 
alendronate was included in 9 studies [20, 40-43, 26, 27, 44, 39, 23] while no treatment was used as 
comparator in 22 of the 39 studies (56.4%). Eleven studies included at more than two active 
interventions in their analysis [13, 32, 18, 40, 45, 42, 15, 43, 44, 39, 24]. 
When compared with no treatment, active osteoporotic drugs (such as alendronate [19, 41, 15, 46, 
26], bazedoxifene [14, 47], denosumab [33, 44, 39], raloxifene [38], risedronate [31, 48], strontium 
ranelate [36, 49], teriparatide [37, 50] and zoledronic acid [13]) were generally cost-effective, at 
commonly-accepted threshold for cost-effectiveness (about 45,000 € per QALY gained), in 
postmenopausal women aged over 60-65 years with low bone mass. In women with additional 
clinical risk factors such as prior fractures, active treatments could even be cost-effective from the 
age of 50 years [26]. Several drug therapies were also reported to be cost-saving in women aged 
over 80 years [49, 41, 26], meaning that the averted costs resulting from prevented fractures exceed 
the cost of the intervention.  
Cost-effectiveness analyses among active comparators revealed that denosumab was cost-effective 
compared with many other osteoporotic agents including generic alendronate, especially in the 
high-risk subgroups [32, 42-44]. When using the subgroup analysis of women at higher risk of 
fractures, bazedoxifene was dominant compared with another selective estrogen receptor modulator 
(i.e. raloxifene) in three studies [21, 51, 16]. One study showed that strontium ranelate was cost-
effective compared with risedronate [45] while two studies suggests that risedronate dominated 
generic alendronate [20, 23]. Zoledronic acid was shown to be cost-effective compared with 
branded bisphosphonates [13] and Murphy et al. [50] concluded that teriparatide was cost-effective 
compared with oral bisphosphonates in severe postmenopausal osteoporosis. 
  
 
Table 1| Characteristics of cost-effectiveness analyses of drugs for postmenopausal osteoporosis 
 
Study (year)  Journal Country Perspective Outcome 
measure 
Model type Time 
horizon 
Discount 
rates 
Industry 
funding  
1-Akehurst (2011) 
[13] 
Journal of Medical 
Economics 
Finland, 
Norway, 
Netherlands 
Healthcare payer QALY Discrete-event 
individual-patient 
simulation model 
Lifetime Not reported Novartis 
2-Alzahouri (2013) 
[25] 
Joint Bone Spine France Healthcare system QALY Markov cohort 
model 
Lifetime 4%, 4% No 
3-Berto (2010) [20] Aging Clinical and 
Experimental 
Research 
Italy Healthcare system QALY Markov cohort 
model 
6 years 3%, 3% Sanofi-
Aventis 
4-Borgstrom 
(2010) [36] 
Osteoporosis 
International 
UK Healthcare payer QALY Markov cohort 
model 
Lifetime 3.5%, 3.5% Servier 
5-Borgstrom 
(2010) [31] 
Osteoporosis 
International 
UK Healthcare payer QALY Markov cohort 
model 
Lifetime 3.5%, 3.5% Alliance for 
Better Bone 
Health 
6-Borgstrom 
(2011) [14] 
Osteoporosis 
International 
France, 
Germany, 
Italy, Spain, 
Sweden, UK 
Healthcare payer QALY Markov cohort 
model 
Lifetime 3%, 3% for all 
countries 
except UK 
3.5%, 3.5% 
Wyeth 
7-Borgstrom 
(2010) [37] 
Journal of Medical 
Economics 
Sweden Societal QALY Markov cohort 
model 
Lifetime 3%, 3% Lilly Europe 
8-Chau (2012) [32] Journal of Medical 
Economics 
Canada Public payer QALY Markov cohort 
model 
Lifetime 5%, 5% Amgen 
9-Darbà (2013) 
[21] 
Clinicoeconomics 
Outcomes Research 
Spain Healthcare payer QALY Markov cohort 
model 
Until patients 
were 82 years 
of age 
3%, 3% Pfizer 
10-Ding (2008) 
[22] 
Journal of Bone and 
Mineral Metabolism 
Japan Healthcare payer QALY State transition 
model 
3 years 5%, 5% No 
11-Fardellone 
(2010) [18] 
Joint Bone Spine France Healthcare payer Fractures 
avoided 
SImulation-based 
models 
3 years Not reported Novartis 
12-Grima (2008) 
[40] 
Osteoporosis 
International 
Canada Healthcare payer QALY Markov cohort 
model 
5 years 5%, 5% Alliance for 
Better Bone 
Health 
13-Hiligsmann 
(2013) [51] 
Journal of Bone & 
Mineral Research 
Belgium Healthcare payer QALY Markov 
microsimulation 
model 
Lifetime 3%, 1.5% Pfizer 
  
 
14-Hiligsmann 
(2010) [45] 
Bone Belgium Healthcare payer QALY Markov 
microsimulation 
model 
Lifetime 3%, 1.5% Servier 
15-Hiligsmann 
(2010) [49] 
Osteoporosis 
International 
Belgium Healthcare payer QALY Markov 
microsimulation 
model 
Lifetime 3%, 1.5% Servier 
16-Hiligsmann 
(2009) [19] 
Value in Health Belgium Healthcare payer QALY Markov 
microsimulation 
model 
Lifetime 3%, 1.5% No 
17-Hiligsmann 
(2010) [41] 
Calcified Tissue 
International 
Belgium Healthcare payer QALY Markov 
microsimulation 
model 
Lifetime 3%, 1.5% Novartis 
18-Hiligsmann 
(2010) [33] 
Bone Belgium Healthcare payer QALY Markov 
microsimulation 
model 
Lifetime 3%, 1.5% Amgen 
19-Hiligsmann 
(2011) [42] 
Pharmacoeconomics Belgium Healthcare payer QALY Markov 
microsimulation 
model 
Lifetime 3%, 1.5% Amgen 
20-Ivergard (2010) 
[38] 
Bone US Societal QALY Markov cohort 
model 
Lifetime 3%, 3% Eli Lilly 
21-Jansen (2008) 
[15] 
Current Medical 
Research & Opinion 
UK, 
Netherlands 
Healthcare payer QALY Markov model 10 years 4%, 4% (NL) – 
(3.5%, 3.5% 
UK) 
Merck & Co 
22-Jonsson (2011) 
[43] 
Osteoporosis 
International 
Sweden Societal QALY Markov cohort 
model 
Lifetime 3%, 3% Amgen 
23-Kanis (2008) 
[26] 
Bone UK Healthcare payer QALY Markov cohort 
model 
Lifetime 3.5%, 3.5% No 
24-Kanis (2008) 
[27] 
Osteoporosis 
International 
UK Healthcare payer QALY Markov cohort 
model 
Lifetime 3.5%, 3.5% No 
25-Kim (2014) [16] Osteoporosis 
International 
Belgium, 
France, 
Germany, 
Ireland, Italy, 
Spain  
Sweden , UK 
Healthcare payer QALY Markov cohort 
model 
Lifetime 3.0%, 3% for 
all countries, 
except for 
the UK (3.5%, 
3.5%) and 
Ireland (4.0%, 
4.0%) 
Pfizer 
26-Lekander 
(2008) [17] 
Bone Sweden, UK, 
US 
Societal QALY Markov cohort 
model 
Lifetime Not reported NR 
  
  
 
27-Lekander 
(2009) [67] 
Journal of Women 
Health 
US Societal QALY Markov cohort 
model 
Lifetime 3%, 3% Wyeth 
28-Lippuner (2012) 
[46] 
Osteoporosis 
International 
Switzerland Societal QALY Markov cohort 
model 
Lifetime 3%, 3% MSD 
29-Moriwaki 
(2013) [68] 
Journal of Bone and 
Mineral Metabolism 
Japan Healthcare payer QALY Markov cohort 
model 
Lifetime 3%, 3% Pfizer 
30-Murphy (2012) 
[50] 
BMC 
Musculoskeletal 
Disorders 
Sweden Healthcare payer QALY Markov 
microsimulation 
model 
Lifetime 3%, 3% Lilly 
31-Parthan (2013) 
[44] 
Applied Health 
Economics & 
Health Policy 
US US third-party 
payer 
QALY Markov cohort 
model 
Lifetime 3%, 3% Amgen 
32-Pham (2011) 
[28] 
Journal of American 
Geriatrics Society 
US Societal QALY Markov cohort 
model 
Lifetime 3%, 3% No 
33-Salpeter (2009) 
[29] 
American Journal of 
Medicine 
US Societal QALY Markov cohort 
model 
Lifetime 3%, 3% NR 
34-Seeman (2010) 
[34] 
Bone Sweden Societal QALY Markov cohort 
model 
Lifetime 3.5%, 3.5% Servier 
35-Strom (2010) 
[47] 
Bone Sweden Societal QALY Markov cohort 
model 
Lifetime 3%, 3% Pfizer 
36-Strom (2013) 
[39] 
Osteoporosis 
International 
UK Healthcare payer QALY Markov cohort 
model 
Lifetime 3.5%, 3.5% Amgen 
37-Thompson 
(2010) [23] 
Value in Health Germany Healthcare payer QALY Markov cohort 
model 
5 years 3%, 3% Alliance for 
Better Bone 
Health 
38-Tosteson (2008) 
[24] 
The American 
Journal of Managed 
Care 
US Healthcare payer QALY Markov cohort 
model 
10 years 3%, 3% No 
39-Wasserfallen 
(2008) [48] 
Journal of Medical 
Economics 
Switzerland Healthcare payer QALY Markov cohort 
model 
Lifetime 3%, 3% Sanofi-
Aventis 
NR Not Reported, QALY Quality-Adjusted Life-Years 
  
  
 
Table 2| Results of cost-effectiveness analyses of drugs for postmenopausal osteoporosis 
 
Study (year)  Population Comparators Results 
1-Akehurst (2011) 
[13] 
Postmenopausal women aged 
50-80 years who have 
experienced one previous 
fracture and have a T-score of -
2.5 
2006 
Finland, 
2007 
Netherlands 
Zoledronic vs calcium/vitamin D, 
bisphosphonates 
The ICER compared with calcium/vitamin D ranged from 
being cost-saving in all age groups in Norway, to €19,000 
in Finland and €22,300 in Netherlands. 
Compared with the other branded bisphosphonates, 
zoledronic acid was cost-saving in many scenarios. 
Zoledronic acid may also be cost-effective compared with 
generic alendronate 
2-Alzahouri (2013) 
[25] 
Postmenopausal 70-year-old 
woman with a T-score of -2.5 
2011 Branded alendronate vs no treatment 
 
ICER compared to no treatment ranged from € 104,183 to 
€ 413,473 per QALY when FRAX decreased from 10 to 
3%  
3-Berto (2010) [20] Postmenopausal women aged 
≥ 65 years with a previous 
vertebral fracture 
NR Risedronate vs generic alendronate ICER ranged from €36,099 (age 65-69) to cost-saving 
(from age 75-79) 
4-Borgstrom (2010) 
[36] 
Postmenopausal women aged 
over 50 years using FRAX 
2006 Strontium ranelate vs no treatment At a threshold of £30,000 per QALY, strontium 
ranelate was generally cost-effective in women from an 
age of 65 years with prior fracture at a T-score of -2.5) 
and in women with a prior fracture (and no information 
on BMD)      
5-Borgstrom (2010) 
[31] 
Postmenopausal women aged 
over 50 years using FRAX 
2006 Risedronate vs no treatment Treatment was cost-effective (at a threshold of £30,000 
per QALY) from the age of 65 years and at all ages in 
women who had previously sustained a fragility fracture. 
6-Borgstrom (2011) 
[14] 
Postmenopausal women aged 
over 60 years using FRAX 
2008 Bazedoxifene vs no treatment ICER ranged from cost-saving (Sweden) to €105,450 
(Spain) in 70-year-old women with a T-score of -2.5 and 
a prior fracture  
7-Borgstrom (2010) 
[37] 
Women aged 70 years with T-
score of -2.7 and 3.3 previous 
fractures (European Forsteo 
Observational Study) 
2007 Teriparatide and PTH(1-84) vs no 
treatment 
The cost per QALY gained of teriparatide vs. no 
treatment was estimated at €43,473 and PTH(1-84) was 
estimated at €104,396 
8-Chau (2012) [32] Women aged 72 years with T-
score of -2.16 and 24% prevalent 
vertebral fracture (FREEDOM 
trial) 
2010 Denosumab vs usual care (no therapy, 
alendronate, risedronate, raloxifene) 
ICER for denosumab vs alendronate was CAN$60,266 
and CAN$27,287 at high fracture risk 
9-Darbà (2013) [21] Women aged 55-82 years with 
established osteoporosis and a 
high risk of fracture 
2010 Bazedoxifene vs raloxifene The ICER showed bazedoxifene to be the dominant 
treatment strategy 
  
  
 
10-Ding (2008) [22] Women aged 55 and over and 
treating with risedronate 
2002 Risedronate vs no treatment For women with a vertebral fracture in the previous 2 
years, the costs per QALY gained were below a threshold 
of $100000 for women aged 70 years or older 
11-Fardellone 
(2010) [18] 
Women with postmenopausal 
osteoporosis 
2007 Zoledronic acid vs current treatment 
strategies 
Costs per vertebral fracture avoided was €1497 vs €1685 
12-Grima (2008) 
[40] 
Postmenopausal women aged 
over 65 years 
2006 Branded risedronate vs generic or 
branded alendronate 
Incremental cost per QALY gained of CAN$3,877 for 
risedronate compared to generic alendronate 
13-Hiligsmann 
(2013) [51] 
Women aged 70 years with T-
score ≤-2.5 
2010 Bazedoxifene vs raloxifene Treatments were equally cost-effective based on efficacy 
data from the overall clinical trial. In the subgroup 
analysis of women at higher risk of fractures, 
bazedoxifene was dominant in most of the simulations 
14-Hiligsmann 
(2010) [45] 
Postmenopausal women aged 
over 75 years with T-score ≤-2.5 
or with prevalent vertebral 
fracture (PVF) 
2006 Strontium ranelate vs no treatment 
Strontium ranelate vs risedronate 
Strontium ranelate was dominant versus risedronate for 
women with osteoporosis aged over 75 years and for 
women with PVF aged 80 years. The cost per QALY 
gained of strontium ranelate compared with risedronate at 
75 years of age was €11,435 for women with PVF 
15-Hiligsmann 
(2010) [49] 
Postmenopausal women aged 
over 70 years with T-score ≤-2.5 
or with prevalent vertebral 
fracture 
2006 Strontium ranelate vs no treatment For women with a T-score≤ -2.5, the costs per QALY 
gained of strontium ranelate were respectively €15,096 
and €6,913 at 70 and 75 years of age while these values 
were €23,426 and €9,698 for women with prevalent 
vertebral fractures. At the age of 80 years, strontium 
ranelate was found to be cost-saving 
16-Hiligsmann 
(2009) [19] 
Women aged 70 years with a 
twofold increase in the fracture 
risk of the average population 
2006 Alendronate vs no treatment ICER of €9,105 and €15,325 under full and realistic 
adherence assumptions, respectively 
17-Hiligsmann 
(2010) [41] 
Women aged 65 years with a 
T-score of -2.5 
2006 Branded bisphosphonates (and generic 
alendronate) vs no treatment 
The costs per QALY gained, for branded bisphosphonates 
(and generic alendronate), were estimated at €19,069 
(€4,871), €32,278 (€11,985), and €64,052 (€30,181) for 
MPR values of 100, 80, and 60%, respectively, assuming 
real-world persistence. These values were €16,997 
(€2,215), €24,401 (€6,179), and €51,750 (€20,569) for the 
same MPR than above, respectively, assuming full 
persistence. 
18-Hiligsmann 
(2010) [33] 
Women aged 72 years, T-score 
of -2.2 and 23.6% with prevalent 
vertebral fracture (FREEDOM 
trial) 
2009 Denosumab vs no treatment The cost per QALY gained was €28,441. This value 
decreased to €15,532 and to €11,603 for women with a T-
score of -2.5 or prevalent 
vertebral fracture, respectively 
  
  
 
19-Hiligsmann 
(2011) [42] 
Postmenopausal women aged 
over 60 years with T-score ≤-2.5 
or with prevalent vertebral 
fracture 
2009 Densoumab vs oral bisphosphonates 
(branded risedronate, branded and 
generic alendronate) 
Denosumab was cost effective compared with branded 
alendronate and risedronate at a threshold value of 
€30,000 per QALY.                                                                                                         
The cost-effectiveness of denosumab compared                                                                                                                                                              
with generic alendronate was estimated at €38,514, 
€22,220 and €27,862 per QALY for women aged 60, 70 
and 80 years, respectively, with T-scores of -2.5 or less.  
20-Ivergard (2010) 
[38] 
Postmenopausal women aged 
55, 60 and 65 years using FRAX 
2008 Raloxifene vs no treatment The cost per QALY gained ranged from US$22,000 in 
women age 55 with 5% invasive breast cancer 
risk and 15–19.9% fracture probability, to $110,000 in 
women age 55 with 1% invasive breast cancer risk and 5–
9.9% fracture probability  
21-Jansen (2008) 
[15] 
Postmenopausal women aged 
over 50 years with a history of 
vertebral fracture and 
osteoporosis 
2004 Alendronate/vitamin D3 vs no 
treatment, alendronate with dietary 
vitamin D supplements and 
ibandronate 
In UK, alendronate/vitamin D3 was cost-effective 
compared to no treatment in women 70 years 
and older with osteoporosis (£17,439 per QALY gained). 
Alendronate/vitamin D3 was cost-saving relative to 
alendronate with dietary supplements.  
Relative to ibandronate, alendronate/vitamin D3 was cost-
effective in women 50 years (£19 095 per QALY gained) 
and economically dominant in women 60 years or older. 
Comparable results were observed for the Netherlands.   
22-Jonsson (2011) 
[43] 
Typical Swedish patient 
population (women aged 71 
years, T-score ≤-2.5 and a 
prevalence of morphometric 
vertebral fractures of 34%) 
2008 Denosumab vs generic alendronate, 
branded risedronate, strontium ranelate 
and no treatment 
The base-case ICERs were estimated at €27,000, €12,000, 
€5,000, and €14,000, for denosumab compared with 
generic alendronate, risedronate, 
strontium ranelate, and no treatment, respectively.   
23-Kanis (2008) 
[26] 
Postmenopausal women aged 
over 50 years with different 
fracture risks  
NR Generic alendronate vs no treatment Using a threshold of £30,000 and £20,000 per QALY, 
alendronate was cost-effective for the primary prevention 
of fracture in women with osteoporosis irrespective of 
age. 
24-Kanis (2008) 
[27] 
Postmenopausal women aged 
over 50 years using FRAX 
NR Generic alendronate vs no treatment Using a threshold of £20,000/QALY gained, treatment 
was cost effective at all ages when the 
10-year probability of a major fracture exceeded 7%. 
25-Kim (2014) [16] Postmenopausal women aged 
over 55 years using FRAX 
2008 Bazedoxifene vs raloxifene Bazedoxifene was cost-saving in all countries. 
26-Lekander (2008) 
[17] 
Postmenopausal women at a T-
score of -2.5 
2006 Hormone therapy vs no treatment Hormone therapy was cost-effective for most sub-groups 
of hysterectomised women, whereas for women with an 
intact uterus without a previous fracture, hormone therapy 
was commonly dominated by no treatment. 
  
 
27-Lekander (2009) 
[67] 
Women with menopausal 
symptoms aged over 50 years 
2006 Hormone therapy vs no treatment The ICER for women with intact uterus was $2,803, and 
for hysterectomized women was $295 
28-Lippuner (2012) 
[46] 
Women aged over 50 years with 
different fractures probabilities 
2008 Branded alendronate vs no treatment Assuming a willingness to pay at 2 time Gross Domestic 
Product per capita, branded alendronate was cost-
effective with a 10-year probability for a major 
osteoporotic fracture at or above 13.8% (range 10.8% to 
15.0%) 
29-Moriwaki (2013) 
[68] 
Osteopenic postmenopausal 
women aged over 65 years 
without a history of fracture 
2012 Alendronate vs no treatment The ICER of alendronate was $227,905 per QALY gained 
in women without risk factors;  $92,937 per QALY 
gained in women with family history of hip fracture; 
$126,251 in women with alcohol intake ( >2units per day) 
and $129,067 currently smoking. 
30-Murphy (2012) 
[50] 
Patients with a BMD T-score of 
-3.0, a historical vertebral 
fracture and an incidence 
vertebral fracture and patients 
with a BMD T-score of -3.0 and 
an incidence vertebral  
2012 Teriparatide vs bisphosphonate The ICERs were €36,995 and €19,371 per QALY gained 
in the two populations. 
31-Parthan (2013) 
[44] 
Overall post-menopausal 
population and high-risk 
subrgoups 
2012 Denosumab vs generic alendronate, 
branded risedronate and branded 
ibandronate  
ICER of denosumab vs generic alendronate was $70,400 
and $7,900 in the overall population and high risk 
subgroup, respectively. Risedronate and ibandronate were 
dominated by denosumab. 
32-Pham (2011) 
[28] 
Cohort of women with 
various life expectancies 
beginning osteoporosis treatment 
between the age of 50 and 90 
years 
2008 Bisphosphonate vs no treatment In the healthiest group, all costs were less than 
$18,000 per QALY. In the median quartiles of life 
expectancy, lifetime costs per QALY were less than 
$27,000 for patients at all ages; treatment became cost-
saving at a starting age of 75 and remained so through a 
starting age of 85. 
33-Salpeter (2009) 
[29] 
50-year-old and 65-year-old 
women given hormone therapy 
or no therapy 
2006 Hormone therapy vs no treatment Hormone therapy in the younger cohort resulted in an 
incremental cost of $2438 per QALY gained. In the older 
cohort, hormone therapy resulted in a cost of $27,953 per 
QALY gained. 
34-Seeman (2010) 
[34] 
Subgroups of patients over 80 
years of age with osteoporosis 
from the SOTI and TROPOS 
trials 
2006 Strontium ranelate vs no treatment 
 
Strontium ranelate was cost-saving 
35-Strom (2010) 
[47] 
Women aged 70 year with prior 
fracture and various T-score 
using FRAX 
2008 Bazedoxifene vs no treatment The ICER ranged from €37,443 (T-score of -1.5) to cost-
saving (from T-score of -3) 
  
 
36-Strom (2013) 
[39] 
Postemnopausal women aged 
over 50 years at different 
degrees of osteoporotic fracture 
risk 
2010 Denosumab vs no treatment, generic 
alendronate, risedronate and strontium 
ranelate 
At a willingness-to-pay of £30,000 per 
QALY and a 10-year fracture probability equivalent to a 
woman with a prior fragility fracture, 
denosumab was cost-effective compared to no treatment 
from the age of 70 years.  
Denosumab was estimated to cost-effectively replace 
strontium, risedronate and generic alendronate at 10-year 
probabilities exceeding 11, 19 and 32 %, respectively.   
37-Thompson 
(2010) [23] 
Postmenopausal women 65 years 
of age or older with a T-score ≤ -
2.5 
2008 Branded risedronate with generic 
alendronate 
Risedronate was cost-saving. 
38-Tosteson (2008) 
[24] 
4 risk groups among women 
with a T-score ≤ -2.5 
2005 No treatment, risedronate, alendronate, 
ibandronate, and teriperatide 
The ICER of risedronate compared with no 
therapy ranged from cost saving for the base case 
to $66,722 per QALY for women aged 65 years with no 
previous fracture. Ibandronate and PTH 
were dominated in all risk groups 
39-Wasserfallen 
(2008) [48] 
Women aged 70 years with 
established osteoporosis and 
previous vertebral fracture 
2005 Risedronate vs no treatment Risedronate was dominant 
ICER Incremental Cost-Effectiveness Ratio, MPR Medical Possesion Ratio, PVF Prevalent Vertebral Fracture, QALY Quality Adjusted Life-Year 
  
  
 
Table 3.a| Quality of reporting of cost-effectiveness analyses of drugs for postmenopausal osteoporosis using CHEERS checklist (articles 1-19) 
 
  Article Ref 
 Item 
No 
[13] [25] [20] [36] [31] [14] [37] [32] [21] [22] [18] [40] [51] [45] [49] [19] [41] [33] [42] 
Title and abstract                     
Title  1 Yes Part Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Part Yes Yes 
Abstract  2 Part Part Yes Part Part Yes Part Yes Part Yes Part Yes Yes Yes Yes Part Part Yes Yes 
Introduction                      
Background and objectives  3 Yes Yes Yes Yes Yes Yes Yes Yes Yes Part Yes Part Part Yes Yes Yes Yes Yes Yes 
Methods                      
Target population and 
subgroups  
4 Part Yes Yes Yes Yes Yes Yes Yes Part Yes No Yes Yes Yes Yes Yes Yes Yes Yes 
Setting and location  5 Yes Yes Yes Yes Yes Yes Yes Yes Part Yes Part Yes Yes Yes Yes Part Part Yes Yes 
Study perspective  6 Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Comparators  7 Yes Yes Yes Yes Yes Yes Yes Yes Part Yes Yes Yes Yes Yes Yes Part Yes Yes Yes 
Time horizon  8 Yes Part Part Part Part Part Part Part Part Part Yes Yes No Yes Yes Yes Yes Yes Yes 
Discount rate  9 Yes Yes No Yes Yes Yes Part Yes Yes Part No Yes Yes Yes Part Yes Yes Yes Yes 
Choice of health outcomes  10 Part Yes Yes Part Part Yes Part Part Yes Part Yes Yes Part Yes Yes Part Yes Yes Yes 
Measurement of effectiveness  11a Yes NA NA Part NA Part Yes Part NA NA NA Yes Yes NA Yes NA NA Part NA 
11b NA Part Part NA Yes NA NA NA Yes Part Part NA NA Yes NA Part Yes NA Part 
Measurement and valuation of 
preference based outcomes  
12 Part Part Part Part Part Part Part Part Part Part Part Part Part Part Part Part Part Part Part 
Estimating resources and costs  13a NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
13b Yes Part Part Part Part Yes Yes Yes Yes Yes Yes Yes Yes Yes Part Part Yes Yes Yes 
Currency, price date, and 
conversion  
14 Part Yes Part Part Part Part Part Part Part Part Part Part Yes Part Part Part Part Part Part 
Choice of model  15 Yes Part Part Yes Yes Yes Part Part Yes Part Yes Yes Part Part Yes Yes Part Yes Yes 
Assumptions  16 Yes Yes Part Yes Yes Yes No Yes Part Yes Part Yes Yes Part Part Yes Yes Part Part 
Analytical methods  17 Part Part Part Part Part Yes Part Yes Part Part Part Part Part Yes Yes Yes Part Part Yes 
  
  
 
Article Ref 
 Item 
No 
[13] [25] [20] [36] [31] [14] [37] [32] [21] [22] [18] [40] [51] [45] [49] [19] [41] [33] [42] 
Results                     
Study parameters  18 Part Yes Yes No No Yes Part Part NA Part No Yes Part Part No Yes Part Part Part 
Incremental costs and outcomes 19 Part Yes Yes Part Part Yes Yes Yes Yes Part Yes Yes No Yes Yes Part No Yes Yes 
Characterising uncertainty 20a NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
20b Yes Yes Yes Part Yes Yes Yes Yes Part Yes Part Yes Yes Yes Yes Yes Yes Yes Yes 
Characterising heterogeneity 21 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No No Yes Yes Yes Yes Yes Yes Yes 
Discussion                     
Study findings, limitations, 
generalisability, and current 
knowledge 
22 Yes Yes Part Yes Yes Yes Part Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Other                     
Source of funding 23 Part No Part Yes Part Part Part Yes Part Part Part Part Part Yes Yes Part Yes Yes Yes 
Conflicts of interest 24 Yes Yes Yes Yes Yes Yes Yes Yes No No Yes Yes Yes Yes Yes No Yes Yes Yes 
Scoring  20 19 18 18 18.5 21.5 17.5 20.5 15.5 17 15.5 20.5 18.5 21.5 20.5 18 19 21 21 
 
  
  
 
Table 3.b| Quality of reporting of cost-effectiveness analyses of drugs for postmenopausal osteoporosis using CHEERS checklist (articles 20-39) 
 
  Article Ref 
 Item 
No 
[38] [15] [43] [26] [27] [16] [17] [67] [46] [68] [50] [44] [28] [29] [34] [47] [39] [23] [24] [48] 
Title and abstract                      
Title  1 Yes Yes Yes Yes Part Yes Yes Part Part Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes 
Abstract  2 Part Part Part Part Part Yes Part Part Part Part Part Yes Part Part No Part Yes Yes Yes Part 
Introduction                       
Background and objectives  3 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Part No Part Part Yes Yes Part Yes 
Methods                       
Target population and 
subgroups  
4 Yes Part Yes Part Yes Yes Yes Yes Yes Yes Yes Part Part Yes Part Part Yes Yes Yes Yes 
Setting and location  5 Yes Yes Part No Yes Part Yes Yes Yes Yes Yes Yes Part Part No Yes Yes Part Yes Yes 
Study perspective  6 Yes Yes Yes Yes No Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Comparators  7 Yes Yes No Part Yes Yes Yes Yes Yes Part Yes Yes No Yes Part Part Part Part Yes Part 
Time horizon  8 Part Part Part Yes No Part Part Part No Part Part Part Yes Part Part Yes Yes Yes Part Part 
Discount rate  9 Yes Part Yes Yes No Yes Part Part Part Part Part Part Part Part Part Part Yes Part Part Part 
Choice of health outcomes  10 Yes Yes Part Yes Part Yes Yes Yes No Part Part Yes Part Part Yes Yes Yes Yes Part Part 
Measurement of 
effectiveness  
11a Part Yes NA NA NA Part Part Part NA NA NA NA NA NA NA NA NA NA NA NA 
11b NA NA Part Yes Part NA NA NA Part Part Part Part Part Yes No Part Part Part Part Part 
Measurement and valuation 
of preference based 
outcomes  
12 Part Part Part Part Part Part Part Part Part Part Part Yes Part Part Part Part Part Part Part Part 
Estimating resources and 
costs  
13a NA NA NA NA No NA NA NA NA NA NA NA Part NA No NA Part Part NA NA 
13b Part Part Yes Yes Part Part Part Part Part Part Part Part Part Part No Part Part Yes Yes Yes 
Currency, price date, and 
conversion  
14 Part Part Part Part No Part Yes Yes Yes Yes Part Yes Part Part No No Part Part Part Part 
Choice of model  15 Part Part Part Part Yes Yes Part Part Part Yes Yes Part Part Part Part Part Part Yes Part Part 
Assumptions  16 Part Part Yes Yes No Yes Yes Yes No Yes Yes Yes Yes Yes No Part Part Part Yes Yes 
Analytical methods  17 Part Part Part No No Part Part Part Part Part Part Part Yes Yes No Part No Yes Yes Yes 
  
  
 
Article Ref 
 Item 
No 
[38] [15] [43] [26] [27] [16] [17] [67] [46] [68] [50] [44] [28] [29] [34] [47] [39] [23] [24] [48] 
Results                      
Study parameters  18 Part Part Part Part Part Part Yes Yes No Yes Part Part Yes Part No Part Part Part Part Part 
Incremental costs and 
outcomes 
19 Part Yes Yes Part No Yes Yes Part Part Yes Yes Yes Part Yes Part No Part Yes Yes Yes 
Characterising uncertainty 20a NA NA NA NA NA NA No NA No NA NA NA NA No NA NA NA NA NA NA 
20b Yes Yes Yes Yes Part Yes Yes Yes Part Yes Yes Yes Yes Part No No Part Yes Yes Yes 
Characterising 
heterogeneity 
21 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No Yes Yes 
Discussion                      
Study findings, limitations, 
generalisability, and current 
knowledge 
22 Yes Yes Yes Yes Yes Part Yes Part Yes Yes Yes Yes Yes Part Part Part Yes Yes Yes Part 
Other                      
Source of funding 23 Part Sub Part Yes Yes Part No Part Yes Part Yes Yes Yes Yes Part Part Yes Yes Part Part 
Conflicts of interest 24 No No Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes No Yes Yes Part Yes No 
Scoring  17 16.5 17.5 18 13 19 18 18 15 19 18 20 17.5 17 7 14 18.5 19 19 17 
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86 
 
RESULTS OF THE QUALITY OF REPORTING ASSESSMENT 
The results of the assessment of reporting quality per study is summarized in Tables 3.a and 3.b. 
Figure 2 shows for each item the proportion of studies reported completely adequate, partially or 
not at all. The most frequent partially or not reported items were ‘measurement of effectiveness’ 
(i.e. description of the methods used for the identification of studies used for effectiveness; items 
11a and 11b), ‘measurement and valuation of preferences based outcomes’ (i.e. description of the 
population and methods used to elicit preferences for outcomes; item 12), ‘currency, price date and 
conversion’ (i.e. reporting of the dates of the estimated resource quantities and unit costs and 
description of the methods for adjusting estimated unit costs to the year of reported costs; item 14) 
and ‘analytic methods’ (i.e. description of all structural or other assumptions underpinning the 
decision-analytic model; item 17). The reporting in the abstract could be improved (item 2). In 
addition, perspective, setting, methods and results of uncertainty analyses were not always included 
while comparators were sometimes considered without (proper) justification. Justification for time 
horizon, discount rates and choice for health outcomes were also not provided in all articles. The 
description of approaches used to estimate resources and costs, as well as the reporting of study 
parameters including values, ranges, references, and if used, probability distributions for all 
parameters was also not complete in several articles. Studies generally provided incremental costs 
and outcomes (item 19), characterize uncertainty and heterogeneity (items 20 and 21) and discuss 
the key findings, limitations, generalizability and how the findings fit with current knowledge (item 
22), although several articles did not satisfactory fulfil these criteria. The source of funding and the 
role of the funder in the identification, design, conduct, and reporting of the analysis was only fully 
reported in about half of the articles. Substantial differences in the quality of reporting were 
observed between articles with an average score of 17.9 out of 24 (range from 7 to 21.5). Average 
score was higher for articles published in 2011-2013 (score of 18.3) in comparison to articles 
published in 2008-2010 (score of 17.3). European studies reported an average score of 17.7 (with a 
mean score of 19.8 for the 8 studies conducted in Belgium) while studies using a US/Canada 
perspective had an average score of 18.6. Articles published in health economic journals (see 
section 3.2 for group classification) have a higher reporting score (score of 19.5) than articles 
published in osteoporosis journals (score of 17.6). 
KEY DRIVERS OF COST-EFFECTIVENESS 
Several key drivers of cost-effectiveness were identified during the systematic review. They are 
discussed below and include individual fracture risk, medication adherence, selected comparators 
and country-specific analyses. 
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Individual fracture risk 
The cost-effectiveness of osteoporotic drugs substantially improves with increasing fracture risk 
and the age of the population, the latter partly due to higher admission rates in nursing home 
avoided. So, for example, the cost-effectiveness of denosumab in women with BMD T-score ≤-2.5 
was estimated at €25,061 and €8,948 per QALY gained at the ages of 60 and 70 years, respectively 
(year 2010 value) [33]. At the age of 80 years, denosumab became cost-saving. Other studies show 
cost-effectiveness varies across populations with different risk for future fractures. For example, in 
women aged 70 years, the cost-effectiveness of strontium ranelate ranged from £34,200 to £13,800 
(year 2006 value) per QALY gained according to BMD T-score [36]. Parthan et al. [44] also 
showed that the incremental cost-effectiveness ratio (ICER) of denosumab versus generic 
alendronate was $70,400 and $7,900 (year 2012 value) in the overall population and high risk 
subgroup, respectively.  
Medication adherence 
Medication adherence has emerged as an important perspective in cost-effectiveness analyses in 
osteoporosis [52, 53]. Adherence with osteoporosis medications has been shown to be poor and 
suboptimal [54], leading to a decrease in treatment effectiveness [55]. As a consequence, poor 
adherence alters the cost-effectiveness of drug therapies [52]. In Hiligsmann et al. [41], the costs per 
QALY gained for branded bisphosphonates were estimated at €19,069, €32,278 and €64,052 (year 
2006 value) for adherence level of 100%, 80%, and 60%, respectively. When comparing drugs with 
potential differences in medication adherence and persistence, the lack of inclusion of these 
concepts could potentially bias the results. Hiligsmann et al. [42, 52] suggests that, if adherence was 
not included, the cost-effectiveness of denosumab compared with oral bisphosphonates would have 
been less favourable.  
Comparators 
An increasing number of studies used active comparators in cost-effectiveness analyses of drugs in 
postmenopausal osteoporosis. Seventeen of the 39 studies (43.7%) included at least one active 
comparator, in comparison with 1 of the 22 studies (4.6%) published between 2002 and 2005 [5]. 
The cost-effectiveness of a drug therapy could differ according to the selected comparator. In 
Parthan et al. [44], in the overall population, denosumab was always dominant compared with 
risedronate and ibandronate, while the cost-effectiveness was less favorable when using generic 
alendronate as comparator. Justification of the comparators is therefore becoming important. 
Interpretation of cost-effectiveness analyses between active comparators requires some caution. For 
most of these analyses, indirect comparisons were required to estimate cost-effectiveness since 
there is limited trial data directly comparing effectiveness between drugs.  
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Country-specific analyses 
The cost-effectiveness of osteoporotic drugs differed markedly between countries. In a study 
assessing the cost-effectiveness of bazedoxifene in 6 European countries [14], the ICER ranged 
from €105,450 in Spain to cost-saving in Sweden (year 2008 value). This difference was explained 
to a large extent by regional differences in fracture risk [14]. Marked variation in the incidence of 
fractures among world regions is recongnized [56]. Additional factors such as fracture cost, drug 
cost and medication adherence could also differ between countries, and hence affect the cost-
effectiveness of drug therapies. Yearly medication costs ranged between €325 and €540 in the 6 
European countries [14], while the costs of hip fracture were between €10,142 and €18,923 (year 
2008 value). 
DISCUSSION  
Our systematic review identified 39 economic evaluations of drugs in postmenopausal osteoporosis 
published between 2008 and 2013. When compared with no treatment, active osteoporotic drugs 
were generally cost-effective, at commonly-accepted thresholds for cost-effectiveness (around 
€45,000 per QALY gained), in postmenopausal women aged over 60-65 years with low bone mass, 
especially those with prior vertebral fractures. In view of the heterogeneity in fracture risk, 
comparators, country setting, model structure and incorporation of medication adherence, and given 
the lack of head-to-head comparisons, it is not yet possible to make clear recommendations on the 
cost-effectiveness between drugs. 
Our review updates prior systematic reviews of economic evaluations conducted in osteoporosis [4, 
57, 5, 58]. Fleurence et al. [4] identified 23 economic evaluations of oral bisphosphonates between 
1990 and May 2006 while Zethraeus et al. [5] analyzed 22 articles about the cost-effectiveness of 
the prevention and treatment of osteoporosis published in the period 2002–2005. These reviews 
already suggested that oral bisphosphonates were cost-effective in women aged over 70 years, 
particularly those with additional risk factors. In addition to oral bisphosphonates, our review 
reveals that new alternative treatments (such as denosumab, strontium ranelate, bazedoxifene, 
zoledronic acid) can also be considered as cost-effective as compared with placebo. Additional 
countries and patient populations have been identified in recent economic evaluations. More 
recently, Si et al. [12] carried out a systematic review (until May 2013) of the evolution of health 
economic models used in osteoporosis. In contrast with this study, we restricted our analysis to drug 
therapies, described and discussed the results of the studies, and provided a critical appraisal of all 
the articles. 
In line with prior studies, some key drivers of the cost-effectiveness were found in our review. First, 
the consideration of patient characteristics is highly important. The development of several fracture 
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risk algorithm such as FRAX enables the estimation of the cost-effectiveness in various types of 
patients with different combinations of clinical risk factors. Second, medication adherence affects 
the cost-effectiveness of interventions in osteoporosis and should therefore be incorporated in future 
economic evaluations. Assessing adherence (from randomized controlled trials, observational 
studies or claims data) and incorporating them in cost-effectiveness analyses could however be 
challenging [52, 53]. The authors should recognize potential limitations of adherence data and use 
sensitivity analyses. Third, indirect or mixed treatment comparisons are becoming a familiar feature 
of technology appraisals at the National Institute of Clinical and Care Excellence in UK, just as they 
make a frequent appearance in leading clinical journals [59]. In our review, relatively few economic 
evaluations included all potential relevant interventions in their analysis. Indirect comparisons 
require correct methodological approaches to adjust between studies or differences in characteristics 
of studies populations. The ISPOR’s Task Force on Indirect comparisons provides guidance on 
technical aspects of conducting network meta-analyses and indirect comparisons [60]. Fourth, the 
transferability of economic evaluations is uncertain since many factors such as fracture risk could 
differ between countries and therefore affects the cost-effectiveness. Cost-effectiveness should 
therefore be evaluated at the national level. Additional key issues for economic evaluations in 
osteoporosis were recently identified by Stevenson et al. [61]. 
With regard to the quality of reporting of these economic evaluations, despite the fact that 
guidelines for conducting health economic evaluations are widely available for many years and 
previous reviews have already criticized economic evaluations for poor reporting, we observed that 
quality of reporting is still largely insufficient for several articles. Several items were partially or 
not reported by most articles. These include the methods used for the identification and synthesis of 
clinical effectiveness data, the description of the population and methods use to value preferences 
based outcomes, the reporting of the dates of the estimated resource quantities and unit costs, and 
all analytic methods supporting the evaluation including by example approaches to validate the 
model or methods for handling population heterogeneity and uncertainty. We hope that the 
availability of the CHEERS statement [10, 11] will lead to improve the reporting and hence the 
quality of economic evaluations of osteoporosis. To improve the comparability and quality of health 
economic evaluation in osteoporosis, defining minimal methodological and structural requirements 
that could be transferable to any specific decision-making context will be an additional step forward 
[17]. 
Although we followed recommendations for conducting reviews of economic evaluations, [62], 
there may have some potential limitations to our study First, many reviewers were involved in the 
quality of reporting assessment and differences in scoring could potentially be due to interpretation 
of reviewers. Differentiating between partially or fully reported was difficult for some items. 
Second, we assigned a score of 0.5 for partial reporting which could be questionable and lead to an 
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upgrade of the overall score of the studies. Using a binary rating (yes when the item was completely 
reported and no otherwise) would have decreased the reporting quality. Third, level of quality may 
be underestimated for studies in which some of the items were not easily applicable or were 
reported elsewhere. Several articles referred explicitly to previously published articles where more 
information could be available, and some articles had different objectives than assessing the cost-
effectiveness of drugs. By example, the main aim of the article of Kanis et al. [27] was to determine 
intervention thresholds, based on cost-effectiveness estimates of alendronate. Fourth, it should be 
acknowledged that poor reporting does not necessarily lead to poor quality and results bias. In our 
review, we have not assessed the methodological quality of the articles. An evaluation of the 
modelling quality of these studies using by example the Philips checklist would be interesting [63]. 
Finally, to identify key drivers of cost-effectiveness, we did not perform a systematic quantitative 
assessment. 
A majority of studies (30/39 articles) were funded by pharmaceutical industries. While research has 
found that studies funded by industry were more likely to report favorable cost-effectiveness ratios 
[64], a review conducted in osteoporosis revealed that funding source (industry versus non-
industry) did not seem to significantly affect the reporting of favourable cost-effectiveness for 
bisphosphonates [65]. 
The results of our review could be important for decision makers when prioritizing health 
interventions. With the increasing use of economic data in health-care decision making (especially 
for reimbursement of drugs), the increasing burden of osteoporosis [1] and the recent development 
of new drug interventions [6], consideration of the cost-effectiveness of anti-osteoporosis 
medications is becoming increasingly important. Alongside cost-effectiveness, other factors such as 
affordability could also play a role in reimbursement decisions. Insights into the preferences of 
patients groups should also be taken into account alongside medical and economic considerations. 
A recent discrete-choice experiment revealed that patients could have preferences for attributes of 
osteoporosis drug therapy [66]. 
In conclusion, this review found an increasing number of published cost-effectiveness analyses of 
drug in osteoporosis. Active osteoporotic drugs are generally cost-effective, when compared with 
no treatment, in postmenopausal women aged over 60-65 years with low bone mass, especially 
those with prior vertebral fractures. Future economic evaluations in osteoporosis should take into 
consideration the patient characteristics as well as medication adherence. More attention should also 
be given to the methods used for the identification and synthesis of clinical effectiveness data, 
especially now there is an increasing need for comparative cost-effectiveness studies. Improving the 
quality of reporting of economic evaluations is also needed. 
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KEY POINTS FOR DECISION MAKERS 
 Active osteoporotic drugs were generally cost-effective in postmenopausal women aged 
over 60-65 years with low bone mass, especially those with prior vertebral fractures. 
 In view of the heterogeneity in fracture risk, comparators, country setting, model structure 
and incorporation of medication adherence, and given the lack of head-to-head comparisons, 
it is not yet possible to make clear recommendations between drugs in terms of cost-
effectiveness. 
 Despite the fact that guidelines for conducting health economic evaluations are widely 
available for many years, we observed that quality of reporting is still largely insufficient for 
several articles. 
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ABSTRACT 
Adherence with medications is poor and suboptimal in many chronic diseases. Non-adherence can 
reduce treatment effectiveness and can have impact on healthcare costs. As a consequence, it may 
alter the cost-effectiveness of drug therapies. This article emphasizes the importance of integrating 
medication compliance and persistence in pharmacoeconomic evaluations using osteoporosis as 
example. A limited number of studies carried out to date have suggested important economic 
implications of poor adherence with osteoporosis medications. Therefore, compliance and 
persistence should be an integral part of clinical studies and pharmacoeconomic analyses in order to 
estimate the cost-effectiveness of drug therapies in the current community practice. Measuring 
adherence and incorporating it into health economic modeling may, however, pose particular 
challenges. 
KEYWORDS 
Adherence, compliance, cost-effectiveness, economic, osteoporosis, persistence. 
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INTRODUCTION 
Pharmacoeconomic evaluations are increasingly used in health care. By comparing costs and 
consequences of health interventions, economic evaluations can serve as a tool to help decision 
makers to efficiently allocate scarce resources. To conduct economic evaluations, researchers often 
obtained efficacy data from randomized clinical trials (RCTs). Although RCTs have, at least 
theoretically, high internal validity, they are associated with high levels of adherence compared 
with those observed in daily practice. The estimates of treatment efficacy and subsequently 
pharmacoeconomic results may therefore not be generalizable to current community practice. In 
order to estimate the cost-effectiveness of the intervention/drug in real-life settings, it is important 
that economic evaluations take adherence into account. Poor compliance and persistence will 
reduce the cost of the intervention, but at the same time might decrease the side-effects and the 
therapeutic potential of drug therapy in term of health effects and costs, and can therefore have 
substantial impact on the effectiveness and cost-effectiveness of drug therapies [1]. 
This study aims to highlight the importance of integrating medication adherence in 
pharmacoeconomic analyses, using osteoporosis as an example. Poor compliance and persistence 
are common problems in the treatment of osteoporosis. Approximately 75% of women in whom an 
oral bisphosphonates, currently the most widely medications prescribed for osteoporosis, is 
initiated, have been shown to be non-adherent within one year and 50% discontinued therapy by 
this time [2, 3]. A few studies carried out to date have suggested important economic implications 
of poor adherence to osteoporosis medications [4-8]. 
More specifically, the purposes of this article are (1) to present and illustrate, by a published 
example including reviews and single studies, the impacts of poor adherence with osteoporosis 
medications on effectiveness, healthcare costs and cost-effectiveness, (2) to review recent economic 
evaluations that have integrated compliance and persistence and (3) to discuss some important 
challenges for incorporating compliance and persistence in pharmacoeconomic analyses conducted 
in osteoporosis. 
DEFINITION AND MEASUREMENTS 
Since a wide variety of definitions for medication adherence have been used in the literature, it is 
important to define the terminology. In line with the definitions issued by an expert consensus 
group in osteoporosis [9], medication adherence is used as a general term to cover medication 
compliance and persistence. Medication compliance may be defined as “the extent to which a 
patient acts in accordance with the prescribed interval, dose and dosing of regimen” and medication 
persistence as “the length of time from initiation to discontinuation of therapy” [10].  
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Medication compliance is typically expressed as the percentage of prescribed doses taken in relation 
to the study period, often called the medication possession ratio (MPR). Studies conducted in 
osteoporosis have estimated the mean MPR over a period of time (typically one year) and/or the 
probabilities of patients being highly or poorly compliant. A threshold of 80% has been most 
commonly used to define high compliance with osteoporosis treatments [11]. The definition of 
‘good compliance’ is however arbitrary and difficult to evaluate. An empirical calculation of an 
optimal threshold for predicting fracture risk has been estimated at 68% [12]. 
Persistence is measured as the number of days on therapy or as a dichotomous variable (persistent 
or not) as to whether a patient continued therapy beyond an elapsed time period (e.g. 12 months). A 
threshold regarding discontinuation period have to be defined for measuring persistence. For daily 
or weekly treatment, a refill gap of 1 month is commonly considered to define non-persistence [13] 
but, as for MPR thresholds, there are no standardized definitions for non-persistence. Gap lengths 
for treatments with longer dosing intervals are less well defined, though a working group recently 
discussed that stopping treatment for 2 months may be a suitable definition for a monthly treatment, 
and a delay of more than 3 months in the case of yearly injections [13]. The operational definitions 
to measure compliance and persistence could therefore differ between studies and may impact on 
the results. 
Medication compliance and persistence can be assessed using direct or indirect methods. Direct 
assessment methods (e.g. observation, serum drug concentration, biochemical analysis) are more 
accurate but are more costly and often impractical [14]. Indirect methods (e.g. retrospective 
prescription claims database) often constitute the only source available to assess adherence and an 
inexpensive way of collecting adherence [15]. Most studies assessing medication adherence have 
used pharmacy prescription refill records. This method however lacks the details of daily dosing 
(e.g. missing doses, wrong timing) and may underestimate medication non-adherence, and 
especially non-compliance. 
IMPACT OF POOR ADHERENCE ON ANTI-FRACTURE EFFECTIVENESS 
Poor adherence reduces the effectiveness of osteoporosis treatment, resulting in lower bone mineral 
density gains and subsequently higher fractures rates [16]. Two meta-analyses were recently 
performed to assess the fracture risk among patients non-compliant versus compliant to therapy for 
osteoporosis [17, 18]. First, a meta-analysis of six articles, including 171,063 patients, suggested 
that the risk of fractures was 46% higher in non-compliant patients (MPR<80%) with 
bisphosphonate therapy compared with compliant patients [18]. The increased fracture risk in non-
compliant patients was lower for non-vertebral (16%) and hip (28%) than for clinical vertebral 
fractures (43%). In another meta-analysis, constituting of 113,376 patients from 8 studies, of which 
the majority were retrospective database analyses considering the effect of adherence to 
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bisphosphonate therapy, fracture risk increased by approximately 30% in non-compliant patients 
(MPR <80%) compared with compliant patients [17]. 
Most of these studies have suggested a nonlinear relationship between MPR and fracture risk[11]. 
For example, a large US database showed no treatment benefit for compliance levels defined by an 
MPR <50% and then an exponential decrease of fractures rates as compliance increased [19]. 
Similarly, a German study observed no risk benefit with compliance levels of less than 60% [20]. 
Elsewhere, however, a linear relationship was observed between MPR (expressed as continuous 
variable) and the probability of hip fractures [21]. Each incremental decrease of 1% in compliance 
resulted in an increase by 0.4% of the risk of hip fracture [21]. 
Non-persistence patients also reported higher fracture rates compared with persistent patients. A 
meta-analysis, including 57,334 patients from five studies, showed that non-persistence increases 
the risk of all fractures by 30% to 40% versus persistence [18]. A recent Swedish observational 
study also showed that the 3-year fracture incidence was related to time on treatment with 
osteoporosis medications [22]. Consistent with RCTs, this study shows that, in real-life settings, at 
least 6 months of treatment with oral bisphosphonates can reduce fracture incidence [22, 23]. No 
treatment effect could therefore be assumed for patients receiving drug therapy for less than 6 
month. 
The magnitude of the effects of medication adherence should be interpreted with some caution [24]. 
A limitation to the observational studies is the concern surrounding bias due to the “healthy adherer 
effect”, which could lead to an overestimation of medication benefits. While the reduced 
effectiveness observed in non-compliant and non-persistent patients may be due to a true biological 
effect, it may also be at least partly caused by confounding factors due to differences between the 
types of patients who remain adherent versus those becoming non-adherent. In the Women's Health 
Initiative’s study [24], adherence to placebo significantly reduced the risk of hip fracture by 50%. 
These results are however not supported by another study that shows no evidence of healthy adherer 
bias was shown in a frail cohort of seniors [25] and further exploration of the healthy adherer effect 
would be required in osteoporosis. 
Acknowledging this potential limitation, poor adherence may be responsible for a large difference 
between efficacy and clinical effectiveness. The consequences of poor adherence on the clinical 
effectiveness at a population level have been shown to be significant in many countries [4, 6, 7, 26]. 
An example of the impact of medication adherence on effectiveness is provided on Figure 1. Using 
Belgian persistence and compliance data to alendronate, an oral bisphosphonate, [21] and 
simulation modeling [27], this study [4] compared the clinical and economic outcomes obtained at 
real-world adherence levels with those expected with full adherence over three years. Outcomes 
were expressed as the number of hip fractures and in quality-adjusted life-years (QALYs), which is 
an attractive outcome measurement for cost-effectiveness analyses that takes into account 
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reductions in both morbidity and mortality. The numbers of hip fractures prevented were 0.0095 
and 0.0247 for the real-world and full adherence scenario, respectively [4]. Therefore, the number 
of hip fractures prevented in the case of real-world adherence represents only 38.5% of that 
estimated with full adherence scenario. The QALYs gain in the real-world adherence scenario was 
estimated at 40.6% to that obtained under full adherence scenario. More than half of the potential 
clinical benefits of oral bisphosphonates in patients with osteoporosis are therefore expected to be 
lost due to poor compliance and failure to persist. Sensitivity analysis has shown that the effect of 
non-adherence on clinical effectiveness was primarily driven by the issues of non-persistence, with 
more than 90% of the clinical burden of poor adherence resulting from non-persistence [4]. 
Figure 1| Impact of medication non-adherence on the clinical effectiveness (expressed as number of 
fractures prevented and quality-adjusted life-year (QALY) gained) of oral 
bisphosphonates 
 
Data from [4]. Using a simulation model, this study [4] estimated the lifetime effectiveness per 
patient for real-world and full adherence with oral bisphosphonate compared with no treatment. 
Analysis was conducted in Belgian patients aged 55 to 85 years either with a bone mineral density 
T-score ≤ -2.5 or a prevalent vertebral fracture at baseline.  
IMPACT OF POOR ADHERENCE ON HEALTHCARE COSTS 
Poor adherence will work in two opposite directions on healthcare resources [1]. Non-adherence 
reduces the cost of therapy but increases healthcare costs associated with the condition being treated 
as a result of reducing clinical effectiveness. The final impact of non-adherence on healthcare costs 
will be primarily dependent on the risk of the population. The impact of poor adherence on therapy 
cost will be the same across different populations but the number of fractures avoided and the 
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corresponding disease-related costs are increasing as the fracture risk of the population increases. It 
could therefore be possible, in high risk populations, that the averted costs of treating the additional 
osteoporotic fractures resulting from non-compliance will exceed the cost of the additional therapy 
stemming from the improved compliance.  
In our example including women aged between 55 and 85 years with either a bone mineral density 
(BMD) T-score below -2.5 or a prevalent vertebral fracture, the full and the real-world adherence 
scenarios had approximately the same total cost [4] (Figure 2), meaning that the additional costs 
from treating non-adherent patients to full adherence are around equal to the averted fracture costs 
resulting from improved adherence. Of course, the change in drug and nondrug costs is function of 
both persistence and compliance [1, 28]. 
Figure 2| Impact of medication non-adherence on aggregated and disaggregated (drug and 
disease) healthcare costs  
 
Data from [4]. Using a simulation model, this study [4] estimated the aggregated and disaggregated costs associated 
with oral bisphosphonate therapy at real-world adherence and full adherence levels, in comparison with no treatment. 
Analysis was conducted in Belgian patients aged 55 to 85 years either with a bone mineral density T-score ≤ -2.5 or a 
prevalent vertebral fracture at baseline. Aggregated costs (total costs) include the costs of therapy (drug and 
monitoring costs) and fracture-related costs (disease costs). 
 IMPACT OF POOR ADHERENCE ON COST-EFFECTIVENESS 
Given that compliance and persistence affect both health outcomes and costs, these concepts should 
be included to accurately estimate the cost-effectiveness of drug therapies. In our example using 
observational data (Figure 3), the impact of medication adherence on the cost-effectiveness is 
substantial. The incremental cost per QALY gained of oral bisphosphonates compared with no 
treatment was estimated at €10,279 and €3,909 at real-world and full (assumed) adherence levels, 
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respectively [4]. Poor adherence therefore results in this example in around a doubling of the cost-
effectiveness from these medications. It means that for example, with a budget of €20,000, 
treatment with oral bisphosphonate could save 1.95 life-years in perfect health at real-world 
adherence levels while, at full adherence, treatment could prevent 5.12 life-years in perfect health. 
The studies addressing compliance and persistence have shown that both aspects of adherence were 
important drivers of cost-effectiveness [5]. 
Figure 3| Impact of medication non-adherence on the cost-effectiveness (expressed as cost in € per 
QALY gained) of oral bisphosphonates compared with no treatment.  
 
Data from [4]. This figure (called the ‘cost-effectiveness plane’) presents the incremental effectiveness and costs of oral 
bisphosphonates compared with no treatment at real-world and full adherence levels. The incremental cost-
effectiveness ratio is represented by the slope of the line from the origin. The analysis was conducted in Belgian 
patients aged 55 to 85 years either with a bone mineral density T-score ≤ -2.5 or a prevalent vertebral fracture at 
baseline. 
APPROACHES TO INTEGRATE NON-PERSISTENCE AND NON-COMPLIANCE IN 
ECONOMIC EVALUATIONS 
Over the recent years, several studies have attempted to integrate medication compliance and/or 
persistence in pharmacoeconomic evaluations conducted in osteoporosis. As compliance and 
persistence are two different constructs, both concepts should be ideally separated. In order to not 
blur the distinction between compliance and persistence, it is also important that compliance was 
defined in the subgroup of persistent patients. Studies generally provide assumptions with respect to 
persistence but generally oversimplify the contribution of compliance. We describe below some of 
the approaches to integrate persistence and compliance. 
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In the first economic models of persistence, including one by the National Institute for Health and 
Clinical Excellence in the United Kingdom, it was assumed that some patients completed the full 5-
year course and the remaining (i.e. non-persistent patients) received no treatment effect but 3 
months of costs [29, 30]. A value of 50% non-persistent patients was selected in the base-case. 
Patients who early discontinue therapy may have a marked impact on the cost-effectiveness as they 
receive drug cost but have no treatment effect. As example, the incremental cost-effectiveness ratio 
(ICER) of generic alendronate in UK women with bone mineral density T-score equal to -2.5 and 
no prior fracture was estimated at €3,163, €3,709 and €4,914  per QALY gained when assuming 
30%, 50% and 70% of non-persistent patients, respectively [29]. Patients are however likely, in 
real-life settings, to discontinue at any time and not only after 3 months [30]. 
More recent studies have therefore added that patients can be at risk of discontinuation over the 
whole period of time [30-32]. Every patient had therefore in every cycle a risk of stopping therapy, 
based on observational adherence studies. For patients stopping therapy in each cycle, it is 
frequently assumed, first, that they receive no further treatment during the remaining modeling time 
and, secondly, that offset time (i.e. effect of treatment after stopping therapy) is similar to the 
duration on therapy. Although the last seems reasonable, assumptions made regarding the offset 
time may have a large impact on the results [30]. Limited data available from extension studies of 
RCTs have suggested the discontinuation of oral bisphosphonate resulted in the gradual loss of its 
effects [33] and found up to 7 years after treatment withdrawal [34]. Further research would 
however be needed to understand offset action of new anti-osteoporosis medications. The first 
assumption may be more critical as around one third of patients were shown to restart treatment 
within 6 months after discontinuation [35, 36]. How these patients change the cost-effectiveness is 
however unclear, and their inclusion in modeling may be difficult as the effectiveness of oral 
bisphosphonates used in an interrupted way is largely unknown. 
Studies have also attempted to include medication compliance. Most studies assumed medication 
costs and fracture reduction efficacy to be proportional to compliance [27, 37, 38]. This approach 
may however be inappropriate since the relationship between MPR and fracture risk has been 
shown in most studies to be nonlinear [11].  
Ström et al. (2009) used another approach to model compliance. They reduced treatment efficacy by 
a proportional factor of the optimal anti-fracture effect [30]. The authors suggested a 20% reduction 
of treatment benefit due to non-compliance in the base-case, based on experts’ opinion. Non-
compliant patients therefore deteriorated the cost-effectiveness because they received less benefit 
but the same cost.  
Hiligsmann et al. (2010) estimated the relative risks of fracture according to MPR [5]. The 
effectiveness from clinical trials was applicable to the population with an MPR value equal to 80% 
and fracture reduction efficacy at other MPR values was estimated based on the relationship 
CHAPTER 5 
 
108 
 
between compliance and fracture risk [19, 21]. For generic oral bisphosphonates, the incremental 
cost-effectiveness ratio was estimated at €4,871, €11,985, and €30,181 for 100%, 80%, and 60% 
compliance, respectively.  
Hiligsmann et al. suggest an original methodology including real-world estimates for compliance 
with oral bisphosphonates [4, 8, 34]. Persistent patients were classified as compliant (MPR ≥80%) 
and poorly compliant (MPR <80%). The probabilities of being compliant or not were derived for 
any given year and poorly compliant patients were assumed to be associated with an increased risk 
of fractures [21, 39]. Drug costs were also related to the mean MPR of the patients. 
Using this approach, the cost-effectiveness of denosumab compared with generic alendronate (an 
oral bisphosphonate) was estimated in the treatment of postmenopausal osteoporotic women [32], 
using real-world adherence data for alendronate and accepting an improved persistence for the 6-
month subcutaneous injection of denosumab based on the results of an open-label study [40]. A 
shorter offset time of the anti-fracture effect after stopping treatment was assumed for denosumab 
as compared to the one selected for alendronate. In the base-case analysis, the cost per QALY 
gained of denosumab compared with generic alendronate was estimated at €22,220 in women aged 
70 years with bone mineral density T-score of -2.5 or less. When assuming a 25% higher adherence 
for oral bisphosphonates, the ICER increased to €41,759. Medication adherence can therefore be 
considered as a key driver of the results. If adherence would have not been included, the ICER of 
denosumab compared to oral bisphosphonates would be less favorable. When comparing drugs with 
potential differences in medication compliance and persistence, the lack of inclusion of these 
concepts could bias the results and lead to suboptimal allocation of resources. 
ECONOMIC VALUE OF ADHERENCE-ENHANCING INTERVENTIONS 
Over the recent years, there has been an increasing interest to determine the effects of programs to 
improve adherence with osteoporosis medications. Several studies have investigated the effects of 
changing the dosing of regimens of bisphosphonates and/or improvements of compliance and 
persistence on the number of fractures prevented [6, 41-44]. Some studies also estimated the 
economic value (in terms of cost per QALY gained) of improving medication compliance and 
persistence [26, 30, 45]. These studies did not assess the cost-effectiveness of a specific program 
but estimated the cost-effectiveness of hypothetical interventions. As mentioned above, depending 
on the baseline risk for fractures such interventions can, but will not necessarily be cost-effective. 
Results of these studies suggest that interventions to improve adherence may likely confer cost-
effectiveness benefits. So, for example, a hypothetical intervention with a one-time cost of $250 and 
reducing discontinuation by 30% had an incremental cost per QALY gained of $29,571 in 
American women aged 65 years starting bisphosphonates [26]. Other studies [4, 31, 47], reported in 
Table 1, estimated the maximum amount per year it would be cost-effective to spend on 
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interventions to improve medication adherence, depending on the level of improvement (between 
10% and 50%). 
Table 1| Maximum cost per year for an adherence-enhancing intervention to be considered as cost-
effective 
Adherence improvement by Sweden, 2009* [30] Belgium, 2010** [4] Ireland, 2012** [45] 
10% €225 €73 €119 
25% (30% for Sweden ) €676 €149 €299 
50% €1130 €239 €726 
* Cost-effectiveness threshold of €60,000 per QALY gained. ** Cost-effectiveness threshold of €45,000 per QALY 
gained. 
CHALLENGES FOR INTEGRATING COMPLIANCE AND PERSISTENCE IN 
PHARMACOECONOMIC EVALUATIONS 
Medication persistence and compliance are important drivers of cost-effectiveness analyses 
conducted in osteoporosis and should therefore be incorporated in pharmacoeconomic analyses. 
Measuring adherence and incorporating it into health economic modeling may, however, pose 
particular challenges. A number of avenues for further research have recently been identified [13].  
First, it is probably needed to have better (and standardized) definition for compliance thresholds 
and for gap lengths for non-persistence. This is particularly important for new osteoporotic 
treatments with different dosing regimens. Persistence data seems to be highly sensitive to gap 
length which remains especially uncertain for longer dosing regimens. Improvements in the 
measurement of compliance and persistence are also required. The development and validation of 
tools to evaluate adherence (including missing doses and wrong timing) to osteoporosis medications 
would be useful [46]. Patient-related outcomes from validated questionnaires may provide robust 
complementary alternatives to medico-administrative database analyses, and especially for 
compliance measurement.  
Second, given the large difference between efficacy and effectiveness, improvements in the 
collection of data, preferably in real-life setting, are expected. Using local and treatment-specific 
data are also important. Currently, the majority of studies have considered the effect of adherence to 
oral bisphosphonate therapies. Further work are expected to assess compliance and persistence with 
recent osteoporosis medications with longer dosing regimens. There is also a need to conduct 
studies to assess efficacy and effectiveness according to types and levels of compliance. Retrieving 
efficacy data from RCTs for high compliance, as currently frequently done, may be incorrect 
because compliance in the trials is not optimal for all the patients. The efficacy from these trials is 
likely to be reduced to some degree because of non-compliance and non-persistence. Therefore, 
using efficacy data from RCT for high compliance probably underestimates the true underlying risk 
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reduction with therapy. Clinical results should therefore also be related to the doses taken and not 
an assumed 100% persistence and compliance [47]. Although compliance and persistence should be 
better reported in clinical trials, data on compliance and relation to effectiveness would ideally be 
derived from register/observational studies. Additional insight into variables associated with non-
compliance (such as age, first or second fracture, multi-medication or comorbidity) would also be 
valuable. Many factors (such as the presence of comorbidities) are associated with medication 
adherence [48] and may therefore have an impact on the economic consequences of non-adherence. 
The effect of these factors should be further investigated.  
Finally, parallel with improvements in the collection of data, further work on the methods to 
incorporate medication compliance and persistence in economic evaluations are also required. This 
should consider the inclusion of patients who restart therapy after discontinuation and better 
estimates of the true cost for compliant and non-compliant patients. Using microsimulation models, 
it would also be possible to integrate an impact of events (such as prior fractures, discontinuation) 
on compliance and persistence. Modeling compliance and persistence as continuous variables rather 
than as dichotomous could also improve the power of the analysis. It is also recommended to 
perform sensitivity analyses on adherence data and assumptions.  
EXPERT COMMENTARY 
Ten years ago, Hughes et al. [49] and Cleemput et al. [50] reviewed the literature on the economic 
impact of non-compliance and identified a need for more and better research. In 2007 and 2009, 
Hughes et al. [1] and Rosen et al. [51] provided an update of the reviews suggesting that the work is 
still sparse, and that the limited evidence available has methodological limitations. 
In osteoporosis, the incorporation of medication compliance and persistence in pharmacoeconomic 
evaluations is relatively recent. Most studies recognize the importance of incorporating adherence 
in health economic models in osteoporosis [5, 13, 30]. Despite this, these concepts are not yet 
routinely included. Moreover, when adherence was included, a lack of methodological rigor and 
consistency in definitions may reduce the impact of medication non-adherence. Few studies have 
included both persistence and compliance aspects of treatment adherence. It should however be 
noted that substantial improvements have been made in some recent studies. As discussed in this 
paper, the incorporation of medication compliance and persistence in pharmacoeconomic 
evaluations may be difficult and challenging, also depending on data availabilities. Further research 
is required and should include the development of appropriate methodology and standards [1]. 
The importance of integrating medication compliance and persistence in pharmacoeconomic 
analyses is evident in osteoporosis, but this extends beyond this disease area. Previous studies have 
shown that non-compliance and non-persistence have substantial economic impact in patients with 
hypertension [52], with diabetes mellitus [53, 54] or with renal transplantation [55]. Health 
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economic modelers should therefore consider the possible impact of non-adherence in all economic 
evaluations of drug or lifestyle interventions. 
FIVE-YEAR VIEW 
Medication compliance and persistence represents a new perspective on health technology 
assessment in osteoporosis [13]. It is our beliefs that, over the next five years, there will an increase 
in the health economic papers incorporating medication compliance and persistence. This will be in 
line with the collection of additional adherence data. Moreover, as strategies to improve compliance 
and persistence may confer clinical and cost-effectiveness benefits, we would expect research on 
the effectiveness and cost-effectiveness of such programs.  
KEY ISSUES 
 Medication non-compliance and non-persistence reduces treatment effectiveness, impact on 
healthcare costs and may therefore alter the cost-effectiveness of drug therapies  
 A few studies carried out to date have suggested important economic implications of poor 
compliance and persistence with osteoporosis medications. 
 Compliance and persistence should be an integral part of clinical (observational) studies and 
pharmacoeconomic analyses in order to estimate the cost-effectiveness of drug therapies in 
the current community practice. 
 Including adherence and incorporating it into health economic modeling may be difficult 
challenging. 
 Depending on their cost and effects, interventions to improve compliance and persistence 
with osteoporosis medications may confer cost-effective benefits. 
 The cost-effectiveness of specific adherence-enhancing interventions should be explored. 
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ABSTRACT 
OBJECTIVES: Medication non-adherence is common for osteoporosis, but the consequences have not 
been well described. This study aims to quantify the clinical and economic impacts of poor 
adherence and to evaluate the potential cost-effectiveness of improving patient adherence using 
hypothetical behavioral interventions. 
METHODS: A previously validated Markov microsimulation model was adapted to the Irish setting 
to estimate lifetime costs and outcomes (fractures and quality-adjusted life-year (QALY)) for three 
adherence scenarios: no treatment, real-world adherence and full adherence over 3 years. The real-
world scenario employed adherence and persistence data from the Irish HSE-PCRS pharmacy 
claims database. We also investigated the cost-effectiveness of hypothetical behavioral 
interventions to improve medication adherence (according to their cost and effect on adherence). 
RESULTS: The number of fractures prevented and the QALY gain obtained at real-world adherence 
levels represented only 57% and 56% of those expected with full adherence, respectively. The costs 
per QALY gained of real-world adherence and of full adherence compared with no treatment were 
estimated at €11,834 and €6,341. An intervention to improve adherence by 25% would result in an 
ICER of €11,511/QALY and €54,182/QALY, compared with real-world adherence, if the 
intervention cost an additional €50 and €100 per year, respectively. 
DISCUSSION: Poor adherence with osteoporosis medications results in around a 50% reduction in the 
potential benefits observed in clinical trials and a doubling of the cost per QALY gained from these 
medications. Depending on their costs and outcomes, programs to improve adherence have the 
potential to be an efficient use of resources. 
KEYWORDS 
Medication adherence, medication persistence, osteoporosis, intervention, cost-effectiveness. 
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INTRODUCTION 
The management of osteoporosis is becoming a major priority in public health. At least one in three 
women over 50 years of age, and one in five men, will suffer an osteoporotic fracture in their 
remaining lifetime [1]. These fractures result in significant morbidity and mortality, reduction in 
quality of life and pose considerable costs to already stretched health care systems [2, 3]. Figures 
derived from the International Osteoporosis Foundation estimate that approximately 300,000 people 
over the age of 50 years have osteoporosis in Ireland. This figure represents 25% of this population. 
The results of an Irish Burden of Illness Study demonstrated that fall related injuries in the elderly 
cost the Irish Health care system approximately €402 million each year [4].  With an increasingly 
elderly population and longer life expectancy the burden is set to increase. 
Fortunately, an increasing number of pharmacological agents have become available in the last ten 
years for the treatment of low bone mineral density. Numerous clinical trials and meta-analyses 
have shown that anti-osteoporosis medications and in particular the oral bisphosphonates 
significantly reduce the risk of both vertebral and non-vertebral fractures [5]. In addition, economic 
analyses, typically based on efficacy estimates drawn from clinical trials, have consistency shown 
these medications to be cost-effective in a wide range of patient profiles for both primary and 
secondary prevention [6, 7]. 
Despite the availability of proven effective pharmacotherapy for managing osteoporosis, studies are 
continuing to show that post fracture treatment with anti-osteoporotic medications remains 
suboptimal [8, 9]. Furthermore in more recent years the issue of non-adherence with drug therapy 
particularly in chronic asymptomatic diseases such as osteoporosis further compromises the clinical 
and economic effects of the management of these patients. Adherence to treatments in patients with 
osteoporosis has been found to be suboptimal in several studies [10-12]. These studies have 
concluded that between 50-75% of patients who were initiated anti-osteoporotic medications have 
discontinued their medications within 12 months of commencement. Although it is well recognized 
that poor adherence reduces the potential benefits of osteoporosis therapy, lowering gains in bone 
mineral density resulting in increased risk of fragility fractures [13], the clinical and economic 
consequences at a population level have been rarely studied [14, 15]. A few studies carried out to 
date have however suggested potential important clinical and/or economic implications of poor 
adherence to osteoporosis medications [16-19]. 
Adherence is influenced by health beliefs such as risk perception, perceived benefits and 
disadvantages of drugs, self-efficacy, as well as stage of change and communication problems with 
physicians [20]. Over recent years, behavioral interventions to improve patient adherence have been 
developed [21, 22]. Although their effectiveness still require further validation, educational 
programmes and patient counselling by nurses may be effective in improving patient adherence. 
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New therapeutic options with longer dosing regimens have also been recently available for the 
prevention and treatment of osteoporosis that may, at least in principle, further help to increase 
adherence. Under limited resources, it is becoming increasingly important to examine how cost-
effective an intervention should be in order for it to be considered worthwhile. Using simulation 
modelling, which allowed us to capture the long-term effects of medications, this study aims to 
quantify the clinical and economic effects of poor adherence with osteoporosis medications in 
Ireland and to estimate the potential cost-effectiveness of hypothetical interventions to improve 
medication adherence according to their cost and effect on adherence. 
METHODS 
A published and validated Markov microsimulation model on the natural history of osteoporosis 
was developed by Hiligsmann et al. (2009) [23] and has been frequently used to assess the cost-
effectiveness of osteoporosis management in Belgium [18, 24-28]. The model was recently updated 
with a 6-month cycle length to estimate the cost-effectiveness of denosumab [28]. We used this 
updated model to assess the clinical and economic burden of poor adherence from the Irish public 
healthcare perspective, i.e. the Health Services Executive (HSE). The model was programmed using 
the software TreeAge Pro 2011 (TreeAge Pro Inc., Williamston, MA, USA). 
The simulation model estimated fracture events, costs and quality-adjusted life years (QALYs) for 
three adherence scenarios: no treatment, real-world adherence and full adherence. The ‘no 
treatment’ scenario included no costs and no benefits of treatment. The real-world scenario 
employed adherence and persistence data from the Irish Health Services Executive-Primary Care 
Reimbursement Services (HSE-PCRS) pharmacy claims database for all treatment-naïve patients 
over the age of 55 years who started osteoporosis medications in Ireland between 2006 and 2009 
and the full adherence scenario assumed that patients were fully adherent over 3 years. Patients 
therefore received treatment in the model for a maximum of 3 years, because most clinical trials last 
only three years and adherence data were collected over this period. However, the model simulated 
a patient’s lifetime (that is, until death or 100 years) in order to capture all relevant costs and 
consequences of fractures experienced during treatment period.  
A description of the different components of the model is outlined in this section. Most model data 
are included in Table 1. More details can be found on Appendix 1. Please also refer to previously 
published research [17, 23] for limitations of the model and an illustration on how the model 
integrates memory [23].  
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Table 1| Fracture incidence, costs, excess mortality and utility values used in the model 
Parameter Women Men Reference 
Incidence (annual rate/1000 persons-years) 
Hip fracture 1.12 (60-64 y), 1.99 (65-69 
y), 4.73 (70-74 y), 9.80 (75-
79 y), 17.47 (80-84 y), 32.97 
(+85 y) 
0.62 (60-64 y), 1.51 (65-69 
y), 2.02 (70-74 y), 5.68 (75-
79 y), 10.69 (80-84 y), 
20.01 (+85 y) 
Health 
Atlas 
Ireland 
CV fracture 1.75 (60-64 y), 2.81 (65-69 
y), 6.67 (70-74 y), 8.32 (75-
79 y), 9.42 (80-84 y), 14.63 
(+85 y) 
1.97 (60-64 y), 1.81 (65-69 
y), 3.38 (70-74 y), 5.61 (75-
79 y), 6.56 (80-84 y), 14.13 
(+85 y) 
[1] 
Wrist fracture 3.28 (60-64 y), 4.42 (65-69 
y), 7.75 (70-74 y), 7.73 (75-
79 y), 9.78 (80-84 y), 12.36 
(+85 y) 
1.22 (60-64 y), 2.11 (65-69 
y), 0.60 (70-74 y), 1.59 (75-
79 y), 1.82 (80-84 y), 3.82 
(+85 y) 
[1] 
Other fracture* 2.55 (60-64 y), 4.98 (65-69 
y), 6.77 (70-74 y), 13.07 (75-
79 y), 15.40 (80-84 y), 35.10 
(+85 y) 
2.31 (60-64 y), 5.56 (65-69 
y), 5.18 (70-74 y), 6.91 (75-
79 y), 22.47 (80-84 y), 
28.67 (+85 y) 
[1] 
Relative risk of fracture attributable to osteoporosis 
Hip fracture 3.39 (60-69 y), 2.25 (70-79 
y), 1.57 (+80 y) 
4.76 (60-69 y), 3.58 (70-79 
y), 2.05 (+80 y) 
[29] 
CV fracture 2.18 (60-69 y), 1.77 (70-79 
y), 1.51 (+80 y) 
2.65 (60-69 y), 2.39 (70-79 
y), 1.93 (+80 y) 
[29] 
Wrist fracture 1.61 (60-69 y), 1.43 (70-79 
y), 1.30 (+80 y) 
1.81 (60-69 y), 1.70 (70-79 
y), 1.50 (+80 y) 
[29] 
Other fracture 1.90 (60-69 y), 1.61 (70-79 
y), 1.42 (+80 y) 
2.23 (60-69 y), 2.05 (70-79 
y), 1.73 (+80 y) 
[29] 
Excess mortality after hip and clinical vertebral fracture 
0-6 m, 6-12 m , subs y 4.53, 1.75, 1.78 5.75, 2.31, 1.69 [32] 
Direct fracture costs (in €2008) 
Hip, 1st 6-month From 11,215 to 13,140 From 12,053 to 14,042 Health 
Atlas 
Ireland 
Hip, yearly long-term 
costs 
From 4,449 to 4,805 From 4,523 to 4,845 HSE and 
[35] 
CV, 1st 6-month From 1,950 to 2,285 From 2,096 to 2,442 [36] 
Wrist, 1st 6-month From 1,624 to 1,903 From 1,746 to 2,034 [36] 
Other, 1st 6-month From 1,947 to 2,281 From 2,093 to 2,438 [36] 
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Health states utility values 
General population 0.83 (60-69 y), 0.77 (70-79 
y), 0.72 (+80 y) 
0.84 (60-69 y), 0.78 (70-79 
y), 0.71 (+80 y) 
[37] 
Hip (1st y / subs. y)** 0.80 / 0.90 [37] 
CV (1st y / subs. y)** 0.72 / 0.93 [37, 53] 
Wrist (1st y / subs. 
y)** 
0.94 / 1.00 [37, 53] 
Other (1st y / subs. 
y)** 
0.91 / 1.00 [37] 
CV: clinical vertebral, M:  month, Y:  year, Subs: subsequent 
* Other fractures included humerus, tibia/fibula, pelvis and ribs fractures 
** Relative reduction in health utility value, represents the proportional loss of QALY due to the fracture 
MODEL STRUCTURE 
Figure 1 provides an overview of the model. The model health states are no fracture, death, hip 
fracture, clinical vertebral fracture, wrist fracture, other fracture and the corresponding post-fracture 
states. Post-fracture states were created as some parameters (e.g. fracture disutility) were estimated 
over a 1-year period [28]. All the patients, one at a time, began in the ‘no fracture’ state and had, 
every 6 months, a probability of having a fracture of the hip, clinical vertebrae, wrist, or other site 
or dying. Patients in a fracture state can stay in the same fracture state if they re-fracture, change to 
another fracture state, die or change in the next cycle to the post-fracture state. Patients being in any 
post-fracture state might have a new fracture (all fracture types are possible), die or move to the ‘no 
fracture’ state. Tracker variables were created to record the number of each fracture type and used 
to adjust transition probabilities, costs and utilities to reflect the impact of prior fractures. 
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Figure 1| Model structure 
 
Transitions to death and from post-fracture states to any fractures states, ‘Death’ and ‘No Fx’ were 
excluded from the graph for simplicity. FX: fracture; CV: clinical vertebral 
FRACTURE INCIDENCE AND MORTALITY RATES 
Analyses were assessed in patients receiving osteoporosis medications. In Ireland at present, there 
are no conditions attached for the reimbursement of anti-osteoporosis therapies. Unlike the United 
Kingdom and other European countries Ireland has access to unlimited prescribing of these 
products. Therefore clinicians make their decision on whether or not to prescribe these products 
based on the results of densitometry and bone mineral density (BMD) levels, history of fracture, 
risk factors, etc. In this study, we assumed that all treated patients have the same risk as patients 
with osteoporosis, based on the definition of the World Health Organization (i.e. BMD T-score ≤-
2.5). All patients were therefore assumed to have the same base-case risk before treatment efficacy 
is impacted.  
In order to accurately reflect the risk of patients with BMD T-score ≤-2.5 in comparison with that of 
the general population, the risk of fracture in the general population was adjusted by relative risk 
parameters, using a previously validated method [29] (see Appendix 1 for further details). The 
incidence of hip fractures in the general population was derived from the Health Atlas Ireland, for 
year 2008 (http://www.hse.ie/eng/services/maps/). Since the incidence of other fractures was not 
known, we assumed that the age- and sex-specific ratio of index fracture to hip fracture in Ireland 
was the same as found in Sweden [1]. This assumption, used in the development of many FRAX® 
models [30], appears to hold true for West European countries, the USA and Australia [31]. 
Age-specific mortality rates are available from the Central Statistics office in Ireland and excess 
mortality was modelled after hip and vertebral fractures [32]. Because excess mortality may be 
No Fx 
Death 
Wrist Fx Other Fx 
CV Fx Hip Fx 
Post Other Post Wrist 
Post Hip Post CV 
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attributable to comorbidities, we conservatively assumed that only 25% of the excess mortality 
following a hip or vertebral fracture could be directly or indirectly attributable to the fractures 
themselves [33, 34].  
FRACTURE COST 
The perspective of the public healthcare payer (i.e. the Health Services Executive) was adopted for 
all cost estimates. Only direct medical costs were reported. All costs were reported as 2008 values. 
Direct hip fracture costs are divided into hospitalization cost (in the first cycle following the 
fracture) and long-term costs for patients being institutionalized following the fracture. The 
hospitalisation cost of hip fracture was obtained from the Hospital In-Patient Enquiry (HIPE) 
system for 2008 and the associated Disease Related Group costs, (http://www.healthatlasireland.ie). 
The cost of nursing home was selected from the average cost of approved private nursing homes in 
Dublin North East and Dublin Mid Leinster (N=185) (requested from the Health Services 
Executive) and the probability of admissions to nursing home after a hip fracture was derived from 
the study of Berringer et al. (2006) [35]. Of 2034 subjects (men and women) living at home at the 
time of fracture, 10% were in nursing home care after one year. Because patients might be 
institutionalized later in life in any case, regardless of their hip fracture, an adjustment was made to 
only include long-term costs attributable to the fracture itself [23].  
Non-hip fractures have been quantified relative to hip fracture on the basis of their costs [36]. So, 
the costs of wrist, clinical vertebral and other fracture represent 17.4%, 14.5% and 17.4% of the 
acute hip fracture cost, respectively. Non-hip fractures were conservatively assumed to be not 
associated with long-term costs. 
FRACTURE DISUTILITY 
Utility values for the general population as well as relative reductions due to fractures in the year 
following the fracture and in subsequent years were derived from a recent systematic review, which 
suggested reference values for countries that do not have their own database [37]. The model took 
into account that the number of fractures is a predictor of quality of life. In the case of an 
occurrence of a second fracture at the same site, the impact of the first fracture event was reduced 
by 50%, as previously suggested [23]. For example, if a patient with a prior hip fracture suffered 
another hip fracture, the relative reduction of utility attributable to the first hip fracture was then 
0.95 and the total reduction of utility attributed to both fractures was therefore 0.76 (= 0.95 X 0.80) 
in the year following the fracture. For an individual with both a hip and vertebral clinical fracture, 
the total impact on QALY was assumed to be equal to the sum of the impacts related to each of the 
fractures [26]. 
DRUG THERAPY 
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Treated patients were assumed to receive the effectiveness of oral bisphoshonates, the most widely 
prescribed anti-osteoporosis medications in Ireland and worldwide. The clinical effectiveness of 
oral bisphosphonates in the treatment of women with osteoporosis was derived from a recent meta-
analysis conducted for the National Institute for Health and Clinical Excellence (NICE) appraisal 
and included large randomised controlled trials on alendronate and risedronate [38]. The relative 
risks of fracture in the treatment group versus the placebo group were 0.71 for hip fracture, 0.58 for 
clinical vertebral fracture and 0.78 for wrist and other fractures assuming the relative risk for other 
non-vertebral fracture. The effect of treatment was assumed to linearly decline to zero after 
stopping therapy, during a duration (called offset-time) equal to the duration of therapy, in line with 
clinical studies [39]. The mean annual drug cost for patients taking osteoporosis medications in 
Ireland was estimated at €422.3 for women and at €417.0 for men. The costs of the drugs are taken 
from the Health Service Executive-Primary Care Reimbursement Services Scheme (HSE-PCRS). In 
this particular scheme, there is no co-payment for the patients. Monitoring cost includes one yearly 
physician visit (€65, Health Services Executive, http://www.hse.ie) and one bone densitometry 
measurement every second year (estimated at €90, Irish Osteoporosis Society, 
http://www.irishhealth.com/article.html?id=7099). Adverse events were not included in the analysis 
since randomised studies have not shown significant differences between placebo and actively 
treated patients [5]. 
MEDICATION ADHERENCE 
Adherence data were obtained from the Irish HSE-PCRS database formerly the General Medical 
Services (GMS) Payments Board scheme. This scheme provides free healthcare to approximately 
30% of the Irish population (approximately 1.2 million). Eligibility for the scheme is means tested 
for those under 70 years of age, and is confined to persons who are unable without undue hardship 
to arrange general practitioner services for themselves and their dependants. Patients registered 
under this scheme are dispensed all medicines free of charge. From July 2001 – December 2008, the 
service has been made available to all those over 70 years of age. While the HSE-PCRS population 
cannot be considered representative of the entire population, as the elderly and the socially 
disadvantaged are over-represented, it is estimated to account for approximately 70% of all 
medicines dispensed in primary care. National prescription files were analysed for the years 2006-
2009 to identify all prescription items relating to medicines dispensed for the management of 
osteoporosis (ATC code M05B) in all patients aged 55 years and above. New users of anti-
osteoporosis medications were defined as those not receiving any medication for osteoporosis in the 
previous 12 months. The final adherence database included a total of 70,669 women and 12,613 
men with the majority of these aged over 75 years. 
Both persistence and adherence to treatment were measured using the pharmacy claims database. 
Persistence is defined as “the duration of time from initiation to discontinuation of treatment” [40]. 
CHAPTER 6 
128 
 
Persistence was defined as a dichotomised variable (persistent or not) as to whether a patient 
continued therapy beyond an elapsed time period. In this study we vary the time periods (i.e. 6 
months to 3 years) and a permissible gap of 9 weeks was selected in the base-case as monthly 
regimens were included in the database. In the subgroup of persistent patients, adherence was 
calculated as the medication possession ratio (MPR) which is the ratio between the number of days 
of medication supplied to the number of days in a time interval. Adherence can be dichotomised 
(adherent or non-adherent) according to the MPR. The conventional approach is to use a cut-off of 
0.8 [41], but this was varied in sensitivity analysis. Patients with a MPR greater than or equal to 0.8 
were therefore considered to be adherent, in the base-case analysis. The probability of patients 
restarting therapy one year after stopping was also estimated. All analyses were performed using 
SAS (v9.1, SAS Institute Inc, Cary USA).  
In the model, patients were at risk of discontinuation within 3 years. For patients who stopped 
taking their therapy, the treatment cost was stopped in the middle of the dropout cycle and the 
offset-time period started at the same time. For those who discontinued therapy within six months, 
no treatment effect was received [42], as at least 6 months of treatment is necessary to reduce the 
risk of fractures [43, 44]. The mean drug cost of these patients, administrated in the first cycle of the 
model, was specifically estimated at €119.13 for women and at €97.40 for men (HSE-PCRS 
database). Patients who discontinued therapy can restart therapy after one cycle without treatment. 
The maximum duration of treatment remains however limited to three years from the start of the 
simulation. 
Poorly adherent patients (MPR <0.8) suffer from a lower treatment efficacy. Poor adherence was 
associated with a 17% increase in fractures rates (RR=1.17, 95% CI 1.09-1.25) [10]. The relative 
risks from the NICE meta-analysis were applicable to the population with adherence of 0.8 or 
greater. So, for instance, if oral bisphosphonates was assumed to reduce the risk of hip fracture by 
29%, then adherent patients would experience a 29% reduction in hip fracture while poorly 
adherent patients would experience only a 17.1% (0.71 X 1.167 = 0.829) reduction in hip fracture. 
Drug costs in the groups of poorly and highly adherent patients were adjusted by the mean MPR of 
the group. In the full adherence scenario, drug cost was equal to the MPR of the group of adherent 
patients (i.e. MPR ≥0.8) (See Appendix 2, Table 3). Adherent patients from the real-world 
adherence scenario and patients from the full adherence scenarios were therefore associated with 
the same drug cost. 
ANALYSES AND SIMULATION 
Patients were stratified into groups according to sex (female/male) and age (55–64 years, 65–69 
years, 70–74 years, and 75+ years). They entered into the model at the age of 60 years, 67 years, 72 
years and 80 years for the different age groups, respectively. First-order Monte-Carlo 
microsimulations (trials) were performed for each scenario, and fractures, costs, and QALYs were 
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recorded over 3 years and over a patient’s lifetime. A single outcome’s value is the sum of the 
outcomes (i.e. costs and QALYs) from the states traversed by an individual. By simulating patients 
one by one, a microsimulation model introduces variability between patients that can be reduced by 
simulating a large number of patients.  200,000 trials were deemed sufficient to guarantee the 
stability of the results [28]. To enable variability analyses, each model was run 10 times with 
200,000 patients. 
The potential loss of benefits resulting from poor adherence was first estimated by comparing the 
outcomes (i.e. number of fractures and QALYs) obtained at real-world adherence levels with those 
expected with full adherence. The number of fractures resulting from poor adherence in patients 
from the database was then determined by multiplying the difference between the lifetime number 
of fractures in the full and real-world adherence scenarios by the number of patients included in the 
different age and sex groups. The incremental cost-effectiveness ratio (ICER) was calculated 
between the three adherence scenarios. ICER is defined as the difference in terms of (lifetime) cost 
between strategies divided by their difference in terms of (lifetime) effectiveness (here measured as 
QALYs). An ICER represents the incremental cost per one QALY gained. Mean ICER and the 95% 
confidence interval (CI) were calculated for each analysis. Future costs and health effects (QALYs) 
were discounted by 4% annually, according to the Irish guideline for cost-effectiveness research 
[45].  
Sensitivity analyses were performed to assess the impact of assumptions on the results. These 
include changes in fracture risk, cost and disutility, excess mortality and assumptions on medication 
adherence. In particular, other refill gaps and MPR thresholds were examined. Additional 
simulations estimated the cost-effectiveness of hypothetical adherence-enhancing interventions 
according to their cost (marginal and one-time costs) and effect on adherence (improvements 
between 10% and 50% [21]). As interventions can be associated with marginal (e.g. monitoring) or 
one-time (e.g. education program) costs, both aspects were investigated. 
RESULTS 
ADHERENCE DATA 
In women, persistence rates were 64.3%, 52.7% and 45.0% after 1, 2 and 3 years, respectively 
(Table 2). These values were 60.0%, 41.1% and 29.4% in men. In the subgroup of persistent 
patients, the probabilities of being highly adherent (MPR ≥0.8) were estimated between 82.3% and 
93.0%. 
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Table 2| Persistence and adherence data in Irish women and men* 
Follow-up 6 month 1 year 1.5 years 2 years 2.5 years 3 years 
Women 
  Non-persistence 26.2% 35.7% 41.9% 47.3% 51.9% 55.0% 
  Poor adherence 13.1% 7.7% 5.9% 4.7% 4.1% 3.5% 
  High adherence 60.8% 56.6% 52.2% 48.0% 43.9% 41.5% 
  N persistent cases 52,192 42,819 35,925 30,051 24,983 20,781 
Men 
  Non-persistence 40.0% 51.8% 58.9% 64.0% 68.1% 70.6% 
  Poor adherence 10.0% 5.1% 3.4% 2.6% 2.3% 2.1% 
  High adherence 50.0% 43.2% 37.7% 33.5% 29.6% 27.3% 
  N persistent cases 7,569 5,557 4,246 3,323 2,567 1,991 
*Refill gap period of 9 weeks; MPR ≥0.8 to define high compliance, <0.8 to define poor adherence. 
Results are sensitive to the refill gap length and to the MPR threshold. So, for example, 56.8%, 
64.3% and 69.0% of women were considered as persistent after one year using a 5, 9 and 13 weeks 
refill gap respectively. The probability of being highly adherent was estimated on average at 94.1%, 
89.1% and 75.7% assuming a threshold of 0.7, 0.8 or 0.9 for high adherence, respectively.  
Re-initiation rates at one year were 25.4% for women and 21.5% for men, with a gap length of 9 
weeks. These values were 42.1% and 34.9%, and 16.9% and 14.5% with refill gap periods of 5 and 
13 weeks respectively. Mean MPR in the group of adherent and non-adherent patients ranged from 
0.95 to 0.96 and from 0.47 to 0.70, respectively.  
MODEL VALIDATION 
The model performed well during validation, producing fracture incidence and mortality rates that 
were similar to the observed data. Under the assumption of no treatment, absolute lifetime risks of 
hip fracture and of any major osteoporotic fractures (hip, vertebral or wrist) were estimated, 
respectively, at 21.3% and 39.6% for a women aged 60 years with the fracture risk of the average 
population, in the range of estimates reported in the literature [46]. Expected life expectancies were 
also very similar to empirical data (differences of less than 0.1 years). Furthermore, tests on model 
parameters and modeling assumptions (such as the effects of changing the value of some 
parameters) were consistent with expected conclusions. Model-based projections of prescription 
drug use were also validated. Using the model, we calculated the percentage of patients on 
osteoporosis drug therapy at 3 years (including patients who have restarted therapy after stopping). 
These values were 52.5% and 35.6% for women and men respectively, consistent with estimates of 
53.4% and 34.3% respectively from the adherence database. To determine the number of 
simulations, a varying number of trials (from 10,000 to 500,000) were run ten times and, as in the 
case of the Belgian version of the model [28], the distance between the upper and lower limits of 
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the 95% confidence intervals of the ICER of osteoporosis medications compared with no treatment 
reached a plateau from 200,000 trials. 
SOCIETAL BURDEN: BASE-CASE ANALYSIS 
Mean lifetime number of hip fracture per patient was 0.49 for the no treatment scenario, 0.47 for the 
real-world scenario and 0.46 for the full adherence scenario. The equivalent values for any 
osteoporotic fractures were 1.32, 1.27 and 1.23, respectively (Table 3). Therefore, the lifetime 
number of hip and all osteoporotic fractures prevented in the case of real-world adherence represent 
56.7% (95% CI 56.2%-57.3%) and 56.3% (95% CI 56.0%, 56.7%) to that estimated with full 
adherence scenario, respectively (Figure 2). The QALYs gain in the real-world adherence scenario 
was estimated at 56.0% (95% CI 54.6%, 57.5%) to that obtained under full adherence scenario. 
When assuming a 3-year time horizon, the number of fractures and the QALYs gain obtained at 
real-world adherence scenarios represent 65.7% (95% CI 65.9%-65.9%) and 65.4% (95% CI 
64.0%, 66.9%) to that estimated with the full adherence scenario, respectively. 
Table 3| Clinical and economic burden of poor adherence with osteoporosis medications: base-
case analysis (results at 3 years and over lifetime). 
Follow-up Adherence scenario Incremental values 
 No Treat RW Full RW vs  No 
Treat 
Full vs 
No Treat 
Full vs 
RW 
Patient cost over 3 years 
  Treatment cost 0 922 1,395 922 1,395 473 
  Disease cost 1,025 865 780 -160 -245 -85 
  Total cost 1,025 1,787 2,175 762 1,150 388 
Outcomes over 3 years       
  Hip fractures per patient 0.044 0.037 0.033 -0.007 -0.011 -0.004 
  All fractures per patient 0.146 0.123 0.111 -0.023 -0.035 0.012 
  QALYs per patient 2.001 2.006 2.008 0.005 0.007 0.002 
Patient cost over lifetime       
  Treatment cost 0 922 1,395 922 1,395 473 
  Total disease cost 11,425 10,769 10,284 -656 -1,140 -485 
      Acute fracture cost 5,170 4,848 4,658 -322 -512 -190 
      Long-term fracture cost 6,255 5,921 5,626 -334 -629 -295 
  Total healthcare cost 11,425 11,691 11,679 266 255 -12 
Outcomes over lifetime 
  Hip fractures per patient 0.495 0.475 0.460 -0.020 -0.035 -0.015 
  All fractures per patient 1.320 1.269 1.229 -0.052 -0.092 -0.040 
  QALYs per patient 6.638 6.661 6.678 0.023 0.040 0.017 
ICER (lifetime cost per lifetime QALY gained)  11,834 6,341 -659 
(95% CI)    (11,197-
12,470) 
(5,944-
6,739) 
(-1,488 
-171) 
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Figure 2| Impact of medication adherence and persistence on outcomes (expressed as number of 
fractures prevented and quality-adjusted life-year) and on (treatment, disease and total) 
costs 
 
Compared with no treatment, real-world adherence scenario was associated with an additional 
lifetime cost of €266.3 and a 0.023 lifetime QALY gain of, giving an ICER of €11,834 per QALY 
gained (95% CI €11,197-€12,470) as illustrated on Table 3. The full adherence scenario was 
associated over lifetime with a lower cost and a higher QALY than the real-world adherence 
scenario, giving a negative ICER of €-659 per QALY (95% CI €-1,488, €-171). Full adherence is 
said to be cost-saving compared with real-world adherence. 
For the 83,282 patients included in the database, the lifetime number of hip and of all osteoporotic 
types of fractures due to medication non-adherence was estimated at 1,271 (95% CI 1,238-1,304) 
and 3,340 (95% CI 3,295-3,386), respectively. These fractures result in a QALY loss of 1,470 (95% 
CI 1,398-1,544). 
SOCIETAL BURDEN: SENSITIVITY ANALYSES 
As observed on Table 4, the percentage of QALY loss due to poor adherence is substantially greater 
in men than in women. Other analysis suggests that the burden of adherence was primarily driven 
by persistence. Full adherence was responsible for 4.5% (= (3,340-3,191)/3,340) of the number of 
fractures, and 7.8% (=((100-56.3)-(100-59.7))/(100-56.3))) of the QALY loss, attributable to poor 
adherence. Definitions of non-adherence (i.e. refill gap period and MPR threshold) also had an 
impact on the results while baseline fracture risk and treatment efficacy markedly affected the 
number of fractures attributable to poor adherence. As more patients were good adherers when 
assuming a MPR threshold of 0.7, this scenario resulted in higher QALY gain and fractures 
prevented. 
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Table 4| Sensitivity analyses on the clinical burden (expressed in % of QALY gain* and in number 
of osteoporotic fractures**) of poor adherence with osteoporosis medications 
 % of QALY gain Number of fractures 
Base-case analysis 56.3 (54.5-57.5) 3,340 (3,295-3,386) 
Women 57.6 (56.2-59.1) 2,814 (2,771-2,856) 
Men 44.7 (42.6-46.8) 527 (519-535) 
5-week refill gap 50.9 (49.1-52.7) 3,779 (3,741-3,818) 
13-week refill gap 59.9 (58.2-61.6) 3,062 (3,033-3,092) 
Full compliance 59.7 (58.2-61.2) 3,191 (3,152-3,229) 
MPR of 90% 54.7 (53.3-56.1) 3,612 (3,579-3,645) 
MPR of 70% 58.0 (56.9-59.2) 3,266 (3,239-3,294) 
Treatment efficacy +20% 58.0 (56.9-59.1) 3,985 (3,952-4,017) 
Fracture risk +25% 54.5 (52.7-56.3) 4,342 (4,295-4,388) 
Fracture risk -25% 57.4 (56.1-58.5) 2,405 (2,375-2,435) 
* Percentage of QALY gain for the simulated scenario compared to that obtained with the full adherence scenario.  
POTENTIAL ADHERENCE-ENHANCING INTERVENTIONS 
Figure 3 presents the cost-effectiveness of potential adherence-enhancing interventions according to 
their cost and effect on adherence. So, for example, an intervention to improve adherence and 
persistence by 25% would result in an ICER of €11,511/QALY (95% CI €9,238-€13,784) and 
€54,182/QALY if the intervention cost an additional €50 and €100 per year, respectively. For 
potential interventions associated with a 50% increase in adherence rates, their cost-effectiveness 
was estimated at €26,999 per QALY (95% CI €25,034-€28,965) and €56,195 per QALY (95% CI 
€52,084-€60,166) for additional annual costs of €100 and €150, respectively. In other terms, a 
program to improve adherence and persistence by 10%, 25% or 50% would remain cost-effective at 
a threshold of €45,000 per QALY if it cost a maximum of €119.4, €299.0 and €726.3 annually per 
patient, respectively.  
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Figure 3| Cost-effectiveness (expressed in cost (in €) per QALY gained) of adherence-enhancing 
interventions according to their cost and effect on adherence. The cost-effectiveness is 
graphically presented by the black lines and the grey lines represent the lower and 
upper limits of the 95% confidence interval.  
 
QALY quality-adjusted life-year 
DISCUSSION 
Poor adherence undermines the potential effectiveness of osteoporosis medications in preventing 
fractures. Using simulation modeling, we estimated that approximately 50% of the expected 
benefits of osteoporosis medications were lost due to non-adherence. Moreover, poor adherence 
resulted in approximately a doubling of the cost per QALY gained from these medications. 
Sensitivity analyses in line with the results of other published studies [47] have shown that non-
persistence is the leading problem with adherence: with more than 90% of the clinical burden of 
poor adherence resulting from non-persistence. We also investigated the economic value of 
improving patient adherence using a variety of hypothetical interventions and our results suggest 
favorable ICER for the majority of intervention effects and cost assumptions. 
Studies in other countries have also shown that adherence with osteoporosis medications may have 
clinical and/or economic implications [16-19] but they have rarely examined the impact of both 
persistence and adherence on clinical and economic outcomes. A similar analysis was conducted in 
Belgian women using a prior version of the same model [17]. This analysis suggested that poor 
adherence with osteoporosis medications reduced the expected number of fractures and QALY gain 
by around 60%. The lower estimate in our study may be explained partially by longer refill gap 
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length for persistence and re-initiation of patients who discontinue therapy. Recent analyses have 
also suggested in other settings that interventions to improve osteoporosis medication adherence 
will likely have favorable ICERs if their efficacy can be sustained [17, 48]. 
Strengths of this study include the large-scale prescribing database that estimates persistence, 
adherence and re-initiation rates in both men and women with varying definitions for non-
adherence (MPR threshold and gap lengths). We have also chosen a validated Markov 
microsimulation [23] that has been frequently used to assess the cost-effectiveness of osteoporosis 
management [18, 24-28]. Conservative assumptions were used and many sensitivity analyses were 
performed to show the potential impact of parameter assumptions and data on the results. National 
healthcare registers were also used to collect data for the model such as fracture incidence, fracture 
cost and the cost of medications. 
Our study also presents some important improvements in the methodology to incorporate 
medication adherence and persistence in modeling of osteoporosis that increase the accuracy and 
reliability of the analysis. So, for the first time ever, patients can restart therapy in the model after 
discontinuation; the cost of highly and poorly adherent patients was related to the mean MPR of the 
group and a specific cost was assumed for patients who discontinued therapy prematurely.  
Moreover, patients were at risk of discontinuation in half of every cycle and the offset time was 
related to time on therapy [49]. One potential weakness of our analysis is that the impact of poor 
adherence on fracture efficacy was not available in Ireland and was derived from a large US study 
[10]. The impact of adherence on fracture risk was however of the same magnitude in many studies 
[13]. In addition, for patients who restart therapy after a period of interruption, the same adherence 
level was applied. Such patients may however resume at a less adherent level but this would require 
further investigation. 
Another potential limitation of this study is that using prescription refill rates may overestimate 
medication adherence because it assumes that patients take all of the dispensed medications, but not 
necessarily persistence.. Prescription refill rates are, however, generally the only way to estimate 
adherence and represent a reliable and inexpensive way of evaluating persistence and 
adherence[50]. Another reason for the underestimation of the burden of poor adherence is the lack 
of inclusion of primary non-adherent patients. This term refers to patients who never fill a 
prescription. These patients were not included in the database since our study was based on 
pharmacy records of filled prescriptions. In addition, our manuscript deals primarily with direct 
costs. Decrease in medication adherence reduces significantly medications effects and subsequently, 
increases the need for surgery. Lack of adherence and the subsequent fracture increase also impact 
on all health care resources utilization including physiotherapy and occupational therapy. Caregiver 
costs as well as loss of productivity and absenteeism were also shown to be significant in 
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osteoporosis management [51] and lack of adherence in osteoporosis medications may potentially 
result in over utilization of pain medication which can also be linked to decrease productivity, 
Another limitation is that highly adherent patients will achieve reductions in fracture risk based on 
meta-analysis from published clinical trials. This seems plausible because trials are likely to reflect 
the highest achievable rate of adherence in actual practice. However, because adherence in all the 
trials (and not unique to osteoporosis) is not optimal for all the patients, the efficacy from these 
trials is likely to be reduced to some degree because of non-adherence and non-persistence. 
Therefore, we probably underestimated the true underlying risk reduction with therapy [52]. 
Another limitation is the use of a dichotomous measure for persistence and adherence which is 
likely to result in a loss of power between patients who are fully non-adherent and those who are 
just below the cut-off point for adherence. 
Finally, like all models, several limitations must be taken into account. The most important are 
availability of data. Although much of the data used to construct the model was extracted from the 
Irish datasets, some data were extrapolated from other countries, as was the case for the Belgian 
model [23]. In particular, the impacts of fractures on health-related quality of life were generally 
derived from a Swedish study [53]. Although fracture disutility tends to be similar between several 
countries [37], differences may be present between Irish and Swedish patients. It could  be argued 
that hip fractures are the fracture type considered to be the key driver in the cost-effectiveness of 
osteoporosis medications [54] and their incidence and costs were estimated from a local database. 
Potential limitations of the model have been previously extensively discussed [17, 23]. In particular, 
threshold for adherence remains uncertain since there is no clinically meaningful definition for high 
adherence. Further studies should re-examine the 0.8 threshold for adherence.  
Generalizability of the results to the whole population may also be uncertain since adherence and 
persistence data were based on a sub-population in Ireland which is more socially deprived and 
elderly. However, we do not expect that adherence and persistence data will substantially differ.  
Our analysis may have important clinical and economic implications. First, it suggests that poor 
adherence can be considered as the critical hurdle to osteoporosis management. Improving 
adherence is therefore becoming urgent but remains a complex issue. Behavioral programs to 
improve adherence with osteoporosis medications have been initiated but few interventions were 
efficacious, and no clear trends regarding successful intervention techniques can be identified [21]. 
New formulations and longer dosages regimens have also been recently available, which in 
principle can help to improve adherence [55]. Less frequent dosing regimens have been frequently 
associated with better adherence [56, 57]. There is a need to conduct additional research with 
behavioral interventions and to consider the impact of specific pharmacological treatments on 
medication adherence. As many determinants of poor adherence have been identified [58, 59], 
understanding patient’s preferences for osteoporosis treatments and involving patients into clinical 
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decision-making may certainly be useful in optimizing treatment selection and in improving 
adherence to therapy. Second, our analysis highlights the importance of integrating medication 
adherence and persistence in pharmacoeconomic analyses conducted in osteoporosis [26-29]. Poor 
adherence represents a new perspective on health economic assessment in osteoporosis [60] and our 
study may provide an interesting background for integrating medication adherence and persistence.  
In summary, this analysis suggests that poor adherence with osteoporosis medications results in 
approximately a 50% reduction in the potential benefits observed in clinical trials and a doubling of 
the cost per QALY gained from these medications. Moreover, depending on their costs and 
outcomes, programs to improve adherence have the potential to be an efficient use of resources. 
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APPENDIX 1. ADDITIONAL MODEL ASSUMPTIONS. 
This appendix aims to provide additional details on the data and assumptions used in the model. It includes information 
on: 1) increased risk attributable to osteoporosis, 2) fracture risk adjustment during simulation after fractures, 3) excess 
mortality after fractures, 4) long-term costs of hip fractures and (5 health state utility values. 
1) Increased risk attributable to osteoporosis 
In order to accurately reflect the risk in the population receiving osteoporosis medications (assumed to be the population 
with a bone mineral density (BMD) T-score ≤-2.5) in comparison with that of the general population, the risk of 
fracture in the general population was adjusted by relative risk parameters. 
Kanis et al. have suggested a method to adjust the fracture risk according to BMD [1]. This method allows estimating 
the relative risk of individuals below a threshold value compared with the fracture risk of the total population of that age 
(e.g. all those with osteoporosis). 
The risk of fracture of those with BMD below the threshold for BMD ( g ) at a certain age is 
Yearly incidence of the age group X       //)ln(/  gRRg  
“Where  is the mean and  is the standard deviation of BMD at the current age and ln (RR) is the e-log of the risk 
ratio of an individual with one standard deviation lower BMD as compared with another.   is the normal distribution 
function with equal 0 and standard deviation equal 1.[1] 
The mean and number of standard deviations of BMD were derived from the NHANES III [2] database for white men 
and women aged 60-69 years, 70-79 years and over 80 years. One standard deviation decrease in BMD was associated 
with an increase in age-adjusted relative risk of 1.8, 1.4 and 1.6 for clinical vertebral, wrist and other osteoporotic 
fracture, respectively [3]. The age-adjusted relative risk for hip fracture ranged from 3.1 at 60 years to 1.9 at 85 years 
[4].  
2) Fracture risk adjustment during simulation 
Fracture risk was adjusted when a new fracture occurred during the simulation. An increased risk of subsequent 
fractures was modeled for women who had a prior fracture at the same location. These increased relative risks were 4.4, 
2.3, 3.3, and 1.9 for vertebral, hip, wrist, and other fractures, respectively [5]. As a multiplicative hypothesis could not 
be supported at this time, we conservatively did not model an increased risk of subsequent fractures at sites different 
from that of the prior fractures. However, an increased relative risk of 2.3 is modeled for a hip fracture after a vertebral 
fracture, because this effect is largely supported by the literature [5]. All these increased relative risks were increased by 
a factor of 1.7 during the year following the fracture [6] and were reduced by 10% per decade above the age of 70 years 
[7]. Further subsequent fractures of the same type are assumed to have no additional effect. 
3) Excess mortality after fractures 
Based on the results of a recent meta-analysis [8], we assumed that hip fracture increases the probabilities of death in 
women (men) by 4.53 (5.75) in the first six months following the fracture (= mean of the periods 0-3 and 3-6 months), 
by 1.755 (2.315) in the period 6-12 months and by 1.779 (1.691) in subsequent years. This last was estimated as the 
mean of the excess mortality estimated between 1 and 10 years.  
The increased mortality following a clinical vertebral fracture has been found in many studies to be very similar and 
even slightly higher than those of a hip fracture [9-12]. Therefore, we suggested an impact of clinical vertebral fracture 
similar to that of hip fracture. 
It is also assumed that other osteoporotic fractures, included wrist fractures, are not associated with an increased 
mortality that could be attributable to the fracture, and this is consistent with published studies [12, 13]. 
We also suggested in a conservative manner that a second and further fractures at the same site will cause no greater 
excess mortality, except the increase for the year after they occur. However, we do assume an interaction of excess 
mortality between a vertebral and an hip fracture, based on the result of Cauley et al.(2000) [12]. 
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4) Long-term cost of hip fractures 
The long-term costs of hip fractures have been based on the proportion of patients being institutionalized following the 
fracture, estimated at 10% [14]. In economic models, it is assumed that a patient who enter into a nursing home will 
remain there for the rest of their lives [15] and thus the annual cost of being in the nursing home is added into the model 
for each remaining year of the patient’s life. However, this is a simplification providing a cost overestimation because 
the individuals might have been institutionalized later in life in any case, regardless of their hip fracture. Therefore, it is 
important to estimate only the long-term costs attributable to hip fracture, which could be reduced through fracture 
prevention [16]. In order to estimate the total cost attributable to fracture, we first reduced the proportion of individuals 
in a nursing home following a fracture (=100%) each year by the institutionalization rate in the general population. The 
annual hip fracture cost was obtained by multiplying the proportion of fractures related to institutionalization with the 
discounted annual cost of institutionalization (€49,539 per year, cost of shared private room). Then, we summed these 
values for each year until the age of average life expectancy. The proportion of long-term costs attributable to hip 
fracture was therefore estimated respectively at 97.0% (97.8%), 95.3% (96.1%) and 89.8% (91.3%) for women (men) 
aged 60-69, 70-79 and over 80 years, respectively. So, a 60 year old woman institutionalized after a hip fracture would 
have an annual long-term cost, for their remaining life years, equal to 0.970 X €49,539 = €48,449. If the fracture occurs 
at the age of 70 years, the annual long-term cost will be 0.953 X €49,539 = €47,211. The annual mean long-term cost of 
hip fracture will therefore depend on the age of the patient at the fracture event and it was, of course, discounted and 
therefore not constant over time.  
5) Health state utility values 
The relative reductions due to fractures in the year following the fracture and in subsequent years were applied to both 
women and men. The systematic review from which data were retrieved [17] included studies that were composed 
mainly of postmenopausal women. Few studies have specifically estimated the impact of fractures on quality of life in 
populations of men. However, the decrease in quality of life due to osteoporotic fractures in men appears comparable to 
that caused by post-menopausal osteoporotic women [18, 19]. Some reference values for fracture disutility (i.e. the 1-
year impact of clinical vertebral and wrist fractures) were derived from a Swedish study, in which the mean reduction in 
quality of life was estimated based on the collection of utility data with the EQ-5D questionnaire at baseline, 4 months 
and 12 months after different fractures on a patient sample of 635 male and female patients [20]. 
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APPENDIX 2. ADDITIONAL RESULTS AND SENSITIVITY ANALYSES 
This appendix aims to provide the readers with additional results. 
Table 1 present persistence and adherence data with osteoporosis medications in Irish men and women according to 
different refill gap periods (from 5 to 13 weeks). 
Table 1| Persistence and adherence data according to different refill gap periods* 
Follow-up 6 month 1 year 1.5 years 2 years 2.5 years 3 years 
Women 
9 weeks refill gap period (base-case) 
Non-persistence 26.2% 35.7% 41.9% 47.3% 51.9% 55.0% 
Poor adherence 13.1% 7.7% 5.9% 4.7% 4.1% 3.5% 
High adherence 60.8% 56.6% 52.2% 48.0% 43.9% 41.5% 
5 weeks refill gap period 
Non-persistence 31.4% 43.2% 51.1% 59.2% 64.6% 67.8% 
Poor adherence 9.5% 4.9% 2.2% 1.7% 1.5% 1.4% 
High adherence 59.0% 51.9% 46.6% 39.1% 33.9% 30.8% 
13 weeks refill gap period 
Non-persistence 22.5% 31.0% 36.7% 41.5% 45.8% 48.8% 
Poor adherence 15.8% 10.5% 8.4% 6.9% 6.2% 5.4% 
High adherence 61.7% 58.6% 54.9% 51.6% 48.0% 45.8% 
Men 
9 weeks refill gap period (base-case) 
Non-persistence 40.0% 51.8% 58.9% 64.0% 68.1% 70.6% 
Poor adherence 10.0% 5.1% 3.4% 2.6% 2.3% 2.1% 
High adherence 50.0% 43.2% 37.7% 33.5% 29.6% 27.3% 
5 weeks refill gap period 
Non-persistence 45.4% 58.2% 66.1% 72.3% 76.5% 78.9% 
Poor adherence 8.3% 3.9% 1.7% 1.3% 1.2% 1.2% 
High adherence 60.3% 52.9% 47.2% 39.5% 34.2% 31.0% 
13 weeks refill gap period 
Non-persistence 36.7% 47.7% 54.9% 59.9% 64.1% 66.7% 
Poor adherence 15.4% 10.2% 7.5% 6.0% 5.3% 4.9% 
High adherence 62.1% 58.8% 56.3% 52.5% 48.9% 46.3% 
* MPR of 0.8 or more to define high adherence 
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Table 2 shows the repartition of persistent patients according to MPR (Medical Possession Ratio) threshold to define 
high adherence. 
Table 2| Repartition of persistent patients according to MPR threshold 
Follow-up 6 month 1 year 1.5 years 2 years 2.5 years 3 years 
Women 
MPR of 0.8 (base-case) 
Poor adherence 17.7% 11.9% 10.1% 8.9% 8.4% 7.8% 
High adherence 82.3% 88.1% 89.9% 91.1% 91.2% 92.2% 
MPR of 0.7 
Poor adherence 8.9% 6.5% 5.6% 5.0% 4.7% 4.4% 
High adherence 91.1% 93.5% 94.4% 95.0% 95.3% 95.6% 
MPR of 0.9 
Poor adherence 23.8% 26.7% 24.9% 24.5% 23.6% 22.5% 
High adherence 76.2% 73.3% 75.1% 75.5% 76.4% 77.5% 
Men 
MPR of 0.8 (base-case) 
Poor adherence 16.7% 10.5% 8.3% 7.3% 7.3% 7.0% 
High adherence 83.3% 89.5% 91.7% 92.7% 92.7% 93.0% 
MPR 0.7 
Poor adherence 8.1% 5.0% 4.2% 4.1% 3.8% 3.4% 
High adherence 91.9% 95.0% 95.8% 95.9% 96.2% 96.6% 
MPR 0.9 
Poor adherence 24.2% 25.9% 23.8% 23.2% 22.6% 21.5% 
High adherence 75.8% 74.1% 76.2% 76.8% 77.4% 78.6% 
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In table 3, the mean MPR in the groups of highly and poorly adherent patients was estimated. These values 
were used in the model to adjust drug cost in both groups.   
Table 3| Mean medical possession ratio (MPR) in the groups of highly* and poorly adherent patients  
Follow-up 6 month 1 year 1.5 years 2 years 2.5 years 3 years 
Women 
Refill gap period of 9 weeks (Base-case) 
Poor adherence 0.679 0.656 0.636 0.615 0.597 0.581 
High adherence 0.962 0.957 0.956 0.954 0.953 0.954 
5-weeks refill gap 
Poor adherence 0.701 0.633 0.587 0.529 0.496 0.472 
High adherence 0.964 0.961 0.962 0.962 0.963 0.963 
13-weeks refill gap 
Poor adherence 0.658 0.650 0.650 0.635 0.627 0.618 
High adherence 0.962 0.955 0.955 0.950 0.949 0.949 
Men 
Refill gap period of 9 weeks (Base-case) 
Poor adherence 0.680 0.680 0.640 0.601 0.606 0.616 
High adherence 0.962 0.957 0.956 0.953 0.953 0.953 
5-weeks refill gap 
Poor adherence 0.704 0.661 0.581 0.516 0.483 0.508 
High adherence 0.964 0.962 0.963 0.962 0.962 0.962 
13-weeks refill gap 
Poor adherence 0.656 0.664 0.646 0.630 0.627 0.640 
High adherence 0.962 0.956 0.953 0.950 0.948 0.949 
* MPR of 0.8 or more to define high adherence 
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Table 4 presents, for the 83,282 patients included in the database, the repartition of the number of hip and of all 
osteoporotic types of fractures due to medication poor adherence and persistence according to sex and age groups. The 
number of fractures resulting from poor was determined by multiplying the difference between the lifetime number of 
fractures in the full and real-world adherence scenarios by the number of patients included in the different age and sex 
groups. 
Table 4| Number (95% confidence interval) of hip and of all osteoporotic fractures due to poor adherence, according to 
sex and age groups. Y: years 
 55-64 y 65-69 y 70-74 y + 75y Total 
Hip fractures 
Women 41 (36-46) 71 (67-74) 231 (221-242) 752 (722-781) 1094 (1064-1125) 
Men 8 (7-9) 10 (9-11) 37 (36-38) 121 (117-126) 177 (172-181) 
Total 49 (44-53) 81 (77-84) 268 (258-279) 873 (842-904) 1271 (1238-1304) 
All osteoporotic fractures 
Women 149 (141-156) 236 (230-242) 655 (638-671) 1774 (1735-1831) 2814 (2771-2856) 
Men 32 (30-33) 34 (33-35) 95 (93-96) 366 (359-374) 527 (519-535) 
Total 180 (173-188) 270 (263-277) 749 (732-767) 2140 (2100-2181) 3340 (3295-3386) 
Table 5 presents the incremental cost-effectiveness ratio between the adherence scenarios according to age and sex 
groups. The ICERs improved with increasing age and was lower in women than in men, especially for those aged over 
75 years as the benefits of prevented fractures is higher in women given the higher life expectancy.  
Table 5| Cost-effectiveness (expressed in cost (in €) per QALY gained) between adherence scenarios according to age 
and sex. 95% confidence intervals are provided in parentheses. RW: Real-World. Treat: Treatment. Y: year. 
 RW vs  No Treat Full vs No Treat Full vs RW 
Women    
55-64 y 69,704 
(54,088-85,119) 
57,033 
(44,903-69,164) 
40,574 
(24,353-56,795) 
65-69 y 29,127 
(24,455-33,800) 
18,579 
(16,565-20,593) 
5,465 
(3,153-7,777) 
70-74 y 10,221 
(8,757-11,686) 
4,313 
(3,314-5,311) 
-3,635 
(-5,954;-1,317) 
+ 75 y 1,823 
(341-3,305) 
-2,111 
(-2,901;-1,320) 
-7,587 
(-9,083;-6,092) 
Total 10,253 
(9,598;10,908) 
4,878 
(4,443-5,313) 
-2,437 
(-3,348;-1,526) 
Men    
55-64 y 78,409 
(62,404-94,415) 
56,438  
(45,597-67,278) 
38,899 
(30,491-47,308) 
65-69 y 46,183 
(38,408-53,959) 
35,013 
(30,548-39,478) 
25,514 
(21,629-29,399) 
70-74 y 27,921 
(25,390-30,452) 
15,750 
(14,388-17,112) 
6,514 
(5,144-7,884) 
+ 75 y 15,661 
(13,487-17,835) 
8,932 
(8,075-9,790) 
3,393 
(2,419-4,367) 
Total 26,159 
(24,260-28,058) 
16,625 
(15,840-17,410) 
8,916 
(8,300-9,532) 
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Table 6 provides additional sensitivity analyses on the incremental cost-effectiveness ratio between the adherence 
scenarios. 
Table 6| Sensitivity analyses on the incremental cost-effectiveness ratio (expressed in cost (in €) per QALY gained) 
between adherence scenarios 
 RW vs  No Treat Full vs No Treat Full vs RW 
Base-case 11,834  
(11,197-12,470) 
6,341 
(5,944-6,739) 
-659 
(-1,488 -171) 
Discount rates 3% 9,498 
(8,692-10,304) 
4,274 
(3,686-4,863) 
-2,646 
(-3,496 -1,800) 
Fracture risk +25% 2,894 
(2,216-3,572) 
-2,186 
(-2,637-1,735) 
-8,274 
(-9,408-7,141) 
Fracture risk -25% 25,767 
(24,418-27,115) 
18,620 
(17,986-19,253) 
8,993 
(8,251-9,735) 
Fracture cost +25% 2,489 
(1,361-3,617) 
-2,852 
(-3,579 -2,124) 
-10,575 
(-12,598 -8,553) 
Fracture cost -25% 19,358 
(18,401-20,316) 
14,408 
(13,914-14,903) 
7,455 
(6,401-8,510) 
Fracture disutility +25% 10,494 
(9,470-11,518) 
5,491 
(5,122-5,859) 
-797 
(-1,613, 18) 
Fracture disutility -25% 13,390 
(12,362-14,418) 
6,904 
(6,555-7,254) 
-1,507 
(-2,508 -506) 
No excess mortality 11,103 
(10,034-12,173) 
2,121 
(1,238-3,004) 
-10,164 
(-12,012 -8,316) 
Treatment efficacy +20% 4,570 
(4,024-5,116) 
342 
(27-657) 
-5,504 
(-6,448 -4,561) 
Refill gap 5 weeks 14,568 
(13,727-15,588) 
6,872 
(6,363-7,381) 
-1,196 
(-2,104 -288) 
Refill gaps 13 weeks 10,786 
(10,152-11,421) 
6,392 
(5,777-7,007) 
-173 
(-1,099, 753) 
Full compliance 11,487 
(10,624-12,351) 
6,386 
(5,821-6,950) 
-1,175 
(-2,224 -127) 
MPR of 0.9 13,975 
(12,976-14,975) 
6,708 
(6,140-7,275) 
-2,063 
(-3,346 -781) 
MPR of 0.7 10,557 
(10,059-11,055) 
6,169 
(5,819-6,519) 
98 
(-471 668) 
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Table 7 presents additional sensitivity analyses on the cost-effectiveness of adherence-enhancing interventions 
compared with real-world adherence scenario, including interventions associated with one-time cost at baseline (such as 
the cost of an education program). 
Table 7| Sensitivity analyses on the cost-effectiveness (expressed in cost (in €) per QALY gained) of adherence-
enhancing interventions  
 Adherence improvement 
 10% 25% 50% 
€100 per year of treatment   
Base-case 128,621 
(108,259-148,984) 
54,182 
(49,476-58,889) 
26,999 
(25,034-28,965) 
Men 128,898 
(105,842-151,955) 
60,914 
(53,693-68,134) 
35,509 
(33,485-38,333) 
Women 128,574 
(102,080-155,069) 
52,951 
(47,661-58,240) 
25,482 
(23,214-27,750) 
+75 years 110,509 
(69,116-151,902) 
41,859 
(31,543-52,175) 
18,549 
(16,877-20,222) 
One-time cost    
€100 32,906 
(26,395-39,416) 
-5,686 
(-7,704 -3,667) 
-15,571 
(-17,080 -14,062) 
€200 95,245 
(79,912-110,559) 
19,790 
(17,176-22,404) 
-4,394 
(-5,428 -3,361) 
€300 157,565 
(133,027-182,103) 
45,266 
(41,156-49,376) 
7,445 
(6,599-8,291) 
€400 216,894 
(186,067-253,722) 
70,741 
(64,888-76,594) 
18,953 
(17,519-20,388) 
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MINI-ABSTRACT 
This review suggests that several interventions, including simplification of dosing regimens, patient 
decision aids, electronic prescription, and patient education may improve medication adherence and 
persistence in patients with osteoporosis. We recommend that promising interventions are subjected 
to further rigorous evaluation to demonstrate that improved adherence translate to greater benefits. 
ABSTRACT 
PURPOSE: This study aims to systematically review, critically appraise and identify from the 
published literature, the most effective interventions to improve medication adherence in 
osteoporosis. 
METHODS: A literature search using Medline, EMBASE, Cochrane library and CINAHL was 
undertaken to identify prospective studies published between January 1, 1999 and June 30, 2012. 
We included studies on adult users of osteoporosis medications that tested a patient adherence 
intervention (e.g. patient education, intensified patient care, different dosing regimens) and reported 
quantitative results of adherence. The Delphi list was modified to assess the quality of studies. 
RESULTS: Of 113 articles identified, 20 studies fulfilled the inclusion criteria. The most frequent 
intervention was education (n=11) followed by monitoring/supervision (n=4), drug regimens (n=2), 
drug regimens and patient support (n=1), pharmacist intervention (n=1) and electronic prescription 
(n=1). Although patient education improved medication adherence in four studies, two large-scale 
randomized studies reported no benefits. Simplification of dosing regimens (with and without 
patient support program) was found to have a significant clinical impact on medication adherence 
and persistence. Monitoring/supervision showed no impact on medication persistence while 
electronic prescription and pharmacist intervention increased medication adherence or persistence. 
CONCLUSIONS: This review found that simplification of dosing regimens, decision aids, electronic 
prescription or patient education may help to improve adherence or persistence to osteoporosis 
medications. We identified wide variation of quality of studies in the osteoporosis area. The 
efficacy of patient education was variable across studies, while monitoring/supervision does not 
seem an effective way to enhance medication adherence or persistence. 
KEY WORDS 
 Adherence, osteoporosis, intervention, persistence. 
INTRODUCTION 
Sub-optimal adherence and persistence with appropriately prescribed medication are prevalent in 
osteoporosis. Several studies have demonstrated that between 50-75% of patients who were 
prescribed anti-osteoporotic medications have discontinued their medications within one year [1-5]. 
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Low medication adherence leads to lower gains in bone mineral density and higher fracture rates 
[6], resulting in substantial clinical and economic burden [7, 8]. Approximately 50% of the potential 
clinical benefits of osteoporosis medications may be lost due to poor adherence, [7, 9] and the cost-
effectiveness of osteoporosis management is significantly affected by reduced medication 
adherence [10, 11].   
There are many strategies aimed at improving adherence and persistence with medications. 
However, evidence across multiple treatments for a diverse range of diseases, suggests that the 
effectiveness of current methods is both variable and modest [12, 13]. With specific reference to 
osteoporosis, there have been several interventions and programs developed in recent years, 
probably in response to the increasing use of bisphosphonates, first introduced around 1990 [14]. 
This study aims to critically appraise the published literature on interventions to improve patient 
adherence and persistence with medications to treat osteoporosis and to determine the most 
effective interventions. A previous review [15] noted a lack of effective intervention in a small 
sample of eight studies. Since then, more interventions have been tested and published, and this 
review provides further examination of interventions to improve adherence and persistence in 
osteoporosis. 
METHODS 
SEARCH STRATEGY 
A literature search undertaken in accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA) guidelines (http://www.prisma-statement.org/) was carried 
out in Medline, EMBASE, Cochrane library and Cumulative Index to Nursing and Allied Health 
Literature (CINAHL) and using the following key words separated by Boolean operators: 
[osteoporosis, low bone density, bone fragility, fractures bone, bone demineralization, pathologic 
osteopenia, low bone mineral density, low bone mass, low bone turnover, low bone mass density 
OR bisphosphonates, diphosphonates, etidronic acid, clodronic acid, pamidronicate, risedronate 
acid, ibandronic acid, alendronate, calcium, colecalciferol, estrogens, hormone replacement therapy 
(HRT), raloxifene, vitamin D] AND [medication adherence, patient compliance, persistence, non-
compliance, non-persistence, concordance, non-concordance], AND [interventions, clinical trial, 
experiment, RCT]. The search period was from January 1, 1999 to June 30, 2012. We restricted our 
search to the last decade because as no adherence intervention for use in osteoporosis was identified 
before that period [15]. References of selected articles and of a prior review [15] were also 
searched. 
SELECTION CRITERIA 
We included interventional studies of adult users of osteoporosis medications (not limited to 
bisphosphonates) or calcium and vitamin D supplements that tested any intervention for an 
CHAPTER 7 
156 
 
improvement in adherence or persistence and reported quantitative measures of adherence and/or 
persistence. Non-English studies or observational studies were excluded. 
EXTRACTED INFORMATION 
Each paper was reviewed independently by two investigators (MH, MS, DH, PL, EM or FGS) and 
disagreements were resolved by consensus. The extracted information included study design, type 
of intervention, other characteristics of intervention, measurement of adherence, persistence, 
outcomes, population, follow-up time, ethics approval, sample size, statistical analysis, results of 
the intervention effect, medication possession ratios or other adherence or persistence measures, 
adjustment for confounders and clinical outcomes. Due to the heterogeneity in the methods of 
adherence measurement and of study outcomes, the analysis was focused on a qualitative 
assessment. 
QUALITY CRITERIA 
The Delphi list [16] was modified to assess the quality of studies. The original checklist contains 17 
domains and 8 items but elements to evaluate interventional behavioral studies were not included. 
Therefore, we added methodological items that were considered relevant for behavioral studies, and 
they included study design, type of intervention, measure of adherence, outcomes, population, 
follow-up time, ethics approval, sample size, statistical analysis and results. We assigned a score of 
1 if the study included the required item, otherwise zero. Therefore, the maximum score for an 
article that included all information related to study design, data collection, analysis and 
interpretation of results was 30 (Appendix 1). Consistency of quality scoring was achieved by 
having at least two reviewers scoring each paper independently. Only few discrepancies became 
evident and these were resolved by consensus. 
RESULTS 
There were 113 articles identified, and a total of 20 studies [17-36] fulfilled the inclusion criteria 
(Figure 1). Literature reviews (n=15), research that lacked a medication adherence intervention 
(n=45), disease management (n=11), economic studies (n=8), descriptions of protocols (n=2), and 4 
other were excluded. The most frequent intervention was education (n=11) followed by 
monitoring/supervision (n=4), simplification of dosing regimens (n=2), drug regimen combined 
with patient support (n=1), electronic prescriptions (n=1) and pharmacist intervention (n=1). 
Interventions were led by physicians (n=5), pharmacists (n=4), nurses (n=3), multidisciplinary 
teams (n=3), clinical personnel (n=3), health educators (n=1) and it was unknown in one study. 
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Figure 1| Flow diagram of studies  
 
 
 
 
 
 
 
 
 
 
 
The characteristics of included studies are reported in Tables 1 and 2. Eleven out of the twenty 
studies [21, 22, 28-36] were published since 2010. Fifteen studies were randomized controlled trials 
[18, 20, 21, 24-27, 29-36] and two were cross-over designs. Other studies were non-randomized 
uncontrolled studies [17, 19, 22, 23, 28]. Most tested an educational program, but these varied 
substantially between studies [17, 19, 21-24, 27, 28, 31, 35, 36] in the content and method of 
delivery, which included: group-based, face-to-face, telehealth program, or telephone counseling 
and written information (letters, leaflets, brochures). In one study [28], pharmacists led the 
intervention in decentralized clinical-pharmacy managed services. Patients included in the studies 
were mainly postmenopausal women with osteoporosis. In total, 14,662 patients were included in 
the studies; 9,420 in the intervention arm and 5,242 in the control arm; 64% of which were from 
four trials of more than 1,000 patients per trial [20, 24, 25, 35]. Most studies reported ethics review 
approval, and the follow-up after conduct of the intervention ranged from 4 to 48 months. 
Excluded 
Lack of adherence intervention = 45 
Reviews = 15 
Disease management = 11 
Economic = 8 
No quantitative data on adherence = 8 
Protocols = 2 
Other = 4 
 
Studies that fulfilled inclusion criteria = 20 
Education = 11 
Monitoring/supervision = 4 
Drug regimens = 2 
Drug regimens plus support = 1 
Electronic prescriptions = 1 
Pharmacist intervention = 1 
 
 
Identified abstracts = 113 
 
  
 
Table 1| Characteristics of studies identified which tested a patient adherence and/or persistence intervention 
References Design Interventions / Description / Lead by Population (inclusion 
criteria) / drug(s) being 
assessed 
N intervention / 
control 
Planned 
follow-up 
Blalock et al. 
(2002) [17] 
Non randomized 
non-controlled trial 
Patient education / 1
st
 intervention: tailored 
educational intervention delivered to individuals 
(written materials and telephone counseling 
session). 2
nd
  intervention included the Osteoporosis 
resource center, workshop and free bone density 
screening / Not stated 
Women / Calcium 714 / 0 1 year 
Clowes et al. 
(2004) [18] 
Randomized 
controlled trial 
Monitoring / Arm A: Patients with nurse at 12, 24 
and 36 weeks. Arm B: Idem + information on 
response to therapy based on BTM measurements / 
Nurses 
Subjects with osteopenia at 
either the spine or hip / 
Raloxifene 
24 and 25 (Arm 
A and B) / 24 
1 year 
Cook et al. 
(2007) [19] 
Non randomized 
non-controlled trial 
Patient education / Telehealth program using 
motivational interviewing and cognitive–behavioral 
techniques / Nurses 
Patients who received a 
prescription for risedronate 
402 / 0 6 months 
Cooper et al. 
(2006) [25] 
Randomized 
controlled trial 
Drug regimens and patient support / Monthly 
ibandronate tablet and patient support (information 
on osteoporosis, newsletter at 3 months) / 
Physicians 
Postmenopausal women 
diagnosed with osteoporosis 
/Weekly alendronate or 
monthly ibandronate tablet 
529 / 547 6 months 
Delmas et al. 
(2007) [20] 
Randomized 
controlled trial 
Monitoring / At week 13 and 25, all patients 
received information about the need to continue 
treatment. Intervention group received feedback on 
their response to therapy based on BTM 
measurements / Physicians 
Postmenopausal women 
diagnosed with osteoporosis / 
Risedronate 
2302 / 1113 1 year 
  
  
 
Freemantle et 
al. (2012) [26] 
Randomized 
(crossover) 
controlled trial 
Drug regimens / Subcutaneous denosumab, 60 mg 
every 6 month versus oral alendronate, 70 mg once 
weekly / Clinic personnel 
Postmenopausal women 
diagnosed with osteoporosis / 
Denosumab or alendronate 
106 
(denosumab) / 
115 
(alendronate)* 
24 months 
Guilera et al. 
(2006) [27] 
Randomized 
controlled trial 
Patient education / Educational leaflet with general 
information about osteoporosis, and attending 
physician spent 15 min reviewing the contents of 
the leaflet with each participant / Physicians 
Postmenopausal women 
diagnosed with osteoporosis / 
Raloxifene 
366 / 379 12 months 
Heilmann et 
al. (2012) [28] 
Non-randomized 
controlled trial 
Pharmacist-directed intervention / Decentralized 
clinical-pharmacy-based osteoporosis management 
service / Pharmacists 
Women with a diagnosis 
code for a fracture / 
Osteoporosis medications 
291 / 71 12 months 
Hill et al. 
(2010) [29] 
Randomized 
controlled trial 
Electronic prescription / Electronic prescription for 
the calcium carbonate product with the Electronic 
medical record system / Physicians 
Women between 19 and 50 
years old, who attended a 
general obstetrics and 
gynecology practice / 
Calcium 
123 / 122 6 months 
Kendler et al. 
(2011) [30] 
Randomized 
(crossover) 
controlled trial 
Drug regimens / Subcutaneous denosumab, 60 mg 
every 6 month versus oral alendronate, 70 mg once 
weekly / Clinic personal 
Postmenopausal women 
diagnosed with osteoporosis / 
Denosumab or alendronate 
126 
(denosumab) / 
124 
(alendronate)* 
12 months 
Lai et al. 
(2011) [31] 
Randomized 
controlled trial 
Patient education and counseling / Participants 
received counseling on osteoporosis, risk factors, 
lifestyle modifications, goals of therapy, side 
effects and the importance of adherence / 
Pharmacists 
Postmenopausal women 
diagnosed with osteoporosis / 
Weekly alendronate or 
risedronate 
100 / 98 12 months 
Montori et al. 
(2011) [32] 
Randomized 
controlled trial 
Patient education and shared-decision making / 
Patients received the osteoporosis choice decision 
aid / Physicians 
Postmenopausal women with 
osteoporosis or osteopenia / 
Bisphosphonates 
52 / 48 6 months 
  
  
 
Nielsen et al. 
(2010) [21] 
Randomized 
controlled trial 
Patient education and information / Group-based 
education program, i.e. “school” group (12 hour) / 
Multidisciplinary team 
Patients diagnosed with 
osteoporosis / Osteoporosis 
medications 
300 / 150 2 years 
Ojeda-Bruno 
et al. (2010) 
[22] 
Non randomized 
non-controlled trial 
Patient education / 2 hour education session / 
Nurses and physicians 
Adults older than 50 years of 
age with a fragility fracture / 
Bisphosphonates 
380 / 0 4 years 
Robbins et al. 
(2004) [23] 
Non randomized 
non-controlled trial 
Patient education / Teaching about osteoporosis, 
estrogen and calcium / Nurses 
Some women from the on-
going 3 year low-dose 
estrogen study 
109 / 0 1 year 
Roux et al. 
(2012) [33] 
Cluster randomized 
controlled trial 
Monitoring / Bone marker was given at week 6 
visit, together with a standardized message about 
the change compared to baseline / Physicians 
Postmenopausal women with 
osteoporosis / Oral 
ibandronate 
249 / 343 12 months 
Shu et al. 
(2009) [24] 
Randomized 
controlled trial 
Patient and physician education / Physicians 
learned specific teaching techniques while patients 
received letters and automated telephone calls / 
Trained pharmacists (for physicians) 
Participants from the parent 
trial and at risk for 
osteoporosis / Osteoporosis 
medications 
1867 patients 
and 436 GPs / 
875 patients 
10 months 
Silverman et 
al. (2012) [34] 
Randomized 
controlled trial 
Monitoring and education / (A) bone marker results 
at baseline, 3 and 12 months; (B) educational 
materials every month and a membership in the 
National Osteoporosis Foundation; (C) bone marker 
and educational information / Study personnel or 
primary care provider 
Postmenopausal women with 
osteoporosis / Oral 
bisphosphonates 
60 (A) / 60 (B) / 
60 (C) / 59 
(control) 
12 months 
Solomon et al. 
(2012) [35] 
Randomized 
controlled trial 
Patient education and counseling / Program of 
telephone based counseling / Health educators 
Individuals newly prescribed 
a medication for osteoporosis 
/ Osteoporosis medications 
1046 / 1041 12 months 
Yuksel et al. 
(2010) [36] 
Randomized 
controlled trial 
Screening and patient education / Tailored 
education program on aspects of osteoporosis / 
Pharmacists 
Patients with osteoporosis / 
Calcium 
129 / 133 4 months 
* Per protocol Analysis 
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Table 2 presents primary outcomes, method of adherence measurement, statistical analysis, results, 
and quality score. All studies used adherence as primary outcome except one study [20] that only 
reported persistence and two studies where adherence was used as a secondary outcome 
(persistence being the primary outcome) [28, 36]. Eight studies reported both adherence and 
persistence data [18, 24-26, 30-32, 35]. Adherence definitions varied: where an explicit cut-off was 
used to define adherence (e.g. >80% of doses taken), this was applied to calculate the proportion of 
patients adhering to therapy at time T, proportion of patients taking their medicine correctly, 
medication possession ratio. In other cases, patients were labeled as adherent without an explicit 
cut-off. Persistence was defined as the proportion of patients continuing treatments at a given 
follow-up time. Adherence and persistence outcome data were collected from prescription records 
(n=7), electronic monitoring (n=5), self-report questionnaire (n=6) and two did not provide the 
information [17, 33]. None of the studies examined adherence or persistence in relation to clinical 
outcomes. Eight studies had adjustments for some potential confounders [20, 21, 25, 26, 30, 31, 34, 
35] which may not be necessary in properly randomized trials where confounding variables would 
presumably be distributed evenly across the arms of the trial. Sixteen studies described the 
characteristics of patients lost during follow-up [7, 18-23, 25-27, 30-32, 34, 35]. 
  
 
Table 2| Continuation of studies identified which tested a patient adherence and/or persistence intervention 
References Measures method Statistical analysis Results Quality 
score  Outcome(s) Assessment 
method 
Statistical method Losses of 
patients to 
follow-up 
taken into 
account 
Adjust
ment 
for 
confoun
ders 
Blalock et al. 
(2002) [17] 
Adherence to calcium intake but 
no explicit definition 
No 
information 
Not reported No No Calcium intake increased 
of 500 mg/d in the 
intervention group. 
16/30 
Clowes et al. 
(2004) [18] 
Adherence was the proportion of 
patients adhering to therapy 
(>75%) at 1 year  
Electronic 
monitoring 
devices 
Kaplan-Meier 
survival curves 
Yes No Arm A: 63% (95% CI 
43%, 82%) 
Arm B: 68% (49%, 86%) 
Control: 42% (22%, 62%) 
P = 0.15 (Arm A) and 
0.05 (Arm B) 
24/30 
 Persistence was defined as 
continuing to take tablets for more 
than 7 of any 14 days immediately 
before the 1 year visit 
    Monitored group: 84% 
(74%, 94%) 
Control: 67% (54%, 87%) 
P = 0.06 (Arm A) and 
0.26 (Arm B) 
 
Cook et al. 
(2007) [19] 
Adherence (percentage of patients 
still adherent at 6 months) but no 
explicit definition 
Pharmacy fill 
records 
Not reported Yes No Intervention: 69% 
Control (unpublished 
national data): 41% 
P < .001 
Effect size: 0.19 
19/30 
  
  
 
Cooper et al. 
(2006) [25] 
Persistence (percentage of 
patients still persistent at 6 
months)  
was defined using discontinuation 
of at least 1-month without any 
medication available 
Prescription 
filling 
Kaplan-Meier 
survival curves 
Yes Yes Intervention: 56.6% 
Control: 38.6% 
Hazard ratio = 0.54  
(0.44-0.66) 
P < 0.0001 
24/30 
 Adherence was defined as the 
proportion of patients who had at 
least five of the six prescriptions 
    Intervention: 80.2% 
Control: 73.3% 
P = 0.008 
 
Delmas et al. 
(2007) [20] 
Persistence at one year Electronic 
monitoring 
Kaplan-Meier 
survival curves 
Yes Yes Intervention: 80% 
Control: 77% 
P = 0.16 
25/30 
Freemantle et 
al. (2012) [26] 
Adherence was defined as the 
proportion of patients who were 
both compliant and persistent to 
treatment. 
Medication 
event 
monitoring 
system 
Cochran–Mantel–
Haenszel test 
Yes Yes Non-adherence with 
denosumab (2
nd
 year): 
7.5% 
Alendronate: 36.5% 
Risk ratio = 0.20 
P < 0.001 
28/30 
 Persistence was defined as the 
proportion persisting with 
treatment after crossover 
    Denosumab: 97.2% 
Alendronate: 72.6% 
Risk ratio = 0.09 
P < 0.001 
 
Guilera et al. 
(2006) [27] 
Adherence was assessed using the 
Morisky test (four questions) 
Self-
completed 
questionnaire 
Student t test and 
Mann Whitney test 
Yes No Intervention: 52.5% 
Control: 47.4% 
P = 0.38 
21/30 
Heilmann et 
al. (2012) [28] 
Adherence was defined as the 
proportion of patients who had a 
medication possession ratio of at 
least 80% 
Pharmacy 
databases 
Chi-square analysis No No Intervention: 46%  
Control: 28% 
P = 0.007 
18/30 
  
  
 
Hill et al. 
(2010) [29] 
Proportion of women who 
reported calcium intake at 6 
months 
Telephone 
survey 
Chi-square analysis 
and t tests 
No No Intervention:  57.0% 
Control: 26.5% 
RR = 2.2  (1.5–3.1) 
P = 0.001 
25/30 
Kendler et al. 
(2011) [30] 
Adherence was defined as the 
proportion of patients who were 
both compliant and persistent to 
treatment at the end of treatment 
period. 
Medication 
event 
monitoring 
system 
Cochran–Mantel–
Haenszel test 
Yes Yes Denosumab: 87.3% 
Alendronate: 76.6% 
Risk ratio = 0.58 
P = 0.043  
28/30 
 Persistence was defined as the 
proportion persisting with 
treatment at the end of treatment 
period 
    Denosumab: 89.7% 
Alendronate: 79.8% 
Risk ratio = 0.54 
P = 0.049 
 
Lai et al. 
(2011) [31] 
Adherence is defined as the 
average 
percentage of participants who 
were both persistent and 
compliant 
Pill count and 
self -report 
Mann-Whitney U 
test 
Yes Yes Self-report: higher 
adherence in the 
intervention group (98.9% 
vs. 96.8%; P = 0.015 at 6 
months); (98.0% vs. 
96.2%; P = 0.047 at 12 
months) 
Pill count: 98.8% vs. 
97.0%; P = 0.028 (6 
months) and 97.7% vs. 
96.5%; P=0.32 (12 
months) 
27/30 
 Persistence was the percentage of 
patients who continued 
bisphosphonate at 12 months 
Prescription 
filling 
Kaplan-Meier 
survival curves and 
log rank test 
  Intervention: 89.8% 
Control: 87.0% 
P = 0.481 
 
  
  
 
Montori et al. 
(2011) [32] 
Adherence was defined as the 
proportion of patients who had 
80% or greater adherence to 
bisphosphonates 
Self-report 
(telephone 
survey) and 
pharmacy fill 
records 
Wilcoxon rank-sum 
tests 
Yes No Intervention: 23 patients 
Control: 14 patients 
P = 0.009 
22/30 
 Persistence was measured as the 
number of days covered 
    Intervention: 170 days 
Control: 180 days 
P = 0.38 
 
Nielsen et al. 
(2010) [21] 
Adherence was defined as patients 
taking their medicine correctly at 
the appropriate time. An explicit 
definition was not provided 
Self-
completed 
questionnaire 
Kaplan-Meier 
survival curves 
Yes Yes Intervention: 92% 
Control: 80% 
P = 0.006 
25/30 
Ojeda-Bruno 
et al. (2010) 
[22] 
Adherence with treatment but no 
clear definition 
Self-report 
(telephone 
survey) 
No statistical 
analysis 
Yes No Intervention: 71% 15/30 
Robbins et al. 
(2004) [23] 
Adherence but no explicit 
definition 
Pill counts and 
electronic 
monitoring 
Not reported Yes No Baseline: 95% (SD 1.7) 
12-months: 96% (SD 1.8) 
15/30 
Roux et al. 
(2012) [33] 
Persistence was defined as the 
proportion patients still treated at 
the last visit, and having taken at 
least 10 out of 12 pills 
Not reported Chi-square analysis  Yes No Persistence at one year: 
Intervention: 75.1% 
Control: 74.8% 
P = 0.932 
22/30 
Shu et al. 
(2009) [24] 
Adherence was expressed as 
medical possession ratio 
Prescription 
filling 
Poisson distribution 
regression analysis 
NR No Intervention: 74% (19%, 
93%) 
Control: 73% (0%, 93%) 
P = 0.18 
20/30 
  
  
 
 Persistence was expressed as 
median days until discontinuation, 
where discontinuation 
was defined as at least 30 days 
without any medication available 
    Interventions: 85 days 
(58, 174 days) 
Control: 79 days (31, 158 
days) 
P = 0.16 
 
Silverman et 
al. (2012) [34] 
Persistence was defined as 
patients who refilled their 
prescription 
Prescription 
filling 
Survival analysis Yes Yes RR group1/control: 1.09 
(p>0.97. 
RR group 2/ control: 0.95 
(p>0.91). 
RR group 3/control:  1.18 
(p>0.23). 
22/30 
Solomon et al. 
(2012) [35] 
Adherence was expressed as 
medication possession ratio 
Prescription 
filling 
Kruskal-Wallis test Yes Yes Intervention: 49% 
Control: 41% 
P = 0.07 
24/30 
 Persistence was defined as days 
from initial prescription until the 
first period during which the 
patient experienced an 
interruption in prescription filling 
lasting longer than 60 days 
 Kaplan-Meier 
survival curves and 
log rank test 
  P = 0.34  
Yuksel et al. 
(2010) [36] 
Calcium intake at the end of 16 
weeks 
During a 
pharmacy visit 
Frequencies and chi-
square analyses 
Yes No Patients reaching total 
daily calcium of 1,500 mg 
(diet + supplement):  
Intervention: 30% 
Control: 19% 
RR = 1.6 (1.0–2.5). 
P = 0.011 
24/30 
NR Not reported, RR relative risk 
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Among studies including a control group (n=16), twelve reported data on adherence [18, 19, 21, 24-
28, 30-32, 35]. In studies where adherence was defined as percentage of patients adherent [18, 21, 
24-28, 30, 31, 35], the adherence ranged from 46% to 92% with the intervention while in the 
control group it varied from 28% to 87%. Nine studies showed a statistically significant (p=0.05) 
improvement in medication adherence by the intervention compared to the control group [18, 19, 
21, 25, 26, 28, 30-32]. Clowes et al. [18] showed that patients receiving feedback information in 
response to therapy based on bone turnover marker measurements experienced an improved 
adherence. Monitoring increased cumulative adherence in this study by 57% compared with no 
monitoring (P=0.004). Patient education and information were found to have a significant impact on 
medication adherence in two small studies [19, 21], but this result was not confirmed by two large-
scale randomized studies [24, 35]. The use of a decision aid had a significant impact on the number 
of adherent patients (23 patients vs. 14 patients, p = 0.009) [32], and pharmaceutical care was 
shown to improve adherence in two studies [28, 31] although, in one of these, a significant 
improvement was only found using self-report questionnaire and not using pill count [31]. The 
simplification of dosing regimens was shown to significantly influence medication adherence. 
Cooper et al. showed that once-monthly ibandronate treatment plus a patient support program 
significantly increased medication adherence compared to once-weekly alendronate [25], while a 
subcutaneous injection of denosumab every 6 months was shown to significantly improve 
adherence compared with weekly oral alendronate [26, 30].  
Among the thirteen studies assessing the impact of intervention on persistence [18, 20, 24-26, 29-
36], only five showed a positive impact of the intervention [25, 26, 29, 30, 36]. Simplification of 
dosing regimens was found to have a significant impact on medication persistence [25, 26, 30]. 
Patients were most persistent with those having the least frequent dosing regimens. Electronic 
prescription also increased persistence with calcium (57% vs. 22%, study vs. control groups, p = 
0.001) [29] and education by pharmacists increased calcium intake at 4 months (30% vs. 19%, 
study vs. control groups, p = 0.011). None of the four studies assessing monitoring/supervision 
intervention showed an impact on persistence [18, 20, 33, 34] and most education programs had no 
significant impact on persistence [24, 31, 35], including the patient support program [32]. 
The quality of the studies was variable with an average quality score of 74% (range from 50% to 
93%). Improved quality scores were obtained in more recent studies with an average quality score 
increasing from 66% to 80% for studies published before and after 2010, respectively. 
DISCUSSION 
We reviewed studies that assessed interventions designed to enhance patient adherence and 
persistence to osteoporosis medications. This study considered new interventions to previous 
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reviews [15]. Some of these provided further evidence on the impact of patient education and 
monitoring/supervision on medication adherence while others tested new interventions or programs. 
From our update, it emerged that the efficacy of patient education is still uncertain. Nielsen et al. 
[21] reported an improvement in adherence but a large-scale randomized trial found no statistically 
significant improvement in adherence of a telephonic motivational interviewing intervention [35]. A 
large well conducted RCT is definitive within the study context, but perhaps not generalizable to all 
forms of education. Other studies [33, 34] confirmed that monitoring and providing feedback to 
patients on bone marker results is not an effective way to enhance persistence and adherence. New 
interventions being tested suggested that less frequent dosing regimens [26, 30], electronic 
prescription [29] and patient decision aids to facilitate decision-making by describing the available 
options [32] could be effective patient-focused intervention to improve adherence and persistence. 
The existing literature on interventions to improve patient adherence and persistence has several 
limitations. First, studies were of limited quality - only 15 studies were randomized trials and only 
one of the studies was a double-blinded trial. While an improvement in the quality of studies was 
observed over time, well-designed randomized controlled trials are needed to assess the efficacy of 
enhancing adherence to osteoporosis medications. We acknowledge, however, that conducting a 
doubled-blind trial for testing an intervention for improving adherence and persistence may be 
difficult and sometimes impossible (e.g. blinding participants to an educational intervention). 
However, the use of cluster randomized controlled trials could be one way to mitigate specific 
methodological constraints. Second, the definitions and measurement of medication adherence and 
persistence were inconsistent, precluding any quantitative synthesis of the evidence. The 
International Society for Pharmacoeconomics & Outcomes Research (ISPOR) has previously 
provided guidance on how to conduct research on medication adherence using both retrospective 
and prospective designs [37, 38]. A new taxonomy for describing and defining adherence to 
medications was also recently published by the ABC project team [39], which may facilitate 
standardization of future research. Adherence to medication is defined as “the process by which 
patients take their medication as prescribed” and persistence to medication as “the time from 
initiation until discontinuation” [39]. Third, information reported by authors of each article was 
limited. Where mean adherence scores were provided for RCTs, no information was available on 
the standard deviations, making it difficult to calculate a standardized effect size, which could be 
used as a comparative measure across studies. There was limited information reported on specific 
relevant points including the extent of patient co-payments, and setting of care (i.e. at research 
centers or within the community). Fourth, no studies examined the impact of the interventions on 
clinical outcomes. Although testing for efficacy using proxy outcomes (e.g. adherence) is 
informative, it would also be appropriate for future studies to assess clinical outcomes (e.g. 
fractures) alongside persistence and adherence. Finally, the durability of intervention effect, and 
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appropriate period of follow-up are important considerations which are largely overlooked.  
Osteoporosis is a chronic disease requiring long-term treatment.  A single intervention is unlikely to 
yield anything more than transient improvements in adherence.  Increased treatment effectiveness is 
most probable with repeated administration of interventions, and can only be demonstrated with 
long-term follow-up of patients, greater than 1 year. 
Problems with internal and external validity of the presented data, and potential biases, could also 
limit the usefulness of some studies. Non-randomized uncontrolled trials [17, 19, 22, 23, 28] are 
prone to non-equivalent patient characteristics at the beginning of the study and differential rates of 
patient drop-out during follow-up. This reduces internal validity, as does the confounding effect of 
time in studies that adopt a pre-post group research design. External validity could also be uncertain 
since samples may not be wholly representative of populations with osteoporosis [17]. 
Measurement bias may also have occurred in those studies that used only measures of self-report to 
determine adherence [21, 22, 27]. It could also occur in those studies where there was lack of 
blinding between the data analysts and treatment groups involved.  Lack of appropriate training of 
staff in the use of tools could lead to an undermining of the interventions’ fidelity. 
There were potential issues in relation to the methodology and execution of the review. While only 
one person conducted the literature search, it was undertaken as comprehensively as possible using 
multiple search terms, increasing confidence that all relevant studies were identified. The quality 
score was used to ensure consistency in the way we evaluated papers, with only a few discrepancies 
observed between reviewers which were only a matter of interpretation.  Since the interventions 
varied across studies, we presented the information by study, and by broad intervention category. 
So, if an intervention was focused on educating patients using different tools, we did not focus on 
the tools, we grouped them as “educational intervention”. Adherence is a multifactorial problem, 
and therefore, there is no single intervention that works across different individuals’ needs. We 
proposed to compare different intervention types and try to identify if there were clear differences 
among them. We would expect to update our review when new relevant interventions become 
available, especially with advances in telehealth technology and social media. 
In summary, this review indicates that several interventions (simplification of dosing regimens, 
electronic prescription, patient decision aids or patient education) may improve adherence and 
persistence to medicines for osteoporosis, although, there were variations in the quality of studies. 
Of the largest and least biased studies, patient education showed however only marginal 
improvement in medication adherence and persistence, while monitoring/supervision seems 
ineffective in enhancing medication adherence. To demonstrate the societal benefits of adherence 
improvement, we recommend that the most promising interventions are subjected to rigorous 
evaluation of clinical effectiveness in pragmatically-designed, randomized, controlled trials. It may 
be necessary to target interventions to specific causes of non-adherence, in an approach consistent 
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with personalized medicine, in acknowledgment that the average effect from trials masks some 
patients who are very responsive to interventions. 
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APPENDIX 1. MODIFIED VERSION OF THE DELPHI LIST 
Domains Original Delphi List Modified List 
1. Study question  Was the research question/objective/hypothesis or aim clearly described 
Yes (1)/ No (0) 
2. Population  
 
Were the eligibility criteria specified?  
Yes/No/Don’t know 
Were inclusion criteria clearly described? 
Yes (1)/No (0) 
Were exclusion criteria clearly described? 
Yes (1)/No (0) 
3. Sample size and power 
Calculations a priori 
 Was sample size and power calculated a priori? 
Yes (1)/ No (0) 
Were the total number of individuals, the total number of participants in the study group and 
total number of patients in the controlled group clearly specified? 
Yes (3, one per each)/ No (0) 
4. Treatment allocation a) Was a method of randomization 
performed?  
Yes/No/Don’t know 
b) Was the treatment allocation 
concealed?  
Yes/No/Don’t know 
Was randomization used in the study 
Yes (1)/ No (0) 
5. Confounders  Were potential confounders clearly described? 
Yes (1)/No (0) 
 
6. Ethics  Was the protocol approved by the Ethics Committee and/or patients signed informed consent? 
Yes (1)/No (0) 
7. Intervention  Was intervention clearly defined?  
Yes (1)/No (0) 
Was the intervention clearly described (who did what, to whom, where and how often)? 
Yes (1)/No (0) 
 
    Comparator  Was a comparator included in the study? 
Yes (1)/No (0) 
Was comparator clearly described? 
Yes (1)/No (0) 
 
  
  
 
8. Outcome measures  Was (were) measure (s) of adherence defined? 
Yes (1)/No (0) 
Was (were) measure (s) of adherence clearly described in the study? 
Yes (1)/No (0) 
Were clinical outcomes included in the study? 
Yes (1)/No (0) 
 
9. Follow-up/withdrawals  Was followed-up time specified in the study? 
Yes (1)/No (0) 
 
10. Blinding  Was the outcome assessor blinded?  
Yes/No/Don’t know  
Was the care provider blinded?  
Yes/No/Don’t know 
Was the patient blinded? 
Yes/No/Don’t know 
Was the study: 
a. Double blind 
Yes (2)/No (0) 
b. Single blind 
Yes (1)/No (0) 
15. Analysis Were the groups similar at baseline 
regarding the most important 
prognostic indicators?  
Yes/No/Don’t know 
Were point estimates and measures of 
variability presented for the primary 
outcome measures? Yes/No/Don’t 
know 
Did the analysis include an intention-
to treat analysis? Yes/No/Don’t know 
Was the statistical method appropriate? 
Yes (1)/No (0) 
Was the analysis adjusted by confounders? 
Yes (1)/No (0) 
Were losses of patients to follow-up taken into account? 
Yes (1)/No (0) 
Were characteristics of patients lost to follow-up clearly described? 
Yes (1)/No (0) 
 
Results  Were adherence results clearly presented (e.g. baseline, interim, and at the end of the study)? 
Yes (3)/No (0) 
Were clinical results clearly presented (e.g. baseline, interim, and at the end of the study)? 
Yes (1)/No (0) 
Were results adjusted by confounders? 
Yes (1)/No (0) 
16. External Validity  Was the included population representative of study population? 
Yes (1)/No (0) 
Total  30 (100% Quality Score) 
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ABSTRACT 
OBJECTIVES: Attribute selection represents an important step in the development of discrete-choice 
experiments (DCE), but is often poorly reported. In some situations, the number of identified 
attributes may exceed what one may find possible to pilot in a DCE. Hence there is a need to gain 
insight into methods to select attributes in order to construct the final list of attributes. This study 
aims to test the feasibility of using the nominal group technique (NGT) to select attributes for 
DCEs. 
METHODS: Patients group discussions (4-8 participants) were conducted to prioritize a list of twelve 
potentially important attributes for osteoporosis drug therapy. The NGT consisted of three steps: (1) 
an individual ranking of the twelve attributes by importance from 1 to 12, (2) a group discussion on 
each of the attributes including a group review of the aggregate score of the initial rankings, and (3) 
a second ranking task of the same attributes.  
RESULTS: Twenty-six osteoporotic patients participated in five NGT sessions. Most (80%) patients 
changed their ranking after the discussion. However, the average initial and final ranking did not 
markedly differ. In the final rank, the most important medication attributes were effectiveness, side-
effects, frequency and mode of administration. Some (15%) patients did not correctly rank from 1 
to 12, and the order of attributes did play a role in the ranking. 
CONCLUSION: The NGT is feasible for selecting attributes for DCE. Although, in this study context, 
the NGT session had little impact on prioritizing attributes, this approach is rigorous, transparent 
and improves the face validity of DCEs. Additional research in other contexts (different decisional 
problems or different diseases) are needed to determine the added value of the NGT session, to 
assess the optimal ranking/rating method with control of ordering effects and to compare the 
attributes selected with different approaches. 
KEYWORDS 
Discrete choice experiment, nominal group technique, patients’ preferences, medication attributes, 
osteoporosis 
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INTRODUCTION 
Over the last decade, discrete choice experiments (DCEs) have been increasingly used to elicit 
preferences for health care [1-3]. The identification and selection of attributes are fundamentally 
important to obtain valuable results [4, 5] but are often poorly reported [5]. Methods used to 
identify attributes include literature review, discussion with experts, professional recommendations, 
surveys, in-depth interviews, focus group and repertory grid techniques [5, 6]. This first stage would 
generate a list of potential attributes for inclusion. In some situations, the number of identified 
attributes may exceed what one may find possible to pilot in a DCE. When the number of attributes 
may need to be restricted, the ISPOR Good Research Practices for Conjoint Analysis Task Force 
has suggested rating and/or ranking exercises may be beneficial to assess the importance of 
attributes in order to construct the final list of attributes to be included [1]. Some of the earlier 
techniques can again be used (focus groups, interviews, etc.) but with a different objective from that 
in the identification stage. 
Nominal group technique (NGT) seems especially suitable for the “second” stage in which 
attributes are selected from the list by ranking them. The NGT is a structured, multi-step, facilitated 
group meeting technique used to elicit and prioritize responses to a specific question [7]. This 
method has been shown to be feasible and reliable for prioritizing health and health care 
research/problems [8, 9], but has never been investigated to select attributes for DCEs. 
This study was therefore designed to assess the use of the NGT to prioritize attributes for inclusion 
in DCE. The study context is preferences for osteoporosis medications among adult patients. With 
the recent introduction of new therapies, conducting a DCE would be useful to understand patients’ 
preferences for these treatments, especially when realizing poor adherence to drug treatment in 
osteoporosis, but a DCE requires a rigorous and transparent approach to select attributes as many 
potential attributes were identified in surveys [10, 11] and prior DCEs [12-14]. While the results 
provide insight into preferences for the attributes of osteoporosis medications, the primary objective 
of this paper was to test the feasibility and usefulness of the NGT to select attributes for DCEs. A 
secondary objective was to assess the influence of attribute ranking order on the selection of 
attributes. 
METHODS 
PATIENTS 
Five patients’ group discussions (consisting of 4-8 participants per NGT session) were conducted in 
June 2011 in the Netherlands and in Belgium to prioritize patients’ preferences for medication 
attributes. Patients were recruited during outpatient clinics or by telephone. Participants were 
considered eligible for inclusion in the study if they were diagnosed with osteoporosis or had a 
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recent fracture that required osteoporosis medication during at least a period of their osteoporosis 
history. They were selected to represent the full clinical spectrum of ages, educational level, history 
of osteoporosis (primary or secondary) and osteoporosis medication (switched, stopped, 
experienced side-effects). The ethics committee of Maastricht University Medical Center approved 
the study and all patients received an information letter before participating and provided written 
consent. 
IDENTIFICATION OF CANDIDATE ATTRIBUTES 
Fourteen potentially important attributes for osteoporosis drug therapy were established from 
literature review [10-15] and discussions with experts. Two attributes (i.e. treatment duration and 
drug interactions) were not included in the final list since these attributes did not meet the important 
conditions of attributes for DCEs such as being capable of being traded and being policy relevant 
[4, 5]. Indeed, treatment duration does not differ between first-line osteoporosis therapies being 
therefore not policy relevant and drug interactions are very rare for all drugs in osteoporosis [16]. 
The final list of 12 attributes (Table 1) was approved by the working group including project 
investigators (rheumatologists, DCE experts), advisors and a patient. A different ordering to present 
and discuss the attributes was used in each of the groups. Attributes were randomly divided into 5 
sets (attributes 1-3, 4-6, 7-8, 9-10 and 10-11) and each of the 5 discussion groups received a 
different ordering of these sets. 
Table 1| List of potentially important attributes 
1. Efficacy (effect) in reducing the risk of future fractures (decreasing by 
between 20-75% of the risk of future fractures) 
2. Side-effects (mild and common; serious and rare) 
3. Biological mechanism of action (bone resorption or bone formation) 
4. Frequency of administration (daily, weekly, monthly, yearly, etc.) 
5. Mode of administration (oral tablet, subcutaneous, intravenous, etc.) 
6. Place of administration (at home, doctor’s office, hospital, etc.) 
7. Same drug during the treatment period (or sequential treatment)  
8. Mono therapy vs. combination therapy (one or two pills) 
9. Out-of-pocket cost (personal contribution) 
10. Cost for the society (other healthcare costs than patient contribution) 
11. Time on market (recently vs. 10 years) 
12. Branded or generic specification 
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NOMINAL GROUP PROCESS 
The NGT process consisted of three steps. After being informed about the purpose of the study (“to 
determine the most important characteristics for drug therapy in osteoporosis from the perspective 
of the patients”) and being given a brief description of the NGT process and of the attributes, each 
participant was asked to rank the list of attributes by importance from 1 (the most important) to 12 
(the least important) on a worksheet. Patients had also the opportunity to include any missing 
attribute. In comparison with a traditional NGT [17], and since many attributes were already 
identified in the literature, we have not included a first stage of silent generation of ideas where 
participants are asked to write down all ideas (here attributes) about a question. 
During a second step (discussion and sharing ideas), a group discussion on each of the attributes 
was performed including a group review of the aggregate score of the initial rankings. In the final 
phase, participants had the opportunity to reconsider their initial ranking in the light of other 
participants' views. They were under no pressure to achieve consensus, and all ratings were again 
made privately. The discussions were facilitated by a medical trainee in rheumatology observed by 
a moderator and tape recorded. The facilitator tried to ensure that all participants were given an 
opportunity to contribute. NGT sessions were conducted until the rank order of the most important 
attributes did not change anymore.  
For each of the 5 groups, the individual rankings were summed across participants to derive the 
rank order at the group level. Some recoding was performed for a few patients who assigned the 
same number to different attributes. Any change between the initial and final round was examined 
to indicate the impact of the NGT on ranking. This analysis was carried out at the group level and at 
the individual level by examining the number of attributes changed by responders and the average 
of the (absolute) change between attribute’s rankings. 
FINAL ATTRIBUTES SELECTION 
The selection of attributes for the DCE was based on groups’ ranking and NGT discussions 
followed by experts’ discussion who decided on the number of attributes that should be included. 
The NGT sessions were especially useful to determine the cutoff level after which attribute of the 
final ranking list, the inclusion should be stopped. The final list of attributes was further approved 
by the working group. No fixed threshold number was used to select attributes for inclusion 
although recent reviews have reported that most DCEs used a number of attributes between 4 and 7 
[18, 19]. 
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RESULTS 
STUDY SAMPLE 
After five group discussions (two in the Netherlands and three in Belgium), the rank order of the 
attributes did not change anymore and no additional groups were invited. The final sample 
consisted of 26 osteoporotic patients. As observed on Table 2, patients represented the full clinical 
spectrum of ages, educational level, osteoporosis diagnosis, fracture history and treatment. Patients’ 
characteristics did not markedly differ between groups. 
Table 2| Participants’ characteristics 
Women 24/26 (92%) 
Belgian 17/26 (66%) 
Age   
   Mean, median, standard deviation 68.0, 67.0, 11.0 
   Range 41-87 
Diagnosis of osteoporosis 25 (96%) 
Osteoporosis since  
   Mean, median, standard deviation 10.2, 8.0, 8.7 
   Range 0-38 
Education  
   No, primary or low secondary 9 (37%) 
   Secondary school 9 (37%) 
   Graduate / University 6 (25%) 
With prior fracture 15 (58%) 
Number of prior fractures  
   Mean, median, standard deviation 1.04, 1.00, 1.22 
   Range 0-5 
Patients on treatment  25 (96%) 
Patients who took another treatment in the past 9 (35%) 
Patients who experienced adverse events 4 (15%) 
MOST IMPORTANT ATTRIBUTES (FINAL RANKING) 
Figure 1 presents the five most important attributes in the different patients’ groups. Drug 
effectiveness was the most important medication attribute followed by side-effects, frequency of 
administration and mode of administration, respectively. While out-of-pocket costs, time on market, 
place of administration (such as hospital, home) and the need for sequential treatment were of some 
relevance, costs for society, mode of action, combination treatment and brand/generic specification 
did not reach the top three most important attributes in any of the groups. 
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Figure 1| Most important attributes for osteoporosis medications 
 
EFFECT OF NGT ON RANK ORDER 
Twenty of the 25 patients (80%) who provided an initial and final ranking changed their ranking 
after the discussion. However, the average initial and final ranking did not differ importantly, with 
two exceptions (Table 3). The importance of mode of action was reduced after discussions (from 
position 5 to position 8) while the out-of-pocket costs increased from position 10 to 5 because, in 
two Belgian groups, the importance of this attribute increased by 3 and 4 places after discussions, 
respectively. Mode of action was considered by most patients as a way of improving effectiveness 
and reducing fractures, although drugs’ effectiveness is largely independent of the biological 
mechanism of drugs. This explanation was provided during the NGT discussions, explaining why 
this attribute was considered less important in the final ranking. 
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Table 3| Ranking of osteoporosis medication attributes before and after NGT meeting. (The 
average ranks assigned to each attribute in the five groups are provided in parentheses) 
 Initial ranking Final ranking 
Effectiveness 1 (2.0) 1 (1.6) 
Side-effects 2 (3.2) 2 (3.8) 
Frequency of administration 3 (5.2) 3 (4.4) 
Mode of administration 4 (5.4) 4 (5.8) 
Out of pocket cost 10 (7.8) 5 (6.0) 
Time on market 6 (6.0) 6 (6.4) 
Place of administration 7 (6.6) 7 (6.6) 
Mode of action 5 (5.8) 8 (6.8) 
Sequential therapy 8 (7.2) 9 (7.0) 
Mono or combination 9 (7.4) 10 (7.4) 
Branded/generic 11 (8.8) 11 (9.0) 
Cost for society 12 (11.6) 12 (11.8) 
Individual patient analyses have revealed different profiles of respondents (Table 4). Some patients 
(profile 1) did not change their ranking after discussion, some (profile 2) made minor changes to 
some parameters and others (profiles 3-4) made more substantial changes in their ranking. After 
discussion, the average absolute change per patient between the twelve attributes’ ranking in the 
second ranking list compared to the first ranking list was 1.3 (standard deviation: 0.8) meaning that, 
on average, each attribute moved (in absolute term) by 1.3 place. The average number of attributes 
changed after discussion was 6.8 (standard deviation: 3.1). As reported on Figure 2, the NGT 
discussion had the lowest impact on the attributes ranked as the three most important in the initial 
ranking while the attributes ranked in the fifth and sixth positions were the most affected by 
discussion. 
Table 4| Different profiles of responders after NGT discussion 
a
 
 
Number of 
patients 
Average absolute change 
between attributes’ rankings:  
mean (standard deviation) 
b
 
Number of attributes 
changed: mean (standard 
deviation) 
Profile 1 (0) 5 0 (0) 0 (0) 
Profile 2 (>0-1) 6 0.85 (0.13) 6.7 (1.4) 
Profile 3 (>1-2) 9 1.76 (0.13) 8.5 (0.7) 
Profile 4 (>3) 5 2.58 (0.27) 10.8 (1.4) 
a
 Profiles of responders were determined based on the average absolute change between attributes’ rankings. Profiles’ 
classification is provided in parentheses in the first column. 
b
 The average absolute change between attributes’ rankings was obtained by summing, for each attribute, the absolute 
change between initial and final ranking (a positive change (+1) or a negative change (-1) are treated the same (+1)) 
and dividing by the number of attributes. 
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Figure 2| Mean absolute change in ranking of attributes after NGT discussion according to their 
rank in the initial round 
a
 
 
a
 This graph shows that the attributes in the first three positions (that differ according to individual patient’s ranking) 
are the most stable after NGT discussions. 
ADDITIONAL FINDINGS 
First, fifteen percent of patients (4/26) did not correctly rank from 1 to 12 since they assigned the 
same number to different attributes. Second, the order of presenting of attributes in the rank system 
and nominal group discussion seems to influence the ranking. When the attributes were presented in 
the first positions of the list, they generally obtained their highest score. Third, group analyses 
suggest that out-of-pocket was not in the top four in the two Dutch groups (5th and 11th position) 
reflecting that, in contrast with Belgian patients (ranked as 3rd, 5th and 8th), they have no out-of-
pocket contribution for medications. No other major differences were observed between groups. 
Finally, only one patient included a missing attribute, i.e. drug interactions, which has been 
previously discussed. 
FINAL ATTRIBUTES SELECTION 
Rankings and NGT discussions revealed four important attributes that were consistently identified 
as important for patients: effectiveness, side effects, mode and frequency of administration. 
Interestingly, out-of-pocket cost was considered important in Belgium but not in the Netherlands 
reflecting that, in contrast with Belgian patients, they have no out-of-pocket contribution for 
medications. This result could suggest that out-of-pocket cost could only be included in countries 
(like Belgium) where it is relevant. Time on market was, for most patients, related to safety and 
lower side-effects which are already included as an attribute. Place of administration is highly 
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correlated with the mode of administration and will rather be incorporated in the description of the 
mode of administration. Other attributes were not sufficiently important for inclusion in the DCE 
based on ranking and discussions. Based on these considerations we decided to include the four first 
attributes for the DCE in the Netherlands and the fifth attribute (out-of-pocket cost) in Belgium 
only. 
DISCUSSION 
We have demonstrated the feasibility of the NGT to prioritize attributes for inclusion in DCEs. 
When many candidate attributes are identified from available sources or patients interviews, this 
approach may be beneficial to assess the importance of these attributes to construct the DCE. In 
situations where the number of identified attributes need to be restricted, a two-stage analysis could 
therefore be performed, in which a self-exploratory analysis reduces the number of attributes (using 
NGT for example) and a DCE is conducted with the restricted list of attributes to further assess 
preferences for attributes’ levels. Other tools (e.g. best-worst scaling, adaptive conjoint analysis 
where attributes are changed simultaneously) could be alternative approaches. 
Starting from a comprehensive list of attributes for osteoporosis medication, generated from 
literature and expert opinion, we identified which osteoporosis medication attributes are important 
from the patients’ perspective. Rankings and discussions revealed four important attributes: 
effectiveness, side effects, mode and frequency of administration. 
These results are interesting for designing DCE experiments, but are also worthwhile by themselves 
when aiming at improving therapeutic adherence. Poor adherence to osteoporosis medications is a 
well-documented problem [20], and results in significant clinical and economic burden [21, 22]. 
Barriers to adherence include side-effects, inconvenient dosing regimens, lack of information and 
cost of medications [23]. Providing patients with adequate information on the treatment options and 
involving them in decision making may contribute to optimize treatment selection and to improve 
adherence to therapy [24, 25]. As drug therapies in osteoporosis differ according to side-effects, 
mode and frequency of administration and these were considered as important attributes in our 
research, sharing this information with the patients could lead to optimize treatment selection and to 
improve adherence to therapy.  
In this study context, the NGT discussions did not substantially affect rank order of preferences for 
the attributes in the total group when compared to rank order before the NGT discussion, pointing 
to considerable agreement for the most important attributes. This could suggest that simple ranking 
exercise (or best-worst scaling) may perhaps be sufficient to determine the most important 
attributes. However, individual analyses have suggested that eighty percent of the patients changed 
their ranking after the discussion that could potentially reflect in a different group ranking. Further 
investigations in other contexts, other diseases or other decisional issues are therefore needed to 
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determine the added value of the NGT meeting when selecting and prioritizing attributes for a DCE 
or even other purposes. 
The approach described here also has the advantage of being rigorous, systematic and transparent, 
and therefore to improve the face validity of DCEs. Many papers have pointed out that conjoint 
analysis did not justify very well the selection of attributes.[5, 19, 26] Recently, Coast et al. 
explored issues associated with attributes development for DCEs and contrasted different 
qualitative approaches in the development of DCEs based on experience generated in interviews 
[5]. Our study generated further insight by providing additional experience from group discussions. 
The benefits of conducting qualitative research were also not restricted to the selection of attributes. 
Discussions were interesting to refining language [5] and to conduct a Bayesian efficient design 
[27].The application of such method did, however, not come without a cost. We estimate that the 
whole process of organizing, running and analyzing the NGT cost about €10.000 (including about 
€1.500 as an incentive for the patients for the time spend and 2-3 months of a full-time researcher). 
We believe that the benefits of the approach make this however highly cost-effective. 
The NGT could also be useful in selecting the initial set of attributes. Participants could first be 
asked to individually generate a list of important medication attributes, followed by a discussion 
phase to refining the list by adding, merging or removing attributes, and by the final individual 
ranking of the most important attributes. This was not done in our study since many potential 
attributes were already identified by the literature review and we also aimed to assess the impact of 
the NGT session on the rank order. Our patients had however the opportunity to add attributes to the 
list. Our study could also have some important implications for further research in this area. First, 
misunderstanding of attributes is frequent and a clear description and explanation of the attributes is 
required. Second, ranking many attributes could impose a substantial cognitive burden on 
respondents. Perhaps it would have been sufficient to ask patients to rank their five most important 
attributes. Rating scales per attribute could also be an alternative with much less effort on the 
respondent's part but with more limited information on the relative importance of attributes. Further 
work should be done to assess and compare ranking/rating exercises. Third, the impact of the NGT 
discussion was shown to substantially differ between patients. It would be interesting in the future 
to understand reasons that could explain this. Finally, our study showed that the attributes’ 
presenting order did have an impact on the results. We therefore recommend controlling for 
ordering effects in ranking exercises. 
A limitation of this study is that we have not compared the attributes derived from NGT with other 
approaches (e.g. experts’ opinions, best-worst scaling). The gold standard would be the revealed 
preference but this outcome is also difficult to assess. Head to head comparisons of different 
techniques could help to assess and understand differences between approaches, although there may 
be practical limitations in developing such studies [5]. 
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In conclusion, a nominal group technique is feasible for selecting attributes for DCE. Although, in 
this study context, the NGT discussions did not substantially affect the patients’ rank order of 
preferences for the attributes when compared to rank order before the group discussion, this 
approach is rigorous, transparent and improves the face validity of future DCEs. Further work 
should be done to determine the added value of the NGT session, to assess the optimal 
ranking/rating method with control of ordering effects and to compare the attributes selected with 
different approaches.  
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ABSTRACT 
INTRODUCTION: The patient’s perspective is becoming increasingly important in clinical and policy 
decisions. In this study, we aimed to evaluate the preferences of patients with, or at risk of, 
osteoporosis for medication attributes, and to establish how patients trade between these attributes. 
MATERIALS AND METHODS: A discrete choice experiment survey was designed and patients were 
asked to choose between two hypothetical unlabelled drug treatments (and an opt-out option) that 
vary in five attributes: efficacy in reducing the risk of fracture, type of potential common side-
effects, mode and frequency of administration and out-of-pocket costs. An efficient experimental 
design was used to construct the treatment option choice sets and a mixed logit panel data model 
was used to estimate patients’ preferences and trade-offs between attributes. 
RESULTS: A total of 257 patients with, or at risk of, osteoporosis completed the experiment. As 
expected, patients preferred treatment with higher effectiveness and lower cost. They also preferred 
either an oral monthly tablet or 6-month subcutaneous injection above weekly oral tablets, 3-month 
subcutaneous, 3-month intravenous or yearly intravenous injections. Patients disliked being at risk 
of gastro-intestinal disorders more than being at risk of skin reactions and flu-like symptoms. There 
was significant variation in preferences across the sample for all attributes except subcutaneous 
injection. 
CONCLUSION: This study revealed that osteoporotic patients preferred 6-month subcutaneous 
injection and oral monthly tablet, and disliked gastro-intestinal disorders. Moreover, patients were 
willing to pay a personal contribution or to trade treatment efficacy for better levels of other 
attributes. Preferences for treatment attributes varied across patients and this highlight the 
importance to clinical decision-making of understanding individual patients’ preferences to improve 
osteoporosis care. 
KEY WORDS 
Discrete-choice experiment, drug treatment, osteoporosis, patients, preferences.  
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INTRODUCTION 
The patient’s perspective is becoming increasingly important in clinical and policy decisions. 
Information about what patients need and prefer, and how they value various aspects of a health 
intervention can be useful when designing and evaluating health care programs [1]. A better 
understanding of patients’ preferences for treatment can help health professionals to improve 
disease management. When differences in efficacy or safety do not determine the choice of a 
specific treatment patient’s,  satisfaction with therapy is important [2]. Addressing patients’ 
concerns with treatment and involving them in clinical decision-making may also improve 
adherence [1]. Patients increasingly want to be informed by their doctors, and to be active in clinical 
decision-making [3, 4]. In recent years, discrete choice experiments (DCEs) have been increasingly 
used to elicit patients’ preferences for health care [5, 6]. DCEs can quantify the relative importance 
of the various attributes that characterize a treatment and allow the trade-offs that respondents make 
between these to be quantified [7].  
The aim of this study was to evaluate osteoporotic patients’ preferences for medication attributes 
using a DCE, and to establish how patients make trade-offs between these attributes. This study 
differs from previously published DCEs in osteoporosis in several ways [8-10], First, this study 
includes recently introduced routes and timing of administration (e.g. subcutaneous and 
intravenous) and the nature of potential side-effects. Given potential differences in preferences 
between administration schemes, information on patients’ preferences for these new administration 
schemes would be extremely useful for health professionals and decision makers [11]. Second, this 
study expands the population studied to include men. Third, a rigorous qualitative research was 
performed to select medication attributes [12]. 
MATERIALS AND METHODS 
DISCRETE CHOICE EXPERIMENT 
A DCE describes an intervention by its attributes (e.g. effectiveness, side-effects, costs) and reports 
how patient’s preference for an intervention are influenced by the type and levels of these attributes 
[7]. In the DCE, patients were asked to choose between two unlabelled drug treatments (A and B) 
and a ‘no treatment’ (opt-out) option. The alternative treatments varied in several attributes, and 
patients were asked to select the treatment they would prefer. Patients were asked to make a series 
of such hypothetical choices. This research followed published DCEs guidelines [1, 13] and used 
rigorous methods to select treatment attributes, to design the DCE and to conduct the statistical 
analysis.  
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ATTRIBUTES AND LEVELS 
The identification and selection of the DCE attributes is fundamental to obtain valid results [14, 15]. 
We conducted a nominal group technique to select the DCE attributes [14]. Full details on this are 
provided elsewhere [12]. In brief, patients’ group discussions (4-8 participants per group, ntotal=26) 
were conducted to prioritize a list of potentially important attributes of osteoporosis drug treatment. 
This list was developed from a literature review and discussions with experts. A ranking exercise 
and group discussions revealed five attributes that were consistently identified as important for 
patients: effectiveness, side effects, mode and frequency of administration and out-of-pocket cost 
(Table 1) [12]. Levels were assigned to these attributes based on the current treatment using a 
literature review and discussion with experts (n=5). For the side-effects of treatment, we focused on 
the types of common side-effects [16]. 
Table 1| Attributes and levels for osteoporosis drug treatment 
Efficacy in reducing the risk of future fractures 20% 
 30% 
 40% 
 50% 
Possible side effects (affecting 1 in 50 patients) Gastro-intestinal disorders 
 Flu-like symptoms 
 Skin reactions 
Mode of administration Oral tablet 
 Subcutaneous injection 
 Intravenous injection 
Frequency of administration Weekly 
 Monthly 
 Every 3 months 
 Every 6 months 
 Yearly 
Cost to you (per month) €5 
 €15 
 €25 
 €40 
 €60 
 
EXPERIMENTAL DESIGN 
It is not feasible to present an individual with all possible treatment combinations from the 
attributes and levels in Table 1. Experimental design techniques were used to draw a sub-set of 
treatment profiles to present to respondents in the DCE [5]. Specifically, a Bayesian efficient 
experimental design was used to select the subset using the software Ngene (Version 1.1.1, 
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http://www.choice-metrics.com/) to select the sub-set. This experimental design maximizes the 
precision of estimated parameters (by maximising the D-efficiency – a summary measure of the 
variance covariance matrix) for a given number of choice questions [17]. In this study, fifteen 
choice sets were created. An example of a choice set is shown in Figure 1. 
Figure 1| Example of a choice set 
Question 1 
 Treatment A Treatment B 
Efficacy (their effect) in reducing the 
risk of future fractures 
30% 40% 
Possible side effects  
(affecting 1 in 50 patients)  
Flu-like symptoms Skin reactions 
Mode of administration Subcutaneous Intravenous 
Frequency of administration 3-month Yearly 
Cost to you €15 (per month) €25 (per month) 
Which treatment would you choose?  Treatment A        Treatment B      No treatment 
(Tick one box only)     
 
The construction of an efficient experimental design depends on the patients’ preferences, therefore 
we conducted a pilot DCE study (n=10). We used the pilot results to obtain preliminary information 
about patients’ preferences and then used this information to create the experimental design for the 
main study. The pilot DCE experimental design used a-priori information about patients preferences 
based on literature review [9] and discussions during the qualitative research (e.g. higher 
effectiveness is preferred). We also wished to avoid presenting respondents with implausible 
treatment options (e.g. a yearly oral tablet), therefore we restricted the experimental design to 
include only realistic combinations between mode and frequency of administration that could 
appear in the design (i.e. oral weekly or monthly tablets, subcutaneous every 3 or 6 months, and 
intravenous every 3-month or yearly). The experimental design based on pilot preference 
information suggested that 200 respondents would be sufficient power to detect the significance of 
most parameters. 
QUESTIONNAIRE, DATA COLLECTION AND PATIENT RECRUITMENT 
In the questionnaire, patients received a thorough description of the DCE task. The attributes and 
levels were carefully explained and an example of a completed choice set was provided. One of the 
choice questions was asked twice to assess test-retest reliability. Each patient therefore received 16 
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choice sets. After completion of the choice tasks, respondents were asked how difficult they found 
the choice tasks on a seven-point scale. The DCE task is provided in Additional file 1. The 
questionnaire also asked questions on patients’ characteristics. Individual 10-year probabilities of a 
hip and a major osteoporotic fracture (FRAX® score) were calculated for each respondent by a 
doctor/researcher and added to the questionnaire afterwards. 
The questionnaire was developed in English by the working group that include a patient, clinical 
and DCE experts and was approved by two native English speakers, experts in osteoporosis. The 
questionnaire was then translated in French and Dutch by a medical translation company 
specialising in the translation of patient reported outcome measures (PharmaQuest Ltd) and the 
translation was checked and approved by two native French and Dutch speakers with medical 
backgrounds. The questionnaire was pilot tested with 15 patients (French-speaking = 10, Dutch-
speaking = 5) to check interpretation problems and face validity; no wording problems arose and 
only minor changes to layout were made. 
Consecutive patients with, or at risk of, osteoporosis to whom medication (or lifestyle changes) was 
at least proposed were recruited during outpatients’ clinics in two Belgian osteoporosis centres 
(Ghent and Liège). Explanation of the task and an example choice task was provided by the doctor 
or a researcher. The questionnaire was mainly completed by the patient at home and returned in a 
postage-paid envelope. Very few patients completed the questionnaire at the clinic but without any 
assistance from the doctor/researcher.  Approval for this study was obtained from the ethics 
committee of Maastricht University Medical Center who coordinated this project and participants 
gave informed written consent.  
STATISTICAL ANALYSES 
From the DCE, we observe the respondent’s choice of one treatment from the three alternatives 
presented in each choice set. Responses are analysed based on random utility theory [18]. In this 
case, the utility that a patient i assigns to a treatment j, Vij, is modelled as the sum of two parts: a 
systematic part based on the attributes included in the DCE and an error part εijt. We specify Vij as:  
Vij = β0 + (β1+η1i) EFFICACYj + (β2+η2i) COSTj  
+ (β3+η3i) ORAL_1Mj + (β4+η4i) SUB_3Mj + (β5+η5i) SUB_6Mj + (β6+η6i) INT_3Mj  
+ (β7+η7i) INT_1Yj + (β8+η8i) FLUSYMPTj + (β9+η9i) SKINREACTj + εij 
β0 is the constant reflecting the preferences for selecting treatment relative to no treatment, β1-β9 are 
the mean attribute utility weights in the population and η1i-η9i are error terms capturing individual-
specific unexplained variation in the utility weights. Dummy coding was used (for ease of 
interpretation of the results) to describe all categorical variables (β3-β9). Reference levels for mode 
of administration and for side effects are weekly oral tablet and risk of gastro-intestinal disorders, 
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respectively. The sign of the coefficient reflects whether the attribute/level has a positive or a 
negative effect on treatment utility compared to the base level. The value of a coefficient indicates 
the relative importance of the attribute/level. 
When developing a statistical model of respondents’ choice it is important to account for 
respondents completing up to 15 choice tasks each and to allow preferences for treatment to vary 
across the sample., therefore, a mixed logit panel data model was estimated using Nlogit, version 5 
[19]. This model allows model parameters (preferences) to vary in the population. This is achieved 
by specifying a random parameter that has a distribution and estimating the mean (β) and standard 
deviation of the error term (η) to capture the parameter’s distribution. If the standard deviation is 
significantly different from zero this is interpreted as evidence of  significant preference variation 
for the attribute in the sample. 
Initially, we estimated models in which preferences for all attributes could vary in the population 
and then in the final model, those attributes for which the estimated standard deviation was not 
significant (5% level), the preferences were specified to be the same in the population (fixed 
parameters). The random parameters for cost and efficacy were drawn from a log-normal 
distribution - this allows us to constrain the parameter estimate to be either negative (for cost) and 
positive (for efficacy) [19]. All other random parameters were drawn from a normal distribution. 
The estimation was conducted by using 2000 Halton draws.  
We also calculated marginal willingness to pay (WTP) and marginal willingness to trade efficacy 
(WTTE) of the attributes/levels. This allows us to compare preferences for all attributes measured 
with a common and interpretable metric either money or efficacy. A WTP (or WTTE) value 
represents how much one is willing to pay (or to trade) for a one unit change in the attribute, and is 
calculating by taking the ratio of the mean parameter for the attribute/level to the mean parameter 
related to the cost (or efficacy). As the cost and efficacy variables were estimated as random 
parameters, the WTP and WTTE calculations must take this into account. As recommended in this 
case, the conditional constrained parameters were used [19]. 
The mixed logit model identifies attributes for which there is significant preference variation, but it 
does not explain why this variation exists. To understand the potential sources of preference 
variation, additional analyses included covariates (such as gender, age) in the model one by one. 
Significant covariates were then included together and non-significant covariates were excluded 
from this model. Adjusted pseudo R-squared and finite Akaike Information Criterion were used to 
enable comparison of models with and without covariates. We also tested whether patients using a 
specific mode of administration had a stronger preference for this administration scheme by 
incorporating interactions between levels and covariates. Furthermore, to explore the impact of 
respondents who failed the test-retest, a sensitivity analysis was conducted by excluding these 
individuals. A subgroup analysis was also conducted in patients with high-risk of fractures (defined 
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as a FRAX®-major risk >10%) and with low-risk of fractures. To assess the significance of the 
differences between populations, a joint model was estimated using interaction terms. 
RESULTS 
PATIENTS’ CHARACTERISTICS 
A total of 301 questionnaires were distributed to patients. Of these, 268 were returned representing 
a response rate of 89%. Eleven questionnaires were excluded because the patient did not complete 
at least five choice sets in DCE task. A total of 257 (85%) questionnaires were included for data 
analysis. Respondents’ socio-demographics and health characteristics are shown in Table 2. There 
was no restriction on participation based on patients race and ethnicity but patients were mainly 
Caucasian. 
Table 2| Patients’ characteristics 
Age (years, mean ±SD) 67.1±10.4 
Female gender 83.3% 
Educational level  
    Primary 8.4% 
    Some high school 35.9% 
    High school graduate 30.3% 
    College or University 25.5% 
Size of household  
    1 person 29.9% 
    2 people 55.1% 
    3 people+ 15.0% 
Monthly household income (€) 
    Up to 999 5.5% 
    1,000-1,499 33.1% 
    1,500-1,999 19.1% 
    2,000-2,499 17.8% 
    2,500-2,999 11.9% 
    3,000+ 12.7% 
Diagnosis of osteoporosis 89.8% 
   Years since osteoporosis (mean ±SD) 8.9±0.3 
With prior fracture(s) 52.5% 
    In the last year 22.8% 
Patients on osteoporotic treatment 69.8% 
Administration mode of current treatment  
    Oral 72.2% 
    Subcutanous 15.4% 
    Intravenous 12.4% 
Number of co-treatments  
    0-1 19.3% 
    2-3 40.6% 
    4+ 40.2% 
10-year probability of a major osteoporotic fracture (FRAX) 
(mean ±SD) 
14.3% ± 7.5% 
10-year probability of a hip fracture (FRAX) (mean ±SD) 6.1% ± 5.3% 
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The difficulty of the task on a seven-point scale (1 for extremely easy and 7 for extremely difficult) 
was estimated on average between 3 and 4. The task was found to be extremely easy for 35 patients 
(13.6%) while 19 patients (7.4%) gave a score of 6 of 7. A total of 219 patients (85.2%) chose the 
same alternative in the test-retest exercise. This is in line with existing test-retest results [15].  
PATIENTS’ PREFERENCES 
The distribution of choices across the choice sets is provided in Additional file 2. The main results 
of the mixed logit model are presented in Table 3. The estimated coefficients for efficacy and costs 
had the expected sign and were statistically significant. The positive sign of the efficacy parameter 
indicates that respondents prefer higher treatment efficacy and the negative sign of the cost 
parameter indicates that respondents prefer paying less money for treatment. Patients prefer a 6-
month subcutaneous injection and a monthly oral tablet compared with a weekly oral tablet (base 
level). There were no significant differences between weekly oral tablet, 3-month subcutaneous and 
yearly intravenous; nor/neither between 6-month subcutaneous injection and monthly oral tablet. 
Regardless of administration mode, patients preferred a longer dosing regimen (monthly vs weekly 
oral tablet; 6-month vs 3-month subcutaneous; yearly vs 3-month intravenous). The positive sign for 
the two side-effects parameters indicates that patients disliked being at risk of gastro-intestinal 
disorders (base) more than being at risk of skin reactions or flu-like symptoms. 
Table 3| Results from the panel mixed logit model 
Attributes and levels Estimate (95% CI) P Value Standard deviation 
Constant 0.90*** (0.62 to 1.17) 0.00 --- 
Efficacy (1% risk reduction) 0.07*** (0.05 to 0.08)
$
 0.00 1.19*** (1.06 to 1.30) 
Cost per month (€1) -0.05*** (-0.04 to -0.06)$ 0.00 1.24*** (1.09 to 1.39) 
Drug administration (reference level: weekly oral tablet) 
    Monthly oral tablet 0.69*** (0.36 to 1.03) 0.00 0.92*** (0.65 to 1.19) 
    Subcutaneous 3-month 0.16 (-0.09 to 0.42) 0.21 NS† 
    Subcutaneous 6-month 0.75*** (0.44 to 1.07) 0.00 NS 
    Intravenous 3-month -0.57** (-1.12 to -0.01) 0.05 2.62*** (2.04 to 3.20) 
    Intravenous yearly 0.28 (-0.12 to 0.68) 0.17 1.56*** (1.17 to 1.94) 
Side effects (reference level: gastro-intestinal disorders) 
    Flu-like symptoms 0.97*** (0.76 to 1.18) 0.00 0.90*** (0.65 to 1.15) 
    Skin reactions 0.63*** (0.41 to 0.85) 0.00 1.04*** (0.81 to 1.26) 
Number of observations 3,822 (257 respondents X 15 choices, minus 33 missing values) 
Pseudo R-squared = 0.42; Log-likelihood -2456.03; AIC = 1.29. 
* p<0.10, ** p<0.05, *** p<0.01; † NS Not significant and not included in the final model; $ For the coefficients of 
efficacy and cost to you, exp(β) is shown. The standard deviation of the log-normal distribution is reported. 
The standard deviation parameters were statistically significant for all attributes except the 
subcutaneous injection, suggesting the presence of preference variation in the importance of the 
attribute/level across respondents. To gain more insight into how preferences vary, the distributions 
of the parameters or kernel density estimates of the individual parameter are provided in Additional 
file 3 – Figure 1.  
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WILLINGNESS TO PAY 
The WTP and WTTE for attributes/levels are presented in Table 4. For example, respondents were 
willing to pay a personal contribution of €19.53 more per month or to give up 13.52% of drug’s 
efficacy for the treatment mode 6-month subcutaneous injection rather than a weekly oral tablet. 
Table 4| Willingness to pay and willingness to trade efficacy for osteoporosis medication 
attributes* 
Attributes and levels Willingness to pay 
(€ per month) 
Mean (95% CI)  
Willingness to trade efficacy 
(% risk reduction) 
Mean (95% CI) 
Efficacy (1% risk reduction) 3.73 (3.01 to 4.44)  --- 
Cost (€1) --- -2.27 (-1.58 to -2.96) 
Drug administration (reference level: weekly oral tablet)  
    Monthly oral tablet 16.16 (12.85 to 19.47)  -10.16 (-7.88 to -12.50) 
    Subcutaneous 3-month 4.24 (3.72 to 4.76) -2.93 (-2.57 to -3.30) 
    Subcutaneous 6-month 19.53 (17.15 to 21.92) -13.52 (-11.82 to -15.22) 
    Intravenous 3-month -15.28 (-23.23 to -7.34) 8.66 (14.31 to 3.01) 
    Intravenous yearly 11.75 (5.64 to 17.85) -5.83 (-1.88 to -9.77) 
Side effects (reference level: gastro-intestinal disorders)  
    Flu-like symptoms 25.21 (13.06 to 20.50) -16.68 (-14.20 to -19.16) 
    Skin reactions 16.78 (13.06 to 20.50) -9.48 (-7.13 to -11.83) 
* Using the conditional constrained distribution 
A positive willingness to pay means that patients are willing to pay a personal contribution for the attribute/level, while 
a negative willingness to trade efficacy means that patients are willing to give up treatment efficacy for the 
attribute/level. 
HIGH VERSUS LOW-RISK PATIENTS 
The results of the model for high-risk and low-risk patients are presented in Table 5. Significant 
differences in preferences were found between these patients groups for the effectiveness and cost 
of treatment – the interactions between risk group and effectiveness and cost parameters  were 
significant (5% level)). Lower effectiveness and higher costs are more acceptable for patients with 
high-risk of fractures. In addition, high-risk patients attached a higher (negative) value to being at 
risk for skin reactions than low-risk patients, and the constant (i.e. preferences for drug treatment 
per se) was higher for high-risk patients. Preferences for drug administration did not differ 
significantly between patients groups.  
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Table 5| Differences between high and low-risk patients’ preferences for osteoporosis drug 
treatment 
Attributes and levels High risk patients 
(FRAX-major >10%) 
Estimate (95% CI) 
SD 
Low-risk patients 
(FRAX-major ≤10%) 
Estimate (95% CI) 
SD 
P Value 
† 
Number of patients 139 114  
Pseudo R-squared 0.39 0.42  
Log-likelihood -1378.35 -1085.55  
Constant 1.50*** (1.17 to 1.83) -0.05 (-0.52 to 0.43) 0.01 
Efficacy (1% risk reduction) 0.04*** (0.03 to 0.04) 
SD: 1.65*** 
0.14*** (0.11 to 0.17) 
SD: 1.01*** 
0.00 
Cost per month (€1) -0.02*** (-0.02 to -0.03) 
SD: 1.45*** 
-0.08*** (-0.06 to -0.09) 
SD: 0.67*** 
0.00 
Drug administration (reference level: weekly oral tablet)  
    Monthly oral tablet 0.57** (0.08 to 1.06) 
SD: 0.94*** 
1.14*** (0.47 to 1.82) 
SD: 1.87*** 
0.14 
    Subcutaneous 3-month 0.14 (-0.19 to 0.47) 
SD: NS 
0.28 (-0.17 to 0.74) 
SD: NS 
0.14 
    Subcutaneous 6-month 0.57*** (0.17 to 0.96) 
SD: NS 
1.55*** (0.97 to 2.14) 
SD: NS 
0.06 
    Intravenous 3-month -0.28 (-0.88 to 0.31) 
SD: 1.82*** 
-0.24 (-1.39 to 0.91) 
SD: 4.84*** 
0.25 
    Intravenous yearly 0.28 (-0.13 to 0.69) 
SD: 0.81*** 
0.75** (0.05 to 1.45) 
SD: 2.15*** 
0.33 
Side effects (reference level: gastro-intestinal disorders)  
    Flu-like symptoms 0.66*** (0.36 to 0.95) 
SD: 0.91*** 
1.51*** (1.07 to 1.95) 
SD: 1.18*** 
0.57 
    Skin reactions 0.45** (0.05 to 0.85) 
SD: 1.31*** 
0.49** (0.10 to 0.87) 
SD: 1.04*** 
0.05 
* p<0.10, ** p<0.05, *** p<0.01; SD Standard deviation; NS not significant; † p Value was estimated in a joint model 
with interaction terms. 
ADDITIONAL ANALYSES 
Excluding respondents who failed the test-retest (n=38) had no impact on the relative importance of 
the attributes (Additional file 3 – Model 1). The inclusion of more covariates into the model did not 
significantly improve the adjusted McFadden’s pseudo-R² but reduced the sample size by 17% due 
to missing values (Additional file 3 – Model 2). Therefore we did not include these covariates in the 
reference model. The only significant covariate effects we observed were that the preference for 
drug treatment was higher for men and patients with higher income (monthly household income 
>€2,500 per month). Other parameters were not affected by the inclusion of covariates. In addition, 
patients did not significantly prefer their current mode of administration over another mode of 
administration. 
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DISCUSSION 
This study suggests that patients with, or at risk of, osteoporosis have preferences for medications’ 
attributes and are willing to trade between attributes when making treatment choices. Our results are 
consistent with a priori expectations that patients prefer higher efficacy, lower costs and less 
frequent dosing regimens. In addition, patients preferred 6-month subcutaneous injection or 
monthly oral tablet over weekly oral tablet or intravenous injections, and they disliked being at risk 
for gastro-intestinal disorders. Patients are willing to trade efficacy or to pay a personal contribution 
for better levels of other attributes. For most of the attributes, there was significant variation in 
patients’ preferences.   
Previous DCEs have investigated women’s preference for osteoporosis drug treatment [8-10]. Our 
results confirm the findings of de Bekker-Grob et al. [9] that patients prefer monthly oral tablet to 
weekly oral tablet and those of Darba et al. [8] suggesting no significant difference in preference 
between weekly oral regimen and yearly intravenous. Fraenkel et al. [10] also showed that 
preferences are strongly influenced by route of administration but suggest that a majority (65%) of 
Americans preferred yearly intravenous infusion over weekly oral tablet. Our study expands on the 
insights of these studies. We expand the population studied to include men, new recent 
administration routes and frequencies (e.g. 6-month subcutaneous injection) and the nature of 
potential side-effects. A rigorous qualitative research was also conducted to select attributes. 
Results of this study could be very useful for health professionals and decision makers, especially 
given the poor adherence to weekly oral regimens and the potential differences in healthcare costs 
associated with osteoporosis medications. Non-adherence to medication is a major problem among 
patients with osteoporosis and affects considerably the effectiveness and cost-effectiveness of drug 
therapy [20, 21]. Determinants of poor adherence include inconvenient regimens [22]. In our study, 
many patients preferred a 6-month subcutaneous injection compared to weekly oral tablets and 
yearly intravenous injections. The recent introduction of 6-month subcutaneous injection of 
denosumab [23] and the recognition of the importance of patients’ preferences could therefore 
potentially improve patient satisfaction and adherence with therapy [24]. Our results could also 
inform health-care decision making, in particular for drug reimbursement, where insights into the 
preferences of patients groups should be taken into account alongside medical and economic 
considerations [25]. 
In addition, the variation in the patients’ preferences for attribute’s levels observed in our study 
highlights the importance to take into account individual preferences into clinical decision-making 
to improve osteoporosis care. Relying solely on sample average preferences will probably be 
insufficient to optimise medical doctors’ sensitivity to the preferences of individual and unique 
patient during a consultation. Informing individual patients about alternative options and their 
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outcomes, and involving them in decision making, would be very important to improve patient’s 
satisfaction and the outcome of medical care [26]. 
Our study has some potential limitations. First, although consecutive patients were invited to 
participate in this study, we cannot exclude selection bias as some patients did not want, or were not 
able, to fill in the questionnaire. Second, generalizability and transferability of our findings may be 
limited recruiting patients in two osteoporosis centres in one country only. A cross-country 
comparison is on-going in seven European countries. Preferences for attributes/levels may differ 
according to a number of factors including age, income, education or prior fractures [27]. While we 
do not find evidence of preference variation associated with these factors in our study, the cross 
country comparison will investigate this further. Third, we focussed on the nature of common side-
effects and not on their frequency and rare complications. Rare adverse events will be as 
(in)frequent in all categories of anti-resorptive drugs. So, adding osteonecrosis of the jaw and 
atypical femoral fracture to the side effect attribute would probably not differentiate between patient 
preferences across existing drugs. Attributes were selected using a rigorous qualitative method as 
recommended in good practice guidelines [1, 13]. Finally, it could be pointed out that the individual 
10-year probability of fractures was not provided to the patients before completing the 
questionnaire. Only 35 (14%) patients reported knowing their FRAX® score.  
CONCLUSIONS 
In conclusion, this study revealed that osteoporotic patients prefer 6-month subcutaneous injection 
and oral monthly tablets, and disliked gastro-intestinal disorders. Moreover, they were willing to 
trade efficacy or to pay a personal contribution for their preferred outcomes. We found differences 
in preferences across patients which highlights the importance of clinical decision-making taking 
individual preferences into account to improve osteoporosis care. 
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SUPPLEMENT FILE 1: QUESTIONNAIRE 
Task: Making choices for drug therapy 
In this task, we are interested in your opinion on drug therapy for osteoporosis. In order to identify 
your opinion, we would like to ask you to make a series of choices between different drug therapies. 
To help you make these choices, please read carefully through the following information. 
The task 
Please imagine that this is your first visit to a rheumatology clinic. You have recently been 
diagnosed with osteoporosis and your doctor has advised you that you should start taking 
medication. 
In each of the following 16 choices, you will be offered two drug therapies (A or B). In each choice 
please state whether you would choose to take drug therapy A, drug therapy B, or no treatment. If 
you choose no treatment you would not receive treatment for your osteoporosis (and please assume 
that there are no other available treatment options). 
The drug therapies you will be offered will differ in five ways: (1) their effect in reducing the risk 
of fractures, (2) side-effects, (3) mode of administration, (4) frequency of administration and (5) 
out-of-pocket costs. These 5 characteristics of the drug therapies will now be explained. 
 Efficacy (their effect) in reducing the risk of relevant fractures (such as fractures of hip, 
wrist, shoulder or vertebrae) – this may be 20%, 30%, 40% or 50%. 
 
Percentages can be a little difficult to understand in this context; so to help explain please 
refer to the following example:  
Based on individual risk factors (such as age, sex, weight, family history of fractures, 
previous fractures), assume that a person’s risk for having a fracture in the next 10 years is 
20%. Assume this value represents the average risk of fractures in elderly osteoporotic 
women. 
In that case, it would mean that: 
- Without any treatment, 20 women out of 100 will sustain a fracture within the next 10 
years (20%) 
- With a treatment efficacy of 50%, 10 out of 100 women will sustain a fracture 
- With a treatment efficacy of 40%, 12 out of 100 women will sustain a fracture 
- With a treatment efficacy of 30%, 14 out of 100 women will sustain a fracture 
- With a treatment efficacy of 20%, 16 out of 100 women will sustain a fracture 
 
 Side-effects – these may be gastro-intestinal disorders (such as nausea, diarrhea, 
constipation, vomiting, and loss of appetite), skin reactions (such as mild redness possibly 
itching followed by some roughness and feeling of tightness) and flu-like symptoms (low 
grade fever, mild muscle and headache). 
Assume only one in every 50 patients treated will have a side effect. Each of these side-
effects is relatively mild, disappears after a few days and has no long-term or severe 
consequences. 
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It is important to remember that the frequency of the occurrence of any side effects during 
the treatment is NOT dependent on the frequency of the administration of the drug. 
 
 Mode of administration – this may be oral tablet, subcutaneous, intravenous 
- Oral tablet: This would be taken in the morning, at least 30 minutes before 
breakfast and it is important not to lie down for at least an hour after taking the 
tablet 
- Subcutaneous (injection under the skin): injection under your skin given to you by 
a doctor or nurse (at home or at the physician’s office) 
- Intravenous (injection into the vein): given by infusion into your vein in a clinic or 
hospital setting. The infusion usually takes approximately 15 minutes  
 
 Frequency of administration – this may be weekly, monthly, once every 3 months, once 
every 6 months or annually 
 
 Personal contribution (cost to you) per month – This may be €5, €15, €25, €40 or €60. If 
you are currently a medical card holder and therefore not paying for your drugs, for the 
purpose of this questionnaire can you please imagine that you should pay this amount 
yourself every month 
 
Example of the task (please do not fill in) 
 Treatment A Treatment B 
Efficacy in reducing the risk of 
future fractures 
30% 20% 
Possible side effects  
(affecting 1 in 50 patients) 
Gastro-intestinal  
side effects 
Flu-like symptoms 
Mode of administration Intravenous Oral tablet 
Frequency of administration Once yearly Once weekly 
Cost to you  €40 (per month) €25 (per month) 
Which treatment would you choose?  Treatment A        Treatment B      No treatment 
(Tick one box only)     
In this example, you are asked to choose between treatment A which reduces your risk of future 
fractures by 30%, has some gastro-intestinal side-effects in one in 50 patients, is administered once 
per year by an intravenous infusion (into a vein) and has an out-of-pocket cost to you of €40 per 
month; Treatment B which reduces your risk of future fracture by 20%, can give mild flu-like 
symptoms to 1 in 50 patients, is taken as an oral tablet once weekly and the costs to you would be 
€25 per month; and no treatment. In the example above, the patient chooses treatment B, and 
therefore ticks the box treatment B. 
 
X 
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Please choose from each of the following 16 choice sets your treatment of choice for the 
management of osteoporosis. 
Question 1 
 Treatment A Treatment B 
Efficacy (their effect) in reducing 
the risk of future fractures 
30% 40% 
Possible side effects  
(affecting 1 in 50 patients)  
Flu-like symptoms Skin reactions 
Mode of administration Subcutaneous Intravenous 
Frequency of administration 3-month Yearly 
Cost to you €15 (per month) €25 (per month) 
Which treatment would you choose?  Treatment A        Treatment B      No treatment 
(Tick one box only)     
Question 2 
 Treatment A Treatment B 
Efficacy (their effect) in reducing 
the risk of future fractures 
20% 50% 
Possible side effects  
(affecting 1 in 50 patients)  
Flu-like symptoms   Skin reactions  
Mode of administration Intravenous Oral tablet 
Frequency of administration Yearly Weekly 
Cost to you  €60 (per month) €5 (per month) 
Which treatment would you choose?  Treatment A        Treatment B      No treatment 
(Tick one box only)     
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Question 3 
 Treatment A Treatment B 
Efficacy (their effect) in reducing 
the risk of future fractures 
20% 40% 
Possible side effects  
(affecting 1 in 50 patients)  
Skin reactions Flu-like symptoms 
Mode of administration Subcutaneous Intravenous 
Frequency of administration 3-month 3-month 
Cost to you €5 (per month) €60 (per month) 
Which treatment would you choose?  Treatment A        Treatment B      No treatment 
(Tick one box only)     
Question 4 
 Treatment A Treatment B 
Efficacy (their effect) in reducing 
the risk of future fractures 
50% 30% 
Possible side effects  
(affecting 1 in 50 patients)  
Skin reactions Flu-like symptoms 
Mode of administration Subcutaneous Oral tablet 
Frequency of administration 6-month Monthly 
Cost to you €25 (per month) €25 (per month) 
Which treatment would you choose?  Treatment A        Treatment B      No treatment 
(Tick one box only)     
Question 5 
 Treatment A Treatment B 
Efficacy (their effect) in reducing 
the risk of future fractures 
40% 30% 
Possible side effects  
(affecting 1 in 50 patients)  
Skin reactions 
Gastro-intestinal 
disorders 
Mode of administration Subcutaneous Subcutaneous 
Frequency of administration 6-month 3-month 
Cost to you €60 (per month) €5 (per month) 
Which treatment would you choose?  Treatment A        Treatment B      No treatment 
(Tick one box only)     
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Question 6 
 Treatment A Treatment B 
Efficacy (their effect) in reducing 
the risk of future fractures 
30% 20% 
Possible side effects  
(affecting 1 in 50 patients)  
Gastro-intestinal 
disorders 
Flu-like symptoms 
Mode of administration Oral tablet Oral tablet 
Frequency of administration Weekly Monthly 
Cost to you €60 (per month) €15 (per month) 
Which treatment would you choose?  Treatment A        Treatment B      No treatment 
(Tick one box only)     
Question 7 
 Treatment A Treatment B 
Efficacy (their effect) in reducing 
the risk of future fractures 
30% 40% 
Possible side effects  
(affecting 1 in 50 patients)  
Gastro-intestinal 
disorders 
Skin reactions 
Mode of administration Oral tablet Subcutaneous 
Frequency of administration Weekly 3-month 
Cost to you €5 (per month) €60 (per month) 
Which treatment would you choose?  Treatment A        Treatment B      No treatment 
(Tick one box only)     
Question 8 
 Treatment A Treatment B 
Efficacy (their effect) in reducing 
the risk of future fractures 
50% 20% 
Possible side effects  
(affecting 1 in 50 patients)  
Skin reactions 
Gastro-intestinal 
disorders 
Mode of administration Subcutaneous Subcutaneous 
Frequency of administration 3-month 6-month 
Cost to you €40 (per month) €5 (per month) 
Which treatment would you choose?  Treatment A        Treatment B      No treatment 
(Tick one box only)     
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Question 9 
 Treatment A Treatment B 
Efficacy (their effect) in reducing 
the risk of future fractures 
40% 30% 
Possible side effects  
(affecting 1 in 50 patients)  
Flu-like symptoms 
Gastro-intestinal 
disorders 
Mode of administration Intravenous Subcutaneous 
Frequency of administration 3-month 6-month 
Cost to you €15 (per month) €40 (per month) 
Which treatment would you choose?  Treatment A        Treatment B      No treatment 
(Tick one box only)     
Question 10 
 Treatment A Treatment B 
Efficacy (their effect) in reducing 
the risk of future fractures 
30% 40% 
Possible side effects  
(affecting 1 in 50 patients)  
Skin reactions 
Gastro-intestinal 
disorders 
Mode of administration Oral tablet Subcutaneous 
Frequency of administration Monthly 3-month 
Cost to you €5 (per month) €60 (per month) 
Which treatment would you choose?  Treatment A        Treatment B      No treatment 
(Tick one box only)     
Question 11 
 Treatment A Treatment B 
Efficacy (their effect) in reducing 
the risk of future fractures 
50% 20% 
Possible side effects  
(affecting 1 in 50 patients)  
Gastro-intestinal 
disorders 
Skin reactions   
Mode of administration Oral tablet Intravenous 
Frequency of administration Monthly Yearly 
Cost to you €40 (per month) €15 (per month) 
Which treatment would you choose?  Treatment A        Treatment B      No treatment 
(Tick one box only)     
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Question 12 
 Treatment A Treatment B 
Efficacy (their effect) in reducing 
the risk of future fractures 
20% 50% 
Possible side effects  
(affecting 1 in 50 patients)  
Flu-like symptoms 
Gastro-intestinal 
disorders 
Mode of administration Subcutaneous Oral tablet 
Frequency of administration 6-month Monthly 
Cost to you €15 (per month) €40 (per month) 
Which treatment would you choose?  Treatment A        Treatment B      No treatment 
(Tick one box only)     
Question 13 
 Treatment A Treatment B 
Efficacy (their effect) in reducing 
the risk of future fractures 
40% 20% 
Possible side effects  
(affecting 1 in 50 patients)  
Flu-like symptoms Skin reactions 
Mode of administration Intravenous Intravenous 
Frequency of administration Yearly 3-month 
Cost to you €40 (per month) €25 (per month) 
Which treatment would you choose?  Treatment A        Treatment B      No treatment 
(Tick one box only)     
Question 14 
 Treatment A Treatment B 
Efficacy (their effect) in reducing 
the risk of future fractures 
20% 50% 
Possible side effects  
(affecting 1 in 50 patients)  
Gastro-intestinal 
disorders 
Flu-like symptoms 
Mode of administration Intravenous Subcutaneous 
Frequency of administration 3-month 6-month 
Cost to you €25 (per month) €40 (per month) 
Which treatment would you choose?  Treatment A        Treatment B      No treatment 
(Tick one box only)     
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Question 15 
 Treatment A Treatment B 
Efficacy (their effect) in reducing 
the risk of future fractures 
40% 30% 
Possible side effects  
(affecting 1 in 50 patients)  
Gastro-intestinal 
disorders 
Flu-like symptoms 
Mode of administration Oral tablet Oral tablet 
Frequency of administration Monthly Weekly 
Cost to you €25 (per month) €15 (per month) 
Which treatment would you choose?  Treatment A        Treatment B      No treatment 
(Tick one box only)     
Question 16 
 Treatment A Treatment B 
Efficacy (their effect) in reducing 
the risk of future fractures 
50% 20% 
Possible side effects  
(affecting 1 in 50 patients)  
Skin reactions 
Gastro-intestinal 
disorders 
Mode of administration Subcutaneous Subcutaneous 
Frequency of administration 3-month 6-month 
Cost to you €40 (per month) €5 (per month) 
Which treatment would you choose?  Treatment A        Treatment B      No treatment 
(Tick one box only)     
 
Could you please state, on the following scale of 1 to 7, how easy or difficult this first task has been 
for you (i.e. the 16 choice questions). (Circle one number only) 
Extremely easy  Extremely difficult 
1 2 3 4 5 6 7 
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SUPPLEMENT FILE 2 - DISTRIBUTION OF CHOICES ACROSS THE CHOICE SETS 
 Treatment A Treatment B No treatment Missing 
Question 1 108 126 19 4 
Question 2 25 215 15 2 
Question 3 148 78 30 1 
Question 4 179 63 14 1 
Question 5 138 90 29 0 
Question 6 37 194 26 0 
Question 7 147 82 26 2 
Question 8 139 88 28 2 
Question 9 164 60 30 3 
Question 10 186 46 23 2 
Question 11 139 83 32 3 
Question 12 112 119 23 3 
Question 13 144 60 48 5 
Question 14 47 177 30 3 
Question 15 125 111 19 2 
SUPPLEMENT FILE 3 - ADDITIONAL RESULTS 
Model 1| Panel mixed logit model including only patients who were reliable in the test-retest exercise 
Attributes and levels Estimate (95% CI) P Value Standard deviation 
Constant 1.02*** (0.74 to 1.31) 0.00 --- 
Efficacy (1% risk reduction) 0.05*** (0.04 to 0.07) 0.00 1.20*** (1.00 to 1.39) 
Cost per month (€1) -0.04*** (-0.04 to -0.05) 0.00 1.16*** (1.02 to 1.31) 
Drug administration (reference level: weekly oral tablet) 
    Monthly oral tablet 0.58** (0.22 to 0.95) 0.00 0.95*** (0.67 to 1.22) 
    Subcutaneous 3-month 0.11 (-0.16 to 0.38) 0.44 NS 
    Subcutaneous 6-month 0.63*** (0.29 to 0.98) 0.00 NS 
    Intravenous 3-month -0.45 (-1.07 to 0.17) 0.15 2.60*** (1.94 to 3.26) 
    Intravenous yearly 0.09 (-0.36 to 0.53) 0.70 1.58*** (1.13 to 2.03) 
Side effects (reference level: gastro-intestinal disorders) 
    Flu-like symptoms 0.94*** (0.70 to 1.17) 0.00 0.90** (0.64 to 1.17) 
    Skin reactions 0.61*** (0.37 to 0.85) 0.00 1.00** (0.76 to 1.23) 
 
Number of observations 3252 (219 X 15 choices, minus 33 missing values) 
Pseudo R-squared = 0.41; Log-likelihood = -2092.78; AIC = 1.298. 
* p<0.10, ** p<0.05, *** p<0.01; NS Not significant  
  
CHAPTER 9 
220 
 
Model 2| Panel mixed logit model including covariates 
Attributes and levels Estimate (95% CI) P Value Standard deviation 
Constant 0.77*** (0.45 to 1.09) 0.00 --- 
Efficacy (1% risk reduction) 0.05*** (0.05 to 0.06) 0.00 1.23*** (1.13 to 1.33) 
Cost per month (€1) 0.05*** (0.04 to 0.06) 0.00 1.17*** (1.03 to 1.31) 
Men 0.84*** (0.48 to 1.20) 0.00 --- 
High income 0.28* (-0.04 to 0.59) 0.09 --- 
Drug administration (reference level: weekly oral tablet) 
    Monthly oral tablet 0.67*** (0.28 to 1.06) 0.00 1.03*** (0.69 to 1.36) 
    Subcutaneous 3-month 0.06 (-0.24 to 0.35) 0.55 NS 
    Subcutaneous 6-month 0.65*** (0.31 to 1.00) 0.00 NS 
    Intravenous 3-month -0.66** (-1.27 to -0.04) 0.04 2.96*** (2.25 to 3.68) 
    Intravenous yearly 0.17 (-0.30 to 0.64) 0.48 1.79*** (1.30 to 2.27) 
Side effects (reference level: gastro-intestinal disorders) 
    Flu-like symptoms 1.12*** (0.86 to 1.37) 0.00 0.99*** (0.70 to 1.27) 
    Skin reactions 0.57*** (0.34 to 0.81) 0.00 0.99*** (0.72 to 1.26) 
Number of observations = 3215 (216 respondents X 15 choices, minus 25 missing values) 
Pseudo R-squared = 0.42; Log-likelihood = -2062.73; AIC =1.29 
* p<0.10, ** p<0.05, *** p<0.01; † NS Not significant 
Other covariates including age, education level, prior fractures, diagnosis of osteoporosis, size of household, being on 
treatment and number of co-treatments were not significant. 
 
Figure 1| Kernel density for the random parameters 
The kernel densities provide a visual representation of the possible variation in preferences for each 
of the attributes. The graphs indicate that there is significant variation in preferences for all 
attributes. For the mode of administration attribute levels, there is preference variation across each 
of the modes. However, the variation differs by mode. While there is preference variation for a 
monthly oral tablet compared with a weekly oral tablet, the majority of respondents prefer a 
monthly oral tablet as indicated by the majority of the distribution of the preferences being positive. 
However, for intravenous three monthly intravenous injection, the distribution of the preferences is 
both positive and negative indicating that while some patients significantly preferred this mode 
others did not. 
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A. Efficacy 
 
B. Cost 
 
C. Oral monthly tablet 
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D. Intravenous every 3 months 
 
E. Yearly intravenous 
 
F. Skin reactions 
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G. Flu-like symptoms 
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The aim of this dissertation was to review the current evidence on health technology assessment for 
treatment of postmenopausal osteoporosis and to provide new perspectives based on data in 
adherence and preference for osteoporosis medications. The increasing burden of osteoporosis and 
major recent innovations in osteoporosis care in the last decade [1], alongside continuing limitations 
in healthcare resources, justify further research into the health-economic aspects of treatment of 
osteoporosis. For decision makers, health technology assessment including economic evaluations 
provides important information that help to allocate healthcare resources. For clinicians, such 
studies provide additional insight into the most optimal treatment strategy for their patients and can 
therefore be taken into account when developing treatment strategies. 
This final chapter provides first an overview of the main findings of the studies included in this 
dissertation. Then, it discusses some methodological considerations about these studies and, finally, 
it ends with a discussion on the implications of our research for clinical practice, policy decision-
making and future/further research. 
MAIN FINDINGS 
ECONOMIC EVALUATION 
The number of economic evaluations in the field of osteoporosis continues to increase [2, 3]. In 
chapter 3, we performed a systematic review of articles and published abstracts assessing the cost-
effectiveness of denosumab. Denosumab is a novel agent for the treatment of postmenopausal 
osteoporosis that showed to be safe and effective in reducing the risk of fractures [4] and 
subsequently received granted marketing authorization in May 2010 in Europe. For decision makers 
and clinicians, it is important to understand the evidence about the societal cost-effectiveness of 
denosumab. Our review included four articles and eight congress abstracts published up to April 
2012. When considering thresholds that are acceptable in most Western countries and especially 
when accounting for differences in adherence between drugs, denosumab was, in most studies, 
shown to be a cost-effective treatment compared with most first-line and second-line options 
(including generic alendronate) in the treatment of women with high fracture risk. Denosumab may 
therefore be considered as a first-line treatment for patients at high risk of fractures. 
Since many other treatments are currently available for the treatment of osteoporosis, we appraised, 
in chapter 4, economic evaluations of all available drugs for postmenopausal osteoporosis 
published after 2007. A total of 39 economic evaluations were identified between 2008 and 2013. 
Active osteoporotic drugs are generally cost-effective compared with no treatment in 
postmenopausal women aged over 60-65 years with low bone mass, especially those with prior 
vertebral fractures. In view of the heterogeneity in fracture risk, comparators, country setting, model 
structure and incorporation of medication adherence, and given the lack of head-to-head 
comparisons, it is not yet possible to make clear recommendations between drugs in terms of cost-
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effectiveness. With regard to the quality of reporting of these economic evaluations, despite the fact 
that guidelines for conducting health economic evaluations are widely available for many years and 
previous reviews have already criticized economic evaluations for poor reporting [2], we observed 
that quality of reporting is still largely insufficient for several articles. Improving the quality of 
reporting of economic evaluations (with perhaps the help of the recent CHEERS guideline [5]) and 
hence the overall quality of economic evaluations in osteoporosis is required. 
In chapter 5, we extensively discussed one important consideration for cost-effectiveness analyses 
in the field of osteoporosis, i.e. the incorporation of medication adherence. In this chapter, we 
reported the substantial impact of poor adherence on cost-effectiveness ratios and discussed 
approaches to incorporate non-adherence and non-persistence in economic evaluations in 
osteoporosis. Given the large impact of poor adherence on economic results, adherence and 
persistence should become an integral part of future economic evaluations in the field of 
osteoporosis. 
ADHERENCE STUDIES 
In chapter 6, we assessed the clinical and economic burden of non-adherence with oral 
bisphosphonates in an Irish setting using a modelling approach. This analysis revealed that poor 
adherence reduced by approximately fifty percent the potential benefits of drug therapy observed in 
clinical trials and doubled the cost per quality-adjusted life-years (QALY) gained of these 
medications. In addition, we showed that interventions to improve medication adherence have the 
potential to be an efficient way of allocating healthcare resources. By example, for a hypothetical 
intervention that increases medication adherence by 50%, it is cost-effective (using a threshold of 
45,000€ per QALY gained) to spend up to 300€ per year for such intervention. These findings 
emphasize the urgent need to improve adherence with osteoporosis medications and to develop and 
evaluate, also from the health economic perspective, adherence-enhancing interventions. 
In chapter 7, we therefore identified studies that tested some form of patient adherence program and 
reported quantitative results of adherence. Several interventions were identified in 20 studies 
(published until June 2012) including educational programs, monitoring/supervision, different drug 
regimens, patient decision aid, pharmacist intervention and electronic prescription. The efficacy of 
education (tested in 10 studies) was variable across studies. Simplification of dosing regimens, 
electronic prescription, patient decision aid and pharmacist intervention were showed to increase in 
medication adherence but only in a limited number of studies. Monitoring and providing feedback 
to patients on bone marker results seems however not an effective way to enhance adherence 
according to 4 studies. We recommend that promising interventions should be subjected to further 
rigorous evaluation. 
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PREFERENCE STUDIES 
Given the burden of poor adherence to oral regimens and the availability of new drug treatment 
with different routes and timing of administration, understanding the preferences of patients for new 
administration schemes could be very useful for decision-makers and health professionals. Chapters 
8 and 9 therefore contributed to the limited evidence about the preferences of patients for 
osteoporosis drug therapy, especially regarding new routes and timing of administration of 
treatment. First, a qualitative research (using the nominal group technique method) was performed 
to identify most important attributes for drug treatment in osteoporosis (Chapter 8). Based on this 
qualitative research, five important attributes were identified (effectiveness, side effects, mode and 
frequency of administration and cost) and hence included in the discrete-choice experiment (DCE). 
Chapter 9 presented the results of the DCE to assess the preferences of patients for drug therapy. 
This study revealed that patients, as expected, preferred treatment with higher effectiveness and 
lower costs, but also that patients preferred 6-month subcutaneous or oral monthly tablet compared 
with weekly oral tablet. Patients also disliked more being at risk of gastro-intestinal disorders than 
being at risk of skin reactions or flu-like symptoms. The DCE also revealed that patients are willing 
to pay or to give up some efficacy for their preferred treatment options. A substantial heterogeneity 
was observed for most parameters underlining the importance of clinical/shared decision-making 
taking into account individual preferences to improve osteoporosis care. 
METHODOLOGICAL CONSIDERATIONS 
Different methods were used in this dissertation including systematic reviews (chapters 3-4-7), a 
modelling study (chapter 6), a nominal group technique (chapter 8) and a DCE (chapter 9). This 
section addresses strengths and limitations of these methods. 
SYSTEMATIC REVIEW 
Systematic reviews were performed to review the evidence about the cost-effectiveness of 
denosumab (chapter 3), about recent cost-effectiveness analyses of all available drugs in 
osteoporosis (chapter 4), and about interventions to improve medication adherence (chapter 5).  
By evaluating all available evidence, systematic reviews are a powerful tool to help decision makers 
and to identify gaps in the current literature. Guidelines to perform systematic reviews of economic 
evaluations in health care and in particular in searching literature databases for health care 
economic evaluations have been developed [6-9]. Assessing the quality of studies is also an 
important step in the process in systematic reviews and has gained further attention in the literature. 
In chapter 3, we used the Philips checklist [10, 11] to assess cost-effectiveness analyses of 
denosumab. This checklist provides a framework to assess the quality of models for the purpose of 
health technology assessment. In chapter 4, we employed the CHEERS checklist [5] in order to 
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assess the quality of reporting of economic evaluations. This checklist was specifically produced 
with the aim of harmonizing the presentation of information. It should however be acknowledged 
that poor reporting does not necessarily lead to poor quality or results in bias. In chapter 7, to assess 
the quality of studies assessing interventions to improve medication adherence, the so-called  
Delphi list was modified [12]. The initial list contains a set of generic core items for quality 
assessment of randomized clinical trials [12] and, for the purpose of our systematic review, 
elements to evaluate interventional behavioral studies were not included. 
While harmonization and quality of reporting is a first necessary step towards synthetizing evidence 
about the cost-effectiveness of health technologies, local, i.e. context-specific, economic evaluation 
will still be required to provide decision makers with relevant information. The transferability of 
economic evaluations has been extensively discussed in the literature [13-16] and several reasons 
could explain potential differences in cost-effectiveness between countries including the incidence 
of the disease, the availability of health resources, clinical practice patterns and relative prices. To 
improve the comparability and quality of health economic evaluation, defining minimal 
methodological and structural requirements that could be transferable to any specific decision-
making context is perhaps the step forward [17].  
MODELLING HEALTH AND COSTS 
In chapter 6, a modelling study was used to assess the clinical and economic burden of poor 
adherence with osteoporosis. In order to capture the long-term consequences of fractures, a lifetime 
modelling study is required. Modelling is a useful tool in health technology assessment allowing to 
synthetize information about healthcare process, to extrapolate results from clinical trials, to 
combine multiple sources of data and to characterize uncertainty [18]. Modelling can also be used 
prior to research [18] to assess the potential economic value of healthcare interventions such as 
adherence-enhancing interventions. Models have however limitations related to the quality of the 
model/assumptions and the data feeding the model [19, 20]. Models should therefore be designed to 
represent the complexity of the healthcare problem with the greatest precision and to remain as 
close as possible to real-life practices including effectiveness, adherence and safety of drugs [20]. In 
our study, we used a previously validated microsimulation Markov model [21]. A Markov model is 
appropriate to characterize disease with a recurrence of events and when the risk is continuous over 
time [22], which is the case for osteoporosis [23]. Most of the existing models in the field of 
osteoporosis are however cohort-based models [21]. The major weakness of this approach is that it 
does not integrate memory and thus future events do not depend on prior events [21]. By simulating 
patients one by point and tracking their history, microsimulation Markov model could address the 
above weakness and has the potential to be more accurate than cohort models, leading to higher 
accuracy of estimates. These models have a better ability to represent the complexity and the 
heterogeneity of disease such as osteoporosis and are beginning to supplant cohort-based models in 
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health technology assessment [24]. Discrete-event simulation could also offer an interesting 
framework to representing complex healthcare problems [25]. 
NOMINAL GROUP TECHNIQUE 
In order to design our DCE, we first needed to identify and select attributes. Attribute development 
is fundamentally important to obtain reliable results but is often poorly reported in DCE in 
healthcare [26]. A literature review was initially performed to identify a list of potential attributes 
for inclusion. As this list exceeded the number of attributes that could reasonably be tested in a 
DCE [27], a nominal group technique was used to select the most important attributes. In our study, 
patients were first asked to rank a list of twelve potentially important attributes; then a group 
discussion took place follow by a second ranking of the same attributes. Our study (chapter 8) 
showed the feasibility of this method in prioritizing attributes for inclusion in DCE. However, 
although most patients changed their ranking after discussion, the nominal group technique 
discussions did not markedly affect rank order of preferences for the attributes in the total group 
when compared with rank order before discussions. Other methods (such as best-worst scaling, 
other rating/ranking exercises) could be alternative approaches. Further work is required on the 
methods for attribute selection for DCE and on the value of the nominal group technique for that 
purpose. Such studies will of course be hampered by the difficulty to identify the ‘gold standard’ of 
what will be the real attributes that subjects take into account in various situations of choices.  
DISCRETE-CHOICE EXPERIMENT 
DCEs are increasingly used to elicit preferences in health and healthcare [28, 29]. DCEs quantify 
the relative importance of various attributes that characterize an health intervention and allows to 
evaluate the trade-offs that respondents make between them [30]. As the number of DCE in health 
care is increasing rapidly, guidelines for conducting discrete-choice experiments have been 
developed [27, 31]. Advanced methods for selecting attributes and levels [26], for constructing 
experimental design [32] and for statistical analyses [27] have been developed. DCE, as a stated-
preference method, has however been criticised because they may not predict real behaviours and 
choices [33]. There has been limited testing of external validity [28]. Such tests are however 
difficult to conduct given market imperfection in health care.  
IMPLICATIONS FOR DECISION MAKING, CLINICAL PRACTICE AND FUTURE/FURTHER 
RESEARCH   
The findings of this dissertation have several implications for decision making, clinical practice and 
future/further research. This chapter describes these implications.  
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DECISION MAKING 
First, cost-effectiveness analyses are increasingly used in reimbursement decisions. Most countries 
now require economic evaluations as part of the reimbursement process. Cost-effectiveness is 
therefore considered as the fourth hurdle to market access besides quality, safety and efficacy [34, 
35]. Reviewing the evidence about the cost-effectiveness of (new) drugs in osteoporosis (chapters 3 
and 4) could therefore be very useful to help decision makers making decisions about these (new) 
drugs. 
Second, part II of this dissertation raised awareness about the urgent need to improve adherence and 
the potential economic value of improving adherence. Decision makers should take initiatives to 
tackle this important problem in the management of osteoporosis. Developing (cost-) effective 
interventions to enhance adherence would therefore be worthwhile [36]. 
Third, chapters 8 and 9 suggested that osteoporotic patients have preferences for medication 
attributes. These findings could be useful for decision making (especially drug reimbursement) 
where insights into the preferences of patients groups should be taken into account alongside 
medical and economic considerations [37].  How to integrate evidence on patient preferences in 
healthcare decision making is however unclear and requires further investigation [38].  
CLINICAL PRACTICE 
First, as physicians’ decisions plays a key role in health care spending, it is important that 
physicians take into account both costs and effects of health interventions and hence help delivering 
health care in an efficient, i.e. cost-effective way. Physicians should therefore understand the 
relevance of cost-effectiveness analyses for healthcare delivery, know how to judge the quality of 
economic evaluations and have an understanding on the evidence about the cost-effectiveness of 
drugs. 
Second, our findings suggest that poor adherence is a major hurdle in osteoporosis management. 
Improving medication adherence is therefore urgently needed. Clinicians should be aware of the 
problem of poor adherence and set up interventions/programs to improve adherence. Enhancing 
adherence is however a complex issue. Several (intentional and unintentional) reasons of poor 
adherence have been identified in the literature [39]. A recent direction in efforts to improve patient 
adherence is to develop interventions tailored to the individual. When messages included in health 
education programs are adapted to characteristics, needs, and interests of the individual, the 
messages provided during the intervention will be more relevant, less redundant and more likely to 
be read, saved, remembered and adhered to. An important problem in translating intention to 
behavioral change is that many individuals, in the end, do not achieve the desired change. Hence, 
informing patients in a neutral and balanced way, e.g. by applying patient decision aids and shared 
decision making, which may consequently result in goal setting by identifying and setting clear 
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action plans is important to translate intentions into actions. Action plans refer to specific strategies 
(sub-behaviors) aimed at realizing steps within specific periods of time in order to be able to 
perform the ultimate desired behavior. One of the challenges of such program was seen in the 
sustainability of such change and a need for long term additional support initiatives. 
Third, information about patients’ preferences may help physicians to improve patient satisfaction 
and adherence with therapy. The substantial heterogeneity in patients’ preferences for medication 
attributes highlights the importance to take into account individual preferences into clinical/shared 
decision-making to improve osteoporosis care. Relying solely on collective-level approaches to 
explore individual patient preferences will probably be insufficient to optimise medical doctors’ 
sensitivity to preferences of the individual and unique patient during a consultation. Informing 
individual patients about alternative options and their outcomes, and involving them in decision 
making, would be very important to improve patient’s satisfaction and the outcome of medical care 
[40]. Patient decision aids have already been shown to improve the quality of clinical decisions 
about osteoporosis medications and may help to improve adherence [40]. 
FUTURE/FURTHER RESEARCH 
Our study gives several directions for future/further cost-effectiveness analyses. First, poor 
adherence represents a new perspective on health economic assessment in osteoporosis and our 
studies could provide relevant background for incorporating medication adherence and persistence. 
Second, quality of reporting of economic evaluations is still insufficient for several recent cost-
effectiveness studies. We recommend that the CHEERS guideline serves as a reference for 
reporting economic evaluations in osteoporosis. Third, the comparability of economic evaluations 
remains difficult since they differ according to modelling, comparators and populations. Defining 
minimal methodological and structural requirements for any osteoporotic model would certainly be 
interesting. In addition, more attention should be given to the methods used for the identification 
and synthesis of clinical effectiveness data, especially now there is an increasing need for 
comparative cost-effectiveness studies. All these steps will help to improve our ability to synthesize 
evidence across (health economic) studies and improve the quality of decision making. 
Developing (cost-) effective interventions to enhance adherence would also be extremely 
worthwhile. Promising programs should be the subject to further rigorous clinical (and economic) 
evaluation. Eliciting patients’ preferences is becoming an interesting approach to include the patient 
perspective but few considerations about the transferability of patients’ preferences are currently 
available in the literature. International comparison of patients’ preferences for osteoporosis 
medications would definitely be interesting. The development and evaluation of a patient decision 
aid to promote shared-decision making could also be interesting to improve osteoporosis care. A 
patient decision aid may result in patients, that are well-informed and involved deliberately choice 
for a certain drug, showing higher motivation and therefore adherence to the drug of first choice. 
GENERAL DISCUSSION 
 
233 
 
Patient decision aids may also have a counter effect, being that patients less often choose for 
starting on a drug regime in the first place. 
In this dissertation, we provided new perspectives to health technology assessment in osteoporosis 
from adherence and preference studies.  Poor adherence to medication affects many other diseases 
including hypertension, HIV infection or psychiatric illness [41]. Understanding the economic 
implications of poor adherence, assessing the value of improving adherence and further evaluation 
of programs to enhance adherence would also be required in all these diseases. In addition, given 
the potential increasing role of preferences in clinical and policy decisions, understanding patients’ 
preferences for health and healthcare would also be worthwhile in many disease areas. 
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This dissertation aimed to review cost-effectiveness analyses of drugs in osteoporosis, to assess the 
burden of medication non-adherence and effectiveness of programs to enhance adherence, and to 
evaluate the preferences of patients for medication attributes. All these studies could be useful for 
decision makers and clinicians in efforts to optimize the management of osteoporosis, while 
considering efficient allocation of scarce healthcare resources. An efficient prescription of 
medications, the development of programs to enhance adherence and a better incorporation of 
preferences in policy and clinical decision making could definitely be useful in tackling the 
increasing burden of osteoporosis. In addition, our research could serve as case to raise awareness 
of the general population on the importance of medication adherence in other diseases. Although 
more research is needed to further explore effectiveness and efficiency of programs to improve 
adherence, and to decide how we can adequately incorporate a patient’s preference in clinical 
decisions, several societal, economic and clinical implications of the research from this dissertation 
are already discussed in this chapter. 
SOCIETAL IMPLICATIONS 
Osteoporosis is an increasingly major public health problem. In western countries, at least one in 
three women and one in five men over 60 years will suffer from an osteoporotic fracture during 
their remaining lifetime [1]. Osteoporotic fractures results in significant morbidity, mortality, and 
reductions in quality of life. In the Netherlands, a recent report by the International Osteoporosis 
Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) 
[2] estimated that approximately 76,000 new fragility fractures were sustained in 2010 and the 
economic burden of incident and previous fragility fractures was estimated at €824 million for the 
same year. Moreover, with increasing life expectancy, it is estimated that the number of fractures 
will even increase by 40% in 2025 [2]. 
Reducing the burden of osteoporosis by optimizing the management of osteoporosis is therefore 
becoming very important. This dissertation identified several directions for a better management of 
osteoporosis. First, we highlighted the substantial clinical and economic burden of non-adherence 
with osteoporosis medications. Improving adherence is therefore urgently needed and should be (or 
become) a priority for decision makers and healthcare professionals. Several promising 
interventions to enhance adherence such as education program or electronic monitoring were 
identified in a systematic review. We also showed that patients expressed preferences for 
medication attributes such as mode of administration and potential side effects and revealed a 
substantial heterogeneity in patients’ preferences. Promoting shared-decision making by 
incorporating the patient’s preference in decision making could certainly be useful to optimize 
osteoporosis management. 
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ECONOMIC IMPLICATIONS 
Considering limited healthcare resources available, it is becoming increasingly important for 
decision makers to make efficient decisions. Assessing the cost-effectiveness of health interventions 
is therefore needed to help decision makers and could in fine lead to optimizing the management of 
osteoporosis and reducing the burden of the disease. This dissertation included several analyses 
about the economic value of anti-osteoporosis medications that could be useful and used by 
decision makers. By example, two reviews of recent cost-effectiveness analysis of drugs were 
performed suggesting that new drugs (such as denosumab) could represent an efficient way of 
allocating healthcare resources. Another analysis revealed the potential economic value of 
adherence-enhancing interventions, suggesting that designing and implementing programs to 
improve adherence could be efficient. 
CLINICAL IMPLICATIONS 
Alongside societal and economic implications, this dissertation should alert clinicians that manage 
patients with osteoporosis in daily management of osteoporosis. By improving insight into factors 
that contribute to the clinical and economic burden of osteoporosis, our studies make clear that 
clinicians should take care of the adherence of their patients. The variation in the patients’ 
preferences for medication attributes observed in our research highlighted the importance to take 
into account individual preferences into clinical decision-making to improve osteoporosis care. A 
first step might be to raise awareness of the avoidable burden by improving adherence and the 
potential role of education and patient preference. 
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Osteoporosis is a bone disease leading to increased fracture risk affecting more than one in three 
women aged over 60 years in western countries. With the rapid development of new anti-
osteoporosis medications in a context of limited healthcare resources, it is important to help 
decision makers to make appropriate and efficient decisions about the use of these medications. 
Health technology assessment (HTA) aims to assess the medical, social, economic and ethical 
implications of health technologies, and is therefore extremely useful to inform and guide health 
policy decisions. In particular, economic evaluations that compare health technologies in terms of 
costs and outcomes are increasingly used to promote a more rational use of health resources. In 
recent years, non-adherence with osteoporosis medications has emerged as a critical obstacle in the 
treatment of osteoporosis but relatively few studies have been conducted to assess the economic 
implications of poor adherence and to estimate the effectiveness and potential economic value of 
programs to enhance adherence. To improve medication adherence, understanding the preferences 
of patients and addressing patients’ concerns with treatment would be worthwhile. 
The increasing burden of osteoporosis and major recent innovations in osteoporosis care, alongside 
continuing limitations in healthcare resources, justified further research into the health-economic 
aspects of treatment of osteoporosis. The aim of this dissertation was therefore to review economic 
evidence on the treatment of osteoporosis and to provide new perspectives from adherence and 
preference studies. More specifically, the first part of the thesis reviewed and critically appraised 
studies about the cost-effectiveness of drugs in postmenopausal women. The second part assessed 
the economic implications of poor adherence with anti-osteoporosis medications, estimated the 
potential economic value of improving adherence and reviewed the published literature about 
interventions to improve adherence. The last part, finally, evaluated the preferences of patients for 
osteoporosis medication attributes and established how patients trade between these attributes. 
Chapter 2 of the thesis provides a general overview of HTA including economic evaluations and 
reviews the various aspects of HTA in osteoporosis, including epidemiology and burden of disease, 
and assessment of the cost-effectiveness of recent advances in the treatment of osteoporosis. 
Chapters 3 and 4 present systematic literature reviews and critical appraisal of cost-effectiveness 
analyses about different drugs in osteoporosis such as denosumab. These reviews suggest that 
osteoporotic drugs are generally cost-effective compared to no treatment in postmenopausal women 
aged over 60-65 years with low bone mass, especially those with prior vertebral fractures. We also 
observed that quality of reporting is still largely insufficient for several cost-effectiveness articles. 
In chapter 5, the importance of incorporating medication adherence in cost-effectiveness analysis in 
osteoporosis was described, explained and justified. 
The next two chapters focus on medication adherence. First, chapter 6 assessed the clinical and 
economic burden of non-adherence with oral bisphosphonates using a modelling approach. This 
analysis revealed that poor adherence may reduce the potential benefits of drug therapy observed in 
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clinical trials by approximately fifty percent and doubles the cost per quality-adjusted life-years 
gained of these medications. In addition, this study suggests that interventions to improve 
medication adherence have the potential to increase efficiency in allocating healthcare resources. 
Chapter 7 reviewed and appraised published articles that tested adherence improvement programs, 
suggesting that several interventions (including education programs, monitoring/supervision, 
different drug regimens) could represent an effective way to improve adherence. 
Finally, chapters 8 and 9 provided evidence on the preferences of patients for osteoporosis 
medications. Given the burden of poor adherence to oral regimens and the availability of new drug 
treatment with different routes and timing of administration, understanding the preferences of 
patients for new administration schemes could be useful for decision-makers and health 
professionals. In chapter 8, a qualitative research (using the nominal group technique method) was 
performed to identify most important attributes for drug treatment in osteoporosis. Based on this 
qualitative research, five important attributes were identified (effectiveness, side effects, mode and 
frequency of administration and cost) and hence included in the discrete-choice experiment (DCE). 
Chapter 9 reported the results of the DCE conducting in a sample of 257 Belgian women, revealing 
that patients have preferences for mode of administration (such as 6-month subcutaneous or oral 
monthly tablet) and that they are willing to pay or to give up some efficacy for their preferred 
treatment options. A substantial heterogeneity was also observed for most parameters underlining 
the importance of shared decision-making and taking into account individual preferences. 
The findings of this dissertation can have several implications for decision making, clinical practice 
and future/further research. First, the review of economic evidence about anti-osteoporosis drugs 
could help decision makers to efficiently allocate healthcare resources. Second, this dissertation 
raises awareness about the urgent need to improve adherence among those patients that have 
deliberately chosen for a drug regimen, after having been well-informed on the pros and cons per 
treatment option, and the potential economic value of improving adherence. Decision makers and 
clinicians have to tackle the problem of poor adherence and set up interventions/programs to 
improve adherence. Third, information about patients’ preferences may help physicians to improve 
patient satisfaction and adherence with therapy while the substantial heterogeneity in patients’ 
preferences for medication attributes highlights the importance to take into account individual 
preferences into shared decision-making to improve osteoporosis care. Finally, this dissertation 
could give several directions for future/further research including the importance to improve the 
quality of reporting of economic evaluations but also to incorporate medication adherence in cost-
effectiveness analyses, the need to develop (cost-) effective interventions to enhance adherence, and 
the importance to understand and incorporate patients’ preferences in clinical and policy decisions. 
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